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SAMENVATTING 
Het hoofdobjectief van dit doctoraatsproject was om fysiologisch-gebaseerde farmacokinetische (PBPK) 
modellen te evalueren m.b.t. hun betrouwbaarheid aangaande de ‘bottom-up’ voorspelling van de 
klaring in kinderen. Verder was het ons doel de hiaten te identificeren die mogelijks oorzaak zijn van 
onnauwkeurigheden in deze voorspellingen. In deze context werd tramadol gebruikt als 
modelgeneesmiddel om de ‘bottom-up’ en ‘top-down’ maturatiefuncties van de klaring te vergelijken 
in de volledige kinderpopulatie, en meer specifiek in neonaten en zuigelingen. De ‘top-down’ 
klaringsmaturatie werd geschat d.m.v. een populatie-farmacokinetisch (popPK) model in een gepoolde 
dataset gaande van neonaten tot volwassenen. 
Hoofdstukken 3 & 4 behandelen het onderzoek aangaande het in vitro metabolisme van tramadol en 
de daaropvolgende constructie van verschillende tramadol PBPK klaringsmodellen, terwijl hoofdstukken 
5 & 6 focussen op het gebruik van het finale tramadol klaringsmodel voor de predictie van de klaring 
van tramadol in kinderen. In Hoofdstuk 3 beschrijven we de resultaten van de in vitro metabolisme 
experimenten met tramadol en de contributies van de verschillende enzymen die betrokken zijn in de 
hepatisch klaring van dit geneesmiddel. Het metabolisme van tramadol werd onderzocht in humane 
levermicrosomen (HLM) en humane recombinante CYP-enzymen (rhCYP). Parameters van het in vitro 
metabolisme (CLint, Km, Vmax) werden geschat via niet-lineaire regressieanalyse. Deze in vitro 
metabolismeparameters van tramadol werden geëxtrapoleerd naar een in vivo hepatische klaring, 
gebruik makend van het in vitro-in vivo extrapolatieprincipe (IVIVE), reeds geïmplementeerd in de 
Simcyp® PBPK Simulator. Terzelfdertijd werd een retrograad klaringsmodel opgesteld in Simcyp®, 
gebaseerd op in vivo klaringsdata. Dit model voorspelt de in vivo klaring, wat werd onderbouwd d.m.v. 
een accurate voorspelling van hepatische enzym- en renale contributies. De IVIVE-klaringsmodellen 
(opgebouwd uit de HLM en rhCYP data) werden vergeleken met het retrograad klaringsmodel wat 
betreft de absolute klaringsvoorspelling en de contributies van de hepatische enzymen. Op theoretische 
gronden werd voor de IVIVE-klaringsmodellen een factor van 1.58 geïncorporeerd, die rekening houdt 
met de opstapeling van tramadol in het intracellulair milieu (‘ion trapping’). De resultaten tonen aan dat 
de voorspelling van de totale tramadolklaring binnen een factor 2 van de geobserveerde klaring valt, 
echter met verschillen in enzymcontributies in vergelijking met de in vivo situatie. Daarboven toonde 
een sensitiviteitsanalyse aan dat de bloed-plasma ratio en de intracellulaire accumulatie in de levercel 
de predictie van de leverklaring sterk beïnvloedden. 
In Hoofdstuk 4 onderzochten we de oorzaak van de verschillen tussen in vitro en in vivo hepatische 
enzymcontributies (Hoofdstuk 3). We stelden een algemene strategie op om correcte enzymcontributies 
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te implementeren in de opschaling van de in vitro naar de in vivo klaring. Eerst werden de 
referentiestoffen dextrometorphan en midazolam geïncubeerd - naast tramadol - in dezelfde HLM 
batch om de activiteit van de CYP2D6 en CYP3A4 enzymen te bepalen. Ten tweede, een retrograad 
model voor beide referentiestoffen liet ons toe om te berekenen wat de in vitro CYP activiteit had 
moeten zijn, teruggerekend vanuit hun respectievelijke in vivo data. Ten derde, een ‘activity-adjustment 
factor’ (AAF) werd berekend als de ratio van de in vitro gemeten/in vitro teruggerekende CYP activiteit 
voor CYP2D6 en CYP3A4. De AAF die werd bekomen voor CYP2D6 en CYP3A4 was 1.97 en 0.91, 
respectievelijk. Dit impliceert dat de in vitro CYP2D6 activiteit circa 2-voud lager ligt dan de 
teruggerekende CYP2D6 activiteit. Deze daling in in vitro CYP2D6 activiteit werd reeds voorheen 
beschreven in de literatuur. De verklaring die werd gegeven was dat het CYP2D6 enzym leidt aan 
enzyminstabiliteit. De correctie van de tramadol IVIVE-klaringsmodellen met de AAF voor CYP2D6 en 
CYP3A4, zorgde ervoor dat de CYP contributies in deze modellen gealigneerd waren met hun in vivo 
contributies (zoals geïncorporeerd in het retrograad klaringsmodel). Er dienen echter nog meer 
geneesmiddelen bestudeerd te worden om deze strategie meer algemeen te valideren. 
Hoofdstuk 5 beschrijft de kwalificatie van het tramadol retrograad klaringsmodel voor volwassenen en de 
evaluatie van de ‘bottom-up’ klaringsvoorspelling in kinderen, gebruik makend van de Simcyp® Simulator, 
t.o.v. de in vivo observaties van de tramadolklaring in kinderen. Het retrograad klaringsmodel 
incorporeert op mechanistische wijze de enzymcontributies van CYP2D6, CYP3A4, CYP2B6 evenals de 
renale klaring. Dit model werd gekwalificeerd op basis van beschikbare in vivo PK parameters van 
tramadol in volwassenen. Als eerste controlestap werden 2 pediatrische HLM batchen (van 1 en 3 maand 
oude kinderen) geïncubeerd met tramadol en de referentiestoffen dextrometorphan (CYP2D6) en 
midazolam (CYP3A4). Dit experiment bevestigde de hypothese dat O-desmethyltramadol voor het 
overgrote deel door CYP2D6 wordt gemetaboliseerd, terwijl de vorming van NDT niet gecorreleerd was 
met de CYP3A4 activiteit. CYP2B6 speelt inderdaad ook nog een rol in de vorming van NDT. In een 
volgende stap werd de tramadol klaringsmaturatie in pediatrische subjecten voorspeld d.m.v. virtuele 
populaties. Twee gepubliceerde popPK modellen die de maturatie van de totale en CYP2D6 
tramadolklaring in neonaten/zuigelingen (exponentieel model) en over de volledige humane 
leeftijdsrange (Hill model) beschrijven, werden geselecteerd als referentie. Echter, het Hill model werd 
verkozen boven het exponentieel model in termen van totale en CYP2D6 klaring zowel voor 
neonaten/zuigelingen als voor de rest van de pediatrische leeftijdscategorieën. Additioneel werd de 
maturatie in renale klaring bekomen door het individueel fitten van urinaire tramadolconcentraties bij 
9 subjecten a.d.h.v. WinNonlin®. Door het visueel vergelijken van de voorspelde Simcyp® ‘bottom-up’ 
klaringswaarden met de bekomen klaringswaarden uit het Hill maturatiemodel, werd besloten dat de 
‘bottom-up’ methode de maturatie in de klaring goed capteert. Desalniettemin werd een algemene 
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onderpredictie geobserveerd in de totale en CYP2D6 klaringen, echter niet in de renale klaring. Een 
verschil in fysiologie (bvb. levergewicht) werd verantwoordelijk geacht voor deze discrepantie, gezien 
de totale en de CYP2D6 klaring een gelijkaardige onderpredictie vertoonden. 
Hoofdstuk 6 bouwt verder op het open einde van Hoofdstuk 5 door de invloed van variaties in systeem-
gerelateerde (biologie/fysiologie) informatie te bestuderen op de ‘bottom-up’ voorspelling van de 
hepatische klaring in pediatrische virtuele subjecten. In deze context werden drie commercieel 
beschikbare PBPK softwarepaketten (PK-Sim®, Simcyp®, en Gastroplus®) onderzocht m.b.t. hun 
verschillende systeem-gerelateerde informatie en de consequentie hiervan op de voorspelling van de 
klaring. In elke software werd een retrograad klaringsmodel opgesteld dat de renale en de hepatische 
tramadol klaring mechanistisch voorspelde in volwassenen. Deze keer werden de retrograde modellen 
gecalibreerd aan de populatiepredictie van het Hill model voor volwassenen, zodat elk verschil tussen 
‘bottom-up’ (PBPK) en ‘top-down’ (Hill) voorspelde klaringswaarden enkel te wijten kon zijn aan een 
verschil in maturatiefuncties. Elk retrograad model werd gekwalificeerd in termen van totale, CYP2D6, 
en renale tramadol klaringen. De pediatrische tramadol klaringen werden vergeleken tussen de 
verschillende PBPK modellen (bottom-up) en het Hill model (top-down) in de range van neonaten tot 
adolescenten. Door de aanwezige variaties in fysiologische data, zoals gebruikt door elke PBPK tool, 
werden relevante verschillen in de voorspelling van de hepatische klaring in kinderen vastgesteld. 
Interessant is dat in het geval van CYP2D6, het PBPK model met het kortste maturatiehalfleven 
resulteerde in de beste predictie van de in vivo tramadol CYP2D6 klaring. Consensus over welke 
fysiologische data het best dienen gebruikt te worden in deze PBPK modellen, zou pediatrische 
klaringsvoorspelling kunnen harmoniseren en optimaliseren. Daarenboven, de combinatie van ‘bottom-
up’ en ‘top-down’ technieken, gebruik makend van een gepaste referentiestof, bezit potentieel om 
systeem-gerelateerde parameters aan te passen om op die manier de pediatrische fysiologie beter te 
capteren. Analoog onderzoek met bijkomende geneesmiddelen is aangewezen om deze resultaten 
verder te confirmeren. 
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SUMMARY 
The main aim of this PhD project was to evaluate a physiologically-based pharmacokinetic  (PBPK) 
approach for a reliable bottom-up clearance prediction in pediatric life, and to identify the gaps that 
underlie potential prediction inaccuracies. In this light, tramadol was used as a model compound to 
compare the bottom-up to the top-down clearance maturation function across pediatric life, with a 
particular focus on neonates/infants. The top-down clearance maturation was estimated from a 
population PK investigation in a pooled data set, ranging from neonates to adults. 
Chapter 3 & 4 outline the investigation of tramadol’s in vitro metabolism and the subsequent 
construction of different tramadol adult PBPK clearance models, while Chapters 5 & 6 focus on using 
this adult PBPK model for the prediction of the pediatric tramadol clearance. In Chapter 3, we describe 
the results from in vitro metabolism experiments for tramadol and the associated enzyme contributions 
to the hepatic clearance of this compound. Tramadol metabolism was investigated in human liver 
microsomes (HLM) and human recombinant enzyme systems (rhCYP). Based on the formation rates of 
tramadol metabolites, in vitro metabolism parameters (CLint, Km, Vmax) were estimated via non-linear 
regression analysis. These in vitro tramadol metabolism parameters were extrapolated to achieve the 
in vivo hepatic clearance, using the so-called in vitro-to-in vivo extrapolation (IVIVE) method, 
implemented in the Simcyp® PBPK Simulator. In parallel, a retrograde clearance model in Simcyp® was 
set up, built from in vivo clearance data. This model predicts the in vivo clearance, substantiated with 
accurate predictions of the involvement of enzymes and renal processes. The IVIVE clearance models 
(from HLM data and from rhCYP data) were compared to the retrograde clearance model in terms of 
absolute clearance and hepatic enzyme contributions. For the IVIVE clearance models, a factor of 1.58 
was incorporated based on theoretical grounds, which accounts for tramadol accumulation in the 
intracellular milieu due to ion trapping. The results indicate that the prediction of tramadol clearance is 
within two-fold of the observed clearance value, albeit with differences in hepatic enzyme contributions, 
compared to in vivo. In addition, a sensitivity analysis indicated that especially the blood-plasma ratio 
and the hepatic accumulation were factors influencing the bottom-up prediction of the clearance. 
In Chapter 4, we describe our efforts to identify the reason for the in vitro inaccuracies in the CYP enzyme 
contributions described in Chapter 3, and propose a general strategy to implement correct enzyme 
contributions in the IVIVE clearance models. First, the probe substrates dextromethorphan and 
midazolam were incubated alongside tramadol in the same HLM batch to determine the in vitro activity 
of CYP2D6 and CYP3A4, respectively. Second, a retrograde clearance model for both compounds 
allowed to calculate what the in vitro CYP activities should have been, by back-calculation from the in 
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vivo clearance in the population. Third, an activity-adjustment factor (AAF) was calculated as the ratio of 
the in vitro measured/in vitro back-calculated activity for CYP2D6 and CYP3A4. The AAF for CYP2D6 and 
CYP3A4 were determined as 1.97 and 0.91. This implies that for pooled HLM assays, the in vitro CYP2D6 
activity is approximately 2-fold lower compared to the expected value. A decrease in HLM CYP2D6 
activity has already been observed in literature. Enzyme instability seemed to be responsible for this 
phenomenon. Hence, correction of the existing IVIVE models with the AAF provided CYP contributions, 
which were aligned in both in vitro systems and agreed well with in vivo contributions. However, more 
compounds should be investigated with this approach to validate our results. 
Chapter 5 outlines the qualification of the adult retrograde clearance model and the evaluation of the 
bottom-up prediction of pediatric clearance , using the Simcyp® Simulator, against in vivo pediatric data. 
The adult retrograde model for tramadol mechanistically incorporated enzyme contributions for 
CYP2D6, CYP3A4, CYP2B6 and renal clearance. This model was qualified based on available tramadol in 
vivo PK parameters in adults. As a first checkpoint, 2 pediatric HLM samples (originating from a 1 and a 
3 month old child) were incubated with tramadol and probe substrates dextromethorphan (CYP2D6) 
and midazolam (CYP3A4). This experiment confirmed our belief that O-desmethyltramadol, as in adults, 
is mainly CYP2D6 mediated, while CYP3A4 activity did not seem to correlate with NDT formation. 
CYP2B6 might indeed also be involved in this conversion step. In a next step, the maturation of tramadol 
clearance was predicted by letting Simcyp® generate virtual pediatric subjects. Two published 
population PK models that respectively described the maturation of total and CYP2D6 tramadol 
clearance in neonates/infants (exponential model) and over the complete lifespan in a pooled 
population (Hill model), were considered as reference. However, the Hill model was preferred over the 
exponential model in terms of total and CYP2D6 clearance in early life as well as over the complete 
pediatric life span. In addition, the maturation of the renal clearance was obtained by fitting urinary 
data for 9 subjects in a one-by-one WinNonlin® modelling effort. By visually comparing the Simcyp® 
bottom-up predicted clearance values to the in vivo Hill maturation model, the bottom-up approach 
seemed to capture the overall maturation trend well. However, a general underprediction was apparent 
in the total and CYP2D6 clearance maturation, but not in the renal clearance. A difference in physiology 
(e.g. liver size) between the real and virtual pediatric subjects was assumed to be the reason, both 
affecting predicted total and CYP2D6 clearance in a similar way. 
Chapter 6 addresses the open ending of Chapter 5 by comparing the influence of variations in system-
related information on the bottom-up prediction of the hepatic clearance using pediatric virtual subjects. 
To this end, three commercially available PBPK softwares (PK-Sim®, Simcyp®, Gastroplus®) were 
investigated for differences in system-related information and their effects on prediction of the 
clearance. In each software tool, a retrograde clearance model was constructed to mechanistically 
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describe hepatic and renal tramadol clearance in adults. This time, the retrograde clearance models 
were calibrated to the population prediction of the Hill model in adults, so that any difference in 
predicted and in vivo pediatric clearance would be solely attributable to differences in maturation. Each 
retrograde clearance model was qualified in terms of total, CYP2D6, and renal clearance. Pediatric 
tramadol clearance predictions were compared between the different PBPK (bottom-up) models and 
the Hill (top-down) model in the range from neonates to adolescents. Since variations were present in 
physiological data used by the PBPK softwares, relevant differences were picked up in the hepatic 
clearance prediction in children. Interestingly, in the case of CYP2D6, the PBPK model with the shortest 
maturation half-life agreed best with the in vivo CYP2D6 maturation. Consensus on the selection of the 
best pediatric data to use, should help to further harmonize and optimize pediatric clearance predictions. 
Moreover, the combination of bottom-up and top-down approaches, using a carefully selected probe 
substrate, holds potential in updating system-related parameters to better represent pediatric 
physiology. Investigations using additional compounds need to be performed to further strengthen 
these results. 
  
     
 x 
 
 
     
 xi 
DANKWOORD 
Het dankwoord. Het enige deel van het doctoraat dat niet onder review staat, maar toch door iedereen 
wordt gelezen. Daarom wil ik mij nu reeds excuseren mocht ik iemand vergeten zijn! Ik ervaarde een 
doctoraat als een confrontatie. Een confrontatie met andere wetenschappers, je naasten, maar 
voornamelijk met jezelf. Door deze periode weet ik beter wie ik ben en wat ik waard ben op 
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uitgedrukt een turbulente periode. Doctoreren betekende voor jou het aanhoren van geraaskal over 
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doctoraat, in muziek, etc. Op momenten wanneer ik weer eens “caught up” geraakte, was jij er om mij 
terug met beide voeten in de aarde te zetten en me opnieuw moed in te spreken om toch maar door te 
doen. Bedankt om mij zoveel te geven, ik hoop dat ik in de komende jaren een even grote steun mag 
zijn voor jou. Ik kijk er ongelofelijk naar uit om samen met jou en ons persoonlijk pediatrisch projectje, 
Roman, de toekomst vorm te geven. 
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1 MEDICINE AND THE CHILD, A COMPLEX RELATIONSHIP 
Before a new drug is approved to enter the market, supportive evidence has to be provided that it is 
safe, effective and of high quality. Therefore, during the end-to-end drug development process, 
preclinical and clinical studies are designed to prove that the drug indeed complies with these criteria 
and is eligible for marketing. In the preclinical phase, the drug is investigated in vitro and in vivo in 
different animal species to obtain information on its mechanism of action, its drug disposition 
characteristics and its safety. Clinical studies are carried out first in healthy volunteers to assess drug 
safety, pharmacokinetics/pharmacodynamics (PKPD) and dosage requirements. Afterwards, the drug is 
given to patients to assess the drug’s efficacy and safety profile [1]. 
Intuitively, when a drug is to be developed for pediatric patients, there are practical and ethical issues 
associated with the clinical testing of drugs in children. Because of this, there is a historic shortage of 
data on the safety, dosing requirements and efficacy of drugs used in children that were previously 
approved in adults, especially in the neonate/infant population. The term “therapeutic orphans” was 
coined in 1968 by Shirkey to describe this phenomenon [2]. This leads to the paradox of clinicians having 
to treat our most vulnerable population with off-label and unlicensed drugs. In off-label drug use, the 
drug is prescribed for a different indication, or is given at a different dose or in a different way as 
opposed to what the label instructs. When a drug is used unlicensed, the drug is imported from another 
country where it is has obtained a license for marketing. Off-label drug use in the pediatric population 
ranges from 60 to 90% of patients, the highest percentage being in infants <1 year of age [3]. Since this 
situation brings about delays, costs and risks for both patients and clinicians, regulatory authorities have 
established strategies and installed regulations to promote clinical research in children [4]. In 2002, the 
Best Pharmaceuticals for Children Act (BPCA) was adopted by the Food and Drug Administration (FDA), 
which provided incentives for pharmaceutical companies to conduct pediatric studies (the carrot). 
Furthermore, the Pediatric Research Equity Act (PREA), passed in 2003, defines the legal framework (the 
stick) in which to develop Pediatric Study Plans (PSP) [5]. Not long thereafter, in 2007, the European 
Pediatric Regulation was developed by the European Medicines Agency (EMA). Its objective is to 
improve the health of children in Europe by facilitating the development and availability of medicines 
for children. The main impact was the establishment of the Pediatric Committee (PDCO) overseeing the 
Agency’s work on a sponsor’s Pediatric Investigational Plan (PIP) [6]. The incentive in both continents is 
a six month extension of the sponsor’s patent protection, even in the case of a negative outcome in 
pediatrics.  
In the drug development process (Figure 1), the phase 1 clinical trials expose 20 to 100 healthy 
volunteers/patients to the drug to document safety & tolerability, pharmacokinetics and dose 
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requirements. Phase 2 trials expose several hundreds of patients to the drug to assess efficacy, the side 
effect profile and perform dose finding, while up to several thousands of patients are enrolled in phase 
three trials to confirm the efficacy and safety profile. Timeline differences with respect to the pediatric 
investigation exist between E.U. (EMA) and U.S. (FDA). The Pediatric Investigational Plan (PIP, EMA) has 
to be submitted at the end of phase 1, while for the Pediatric Study Plan (PSP, FDA) this needs to take 
place at the end of phase 2. Several contact moments occur between the sponsor and the regulatory 
authority leading to potential adaptations of the sponsor’s pediatric plans. This is necessary since an 
initial pediatric plan is submitted as early as after phase 1. At that time, a lot of preclinical data (e.g. in 
vitro ADME, animal pharmacology/toxicology data) and minimal clinical data pertaining to the adult 
dose regimen and safety are available to inform the pediatric plan. As more clinical information is 
generated, newly obtained insights in the adult population should allow to better inform the design of 
the pediatric clinical trials [5]. The question of when to perform pediatric clinical trials is of the essence 
and should always be governed by a risk/benefit analysis. At the time new compounds enter phase 1 
clinical trials, this ratio is high. To initiate a pediatric clinical trial, there should minimally be some adult 
in vivo PK, safety and/or efficacy data available in order to lower this ratio. Therefore, Shaddy et al. [7] 
suggested that pediatric clinical trials may be deferred until after phase 3, with the risk/benefit ratio 
being typically much lower at that moment in the drug development process. However, if e.g. disease 
progression, or the drug’s PKPD relationship is not similar in children and adults or the disease 
exclusively occurs in children, clinical trials in adults will minimally affect this risk/benefit ratio. In such 
cases, it might become relevant to investigate (predictive) juvenile animal models or use model-based 
approaches on limited adult data to optimize first-time-in-pediatric studies. 
 
 
 
 
 
 
 
FIGURE 1: OVERVIEW OF THE DRUG DEVELOPMENT PROGRAM, WITH AN EMPHASIS ON PEDIATRIC DEVELOPMENT [8] 
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2 CURRENT KNOWLEDGE ON PEDIATRIC ADME 
Developing appropriate drugs for children is a daunting task. Children constitute a vulnerable and 
heterogeneous population in which the physiology is changing rapidly, especially in the younger ages. 
Therefore, the pediatric population really consists of several subpopulations, mostly stratified in the 
following largely arbitrary age categories: term newborn infants (0-27 days), infants and toddlers (28 
days to 23 months), children (2 to 11 years), and adolescents (12 to 16-18 years). Because of this 
changing physiology, it is impossible to apply a one-dose-fits-all approach across the whole pediatric 
age range. The following section provides an overview of the most important changes affecting drug 
disposition, with a possible implication for drug therapy. When drugs are dosed extravascularly to 
patients, the processes determining the concentrations of the drug in several tissues and blood are 
absorption, distribution, metabolism, and excretion (ADME). 
 
2.1 ABSORPTION 
Given the focus of this thesis on drug disposition after i.v. administration, the physiological changes 
affecting absorption will only be described high level. In short, parameters determining the rate and 
extent of oral absorption are gastric emptying time, gastrointestinal pH, and gastro-intestinal transit 
time. The fasted/fed state may also affect drug absorption, certainly given the high and very frequent 
milk intake [9]. As Bowles et al. [10] summarize, the oesophageal transit time of liquids seems similar in 
children and in adults, whereas gastric emptying is delayed, gastric pH elevated due to the low acid 
secretion, and intestinal transit reduced and irregular. Gastrointestinal enzyme activities of α-amylase 
and other pancreatic enzymes in the duodenum are low up to 4 months of age. Also concentrations of 
bile acids and lipase are typically low in neonates. This may decrease the absorption of lipid-soluble 
drugs [11]. Globally, absorption seems to be slower in children than in adults and bioavailability is 
strongly influenced by all these factors. Absorption from intramuscular and subcutaneous injection sites 
may be limited due to reduced peripheral blood flow in neonates and may suddenly increase due to 
physiological changes with subsequent toxic drug levels. Skin absorption is enhanced in neonates/young 
infants. In addition, the ratio of the BSA relative to body mass in pediatric life exceeds the adult ratio. 
As a consequence, drugs dosed per surface area may induce toxic effects more rapidly (Figure 2) [10-
12].  
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2.2 DISTRIBUTION 
Drug distribution describes the reversible mass transfer of drug from plasma (blood) to the different 
tissues. The pharmacokinetic parameter associated with drug distribution is the volume of distribution 
(Vd). The Vd represents the hypothetical volume that is needed to dissolve the drug dose to achieve the 
concentrations measured in plasma. Drug distribution alters with organ composition, organ blood flow, 
and drug plasma protein binding. In neonates, extracellular spaces and total body water content are 
higher, compared to adults. As a consequence, the volume of distribution for compounds mainly 
distributing in extracellular water will be higher (such as aminoglycosides). In addition, the adipose 
tissue consists of a relatively higher water content and a lower lipid fraction (Figure 2) [12]. In preterm 
infants, the lipid fraction even goes down to about 1%, compared to 15% of total body weight in term 
neonates. Therefore, lipid-soluble drugs may accumulate less in these premature infants [11]. As an 
example, the Vd for gentamycin and sufisoxazole is twice or more that in adults, while diazepam and 
flunitrazepam display a reduction in Vd [13]. 
Compounds highly bound to plasma proteins may display altered fractions of unbound drug, because 
the concentration of plasma proteins (albumin and α1-acid glycoprotein) is decreased in early life. 
Typically, albumin levels in adults reach 40 g/L, while there is a higher variation in α1-acid glycoprotein 
levels (400-1000 mg/L). This is because the latter is increased in conditions such as stress and 
inflammation, while it is decreased in renal and hepatic disease. In early life, albumin levels are reduced 
by 20%, while α1-acid glycoprotein levels are approximately halved [14]. Because oftentimes it is hard 
to obtain a sufficient number and volume of blood samples, which is typically needed for equilibrium 
dialysis, McNamara and Alcorn provided a method for calculating the unbound fraction of a drug, based 
on the difference in protein levels in adults versus neonates/infants. This approach offers a way to 
predict the unbound fraction of a drug in early life [15].However, plasma protein binding may be 
decreased further due to changes in affinity as a result of a lower blood pH and conformational changes 
in the fetal protein, and competition with endogenous compounds, such as bilirubin and free fatty acids 
that compete for binding. This however, does not necessarily imply that the drug effect will have 
increased, since unbound drug concentrations may be unchanged. Situations in which altered unbound 
plasma concentrations of a drug are anticipated, are mostly due to changes in elimination capacity or 
driven by saturation kinetics of plasma protein binding [16, 17]. However, because the bound drug 
fraction is decreased, a rise in the unbound fraction in plasma may be observed with an increased 
distribution of the drug in the tissues as a consequence. For theophylline, reduced protein binding 
implied a different therapeutic range for this drug in neonates. For this group, serum concentrations 
should be between 6-13 mg/L, while in older patients 10-20 mg/L is targeted [13].  
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FIGURE 2: CLEAR ILLUSTRATION DISPLAYING THE KEY CHANGES IN PHYSIOLOGICAL PARAMETERS THAT GOVERN AGE RELATED DIFFERENCES 
IN DRUG DISPOSITION, FROM KEARNS ET AL. [12]. (A) PANEL A SHOWS CHANGES IN METABOLIC CAPACITY OF DIFFERENT CYP AND UGT 
ENZYMES AS A FUNCTION OF POSTNATAL AGE. THE METABOLIC ACTIVITY IS CLEARLY REDUCED AT BIRTH AND MATURES FOLLOWING AN 
ENZYME-SPECIFIC PATTERN; (B) IN PANEL B, THE CHANGE OF BODY COMPOSITION WITH AGE IS DISPLAYED. THE HUMAN BODY CAN BE 
SUBDIVIDED INTO MAINLY 3 DISTRIBUTION SITES: TOTAL BODY WATER, EXTRACELLULAR WATER, AND BODY FAT. IN THE FIRST 6 MONTHS, 
THE TOTAL AND EXTRACELLULAR WATER ARE HIGHER. (C) PANEL C INDICATES THE CHANGES OF THE GASTROINTESTINAL STRUCTURE AND 
FUNCTION OVER AGE, NORMALIZED TO ADULTS; (D) IN PANEL D THE ACQUISITION OF RENAL FUNCTION IS ILLUSTRATED FOR GLOMERULAR 
FILTRATION (GFR) AND PARA-AMINOHIPPURIC ACID (PAH) CLEARANCE. THE GFR IS A MEASURE OF THE FILTRATION CAPACITY OF THE KIDNEY, 
WHILE PAH EXCRETION INDICATES ACQUISITION OF ACTIVE TUBULAR SECRETION; (E) AS REFLECTED IN PANEL E, THE THICKNESS, PERFUSION, 
AND HYDRATION OF  THE SKIN AND THE RELATIVE SIZE OF THE SKIN SURFACE AREA ALL FOLLOW SPECIFIC PATTERNS WITH AGE. CLEARLY, 
PARAMETERS STEADILY DECLINING OVER AGE ARE THE PERFUSION AND HYDRATION OF THE SKIN, WHILE THE THICKNESS VASTLY INCREASES 
AROUND PRE-TERM AGE AND STAGNATES THEREAFTER. IN ADDITION, THE BODY-SURFACE AREA/WEIGHT RATIO IS HIGH AT FIRST BUT THEN 
DIMINISHES RAPIDLY TO ADULTHOOD 
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Membrane differences exist between neonates/infants and adults, which affects drug binding to 
erythrocytes and membrane permeability. The erythrocyte:plasma concentration ratio of digoxin is 
reported to be 3 times higher, compared to adults. Apparently, neonatal erythrocytes have about three 
times more digoxin-binding sites, compared to adults [14]. Membrane permeability in neonates and 
infants is higher than for older children, and has an important consequence for drugs crossing the blood-
brain barrier. This would be, in part, related to the still immature myelinization, counteracting drug 
passage. This observation is underpinned by the occurrence of kernicterus, which is caused by excessive 
plasma levels of bilirubin crossing the blood-brain barrier. Lipophilic H1-receptor antagonists also cross 
the blood-brain barrier and cause fatigue, somnolence, lethargy and impairment of cognitive function 
[11, 13]. 
For most low molecular weight drugs, distribution is governed by passive diffusion along the 
concentration gradients. However, for drugs with low permeation through biological membranes, drug 
distribution (and elimination as well) may be influenced by an active transport system. Transporters may 
transfer the drug out of cells (efflux, e.g. P-gp, MRP, BCRP) or into the cells (influx, e.g. OCT, OAT, OATP). 
In addition, due to a significant overlap between drugs being substrates for transporters and CYP 
enzymes, the disposition of these drugs is not only often times complex but also makes them prone to 
potential drug-drug interactions [18]. In pediatrics, functional transporter activity changes as a function 
of age. Although the importance of active transport is well-recognized and developmental patterns for 
transporter-specific expression and activity emerge, a lot remains to be clarified [19]. 
 
2.3 METABOLISM 
Metabolism describes the process of degrading a drug substance and is typically divided in phase I and 
phase II reactions. In general, these reactions serve to convert hydrophobic chemicals into more 
hydrophilic products that can easily be excreted in urine or bile. Phase I reactions are functionalization 
reactions and involve oxidation, reduction and hydrolysis reactions, while phase II reactions are 
conjugation reactions. Many drugs are prone to metabolism by the sequence of phase I then II, while 
others only undergo either of the 2 phases. Drug metabolizing enzymes that catalyze phase I reactions 
include the Cytochrome P450 enzyme family (CYP), alcohol dehydrogenases (ADH), and flavin 
monooxygenases (FMO). Enzymes that catalyze phase II reactions include UDP-
glucuronosyltransferases (UGT), sulfotransferases (SULT), glutathione-S-transferases (GST), N-
acetyltransferases (NAT), and methyltransferases (MT). Phase I reactions mostly result in inactive drug 
metabolites, which no longer exert an effect, while phase II reactions vastly improve water solubility 
and hence ‘excretion’ of the drug. Prodrugs are an exception to this principle, as they require in vivo 
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conversion of the drug substance to the active metabolite in order to be biologically active (e.g. 
carbamazepine, enalapril and oseltamivir). Some metabolites may be as active as their parent drugs (e.g. 
morphine-6-glucuronide and desvenlafaxine), while others are responsible for adverse events (e.g. the 
reactive NAPQI-metabolite of paracetamol) [20-23]. 
The major site of human metabolism is the liver, for both endogenous compounds (e.g. steroid 
hormones, cholesterol, fatty acids, and proteins) as well as exogenous drugs. Circulating drug is 
efficiently exposed to liver cells, which is assured by the liver architecture. About 80% of liver cells, called 
hepatocytes, are responsible for uptake, metabolism, and excretion of drug substance. In addition, upon 
oral delivery, most drugs are absorbed by the gut and taken to the liver through the portal vein. In the 
enterocytes lining the gut wall, high concentrations of drug metabolizing enzymes, such as CYP3A4, are 
present as well. Significant metabolism may occur at these two sites for susceptible drug substrates, 
causing a substantial decrease in the oral bioavailability of these drugs. These two tissues are involved 
in what is called the ‘first-pass effect’ [20]. 
2.3.1 THE CYTOCHROME P450 ENZYME SYSTEM 
The Cytochrome P450 enzyme system (CYP) is the major detoxifying system for the majority of clinically 
used drugs in humans. It is a superfamily, divided into families (by gene family), subfamilies (amino acid 
similarity) and individual enzymes (individual genes). Although most tissues express CYP enzymes, their 
activity and expression is highest in the liver and the intestines. Clinically relevant CYP members are 
indicated in Figure 3, adapted from Zanger et al. [24]. For every relevant CYP enzyme, the relative 
contribution of the enzyme is mentioned, based on data from 248 clinically used drugs. There are a 
number of factors affecting the CYP’s activity or expression, including sex, inflammation, age, interaction, 
and polymorphisms. It is well known that several endogenous compounds, as well as other drugs may 
affect the activity of CYPs (inhibition vs. induction). Polymorphism is the term signifying allelic variation 
resulting in altered enzyme activity or expression. In this way, different ‘phenotypes’ exist in the 
population. Important phenotypic polymorphisms have been described for CYP2B6, CYP2C9, CYP2C19, 
and CYP2D6 [22, 25]. 
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2.3.2 ENZYME ONTOGENY 
In the developing infant, systemic clearance is mainly determined by hepatic and renal elimination 
mechanisms. Hepatic clearance is determined by the efficiency with which metabolic conversions are 
executed. In the first two years of life, there is a dramatic increase in the activity of phase I and II 
reactions, when normalized to milligram of hepatic microsomal protein present. This makes hepatic 
clearance strongly age-dependent. On top of this, this so-called ‘ontogeny’ is different for the different 
phase I and II enzymes and cannot be described by one function (Figure 4) [13, 26, 27].  
In Figure 4, maturation of phase I and II enzymes is subdivided into 3 classes, based on the work of Hines 
et al. [28]. The first class represents enzymes, which are expressed at high levels during prenatal life and 
drop after birth, e.g. CYP3A7, FMO1, SULT1A3. A second class of enzymes show consistent levels 
throughout in utero development and postnatal life, i.e. CYP3A5, SULT1A1, thiopurine 
methyltransferase (TPMT). A third class of enzymes primarily develop after birth, i.e. most CYP and UGT 
FIGURE 3: PIE CHART FROM ZANGER ET AL. [24] INDICATING THE FRACTION OF CLINICALLY USED DRUGS METABOLIZED BY THE DIFFERENT 
CYP ENZYMES AND FACTORS INFLUENCING VARIABILITY. THE 2 MAJOR CYP ENZYMES ARE CYP3A4 AND CYP2D6, WHICH COVER ALREADY 50% 
OF THE METABOLIZED COMPOUNDS. IMPORTANT VARIABILITY FACTORS ARE INDICATED IN BOLD. ARROWS INDICATE THE DIRECTION OF 
POSSIBLE INFLUENCE (↑, INCREASED ACTIVITY; ↓, DECREASED ACTIVITY; ↑↓, INCREASED OR DECREASED ACTIVITY). 
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enzymes [29]. Typically these enzymes will also display increased weight-normalized clearance values, 
compared to adults. 
 
 
 
 
 
 
 
 
FIGURE 4:  THREE CLASSES OF ENZYME MATURATION MAY BE DISCERNED. CLASS 1 REPRESENTS ENZYMES THAT ARE EXPRESSED AT HIGH 
LEVELS DURING PRENATAL LIFE AND DROP AFTER BIRTH, E.G. CYP3A7. CLASS 2 ENZYMES SHOW A CONSISTENT EXPRESSION THROUGHOUT 
PRE- AND POSTNATAL LIFE, E.G. SULT1A1. CLASS 3 ENZYMES DISPLAY A MATURATION PATTERN THAT IS INITIALLY LOW AT BIRTH BUT 
INCREASES THROUGHOUT POSTNATAL LIFE., ADAPTED FROM DE BOCK ET AL. [30] 
 
An update to these developmental classes has already been published by Hines in 2013 [31], and is 
represented in Table 1. Next to the addition of some enzymes (e.g. Carboxylesterases CES1/2), the most 
important update concerns some of the CYP enzymes that have switched from class 3 to class 2 (class 2 
meaning that enzymes show consistent levels throughout pre- and postnatal life, e.g. CYP2C19 and 
CYP3A5). 
 
 
 
 
 
 
TABLE 1: AN UPDATED VISION ON THE CLASSES OF HUMAN HEPATIC DRUG METABOLIZING ENZYME DEVELOPMENTAL TRAJECTORIES., 
REPRESENTED IN FIGURE 4, ADAPTED FROM HINES ET AL. [31]. 
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Moreover, each CYP enzyme seems to have its own individual ontogeny function (Figure 5). As Zanger 
et al. [24] described, individual CYP expression is influenced by a unique combination of genetic 
polymorphisms, induction by xenobiotics, regulation by cytokines and hormones, disease states, as well 
as sex, age, and other factors. Some CYP enzymes are already mature at birth, while others take a longer 
time to develop. The ontogeny profiles in Figure 5 were taken from the Simcyp® M&S platform (Simcyp® 
v14, Certara, CA), which are based on an extensive literature search. Most enzyme ontogeny 
information available to date, is derived from in vitro sources (ex vivo human liver tissue) [31]. Some 
reports, however, noted a potential difference in in vitro vs. in vivo derived maturation functions [32-
34]. The CYP1A2 curve in Figure 5 is an example of an in vivo derived ontogeny function. It increases to 
about 1.6-fold of the adult activity at 2 years of age. Figures 4 and 5 however, need to be interpreted 
with caution, since often times this type of figure is subject to misinterpretation. The y-axis represents 
the fraction of adult activity on the (sub)cellular level, being the ‘maturation’ of cellular differentiation 
and organization. However, ‘growth’, represented by the gain in liver mass, is also affecting the total 
elimination capacity of eliminating organs. Although the latter process is as important as the enzyme-
specific maturation functions, this is not taken into account in this graphic. In essence, this means that 
for e.g. the CYP2C8 liver enzyme, activity at the cellular level is mature around 0.5 years, but the total 
liver size still is only ca.15% of the adult liver size. Taken together, the total hepatic elimination capacity 
of CYP2C8 will still be much lower compared to the adult elimination. This understanding is essential 
when tailoring the drug dose for pediatrics.  
 
 
 
 
 
 
 
 
 
FIGURE 5: OVERVIEW OF THE DIFFERENT MATURATION TRAJECTORIES FOR THE MOST IMPORTANT CYP ENZYMES.  MATURATION FUNCTIONS 
WERE EXTRACTED FROM THE SIMCYP® PBPK PLATFORM, SET UP AFTER AN EXHAUSTIVE LITERATURE RESEARCH 
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The authors hypothesized that this increased CYP1A2 activity might be due to specific hormonal or 
dietary influences [33]. Although in vivo-derived ontogeny is preferred over in vitro ontogeny, the in vivo 
metabolic activity is obscured by protein binding, hepatic blood flow and liver size. Unless these 
physiological parameters are measured in the different individuals, they need to be predicted which 
involves some level of uncertainty. This may eventually be reflected into the ontogeny function [33]. 
Maturation of CYP activity in early life may obscure underlying CYP-specific polymorphisms, described 
for e.g. CYP2C19 and CYP2D6. For CYP2C19, different genotypes result in phenotypically different (poor 
– intermediate – extensive metabolizer) subgroups. Adult patients who are CYP2C19 PM are reported 
to have a higher pantoprazole exposure and a longer elimination half-life. In neonates/infants, a 
significant difference in pantoprazole exposure for CYP2C19 PM could not be detected [35]. However, 
a study conducted in children, from 5 years of age and older, reported pantoprazole plasma 
concentrations that were 6 times higher in CYP2C19 PM. Based on these findings, the pantoprazole drug 
label includes the following statement, “For known pediatric poor metabolizers, a dose reduction should 
be considered” [36]. In contrast, a genotype – phenotype concordance for CYP2D6 could already be 
observed 2 weeks after birth [37]. For atomoxetine and pimozide, a dosage adjustment is also 
recommended in the label whenever this drug is co-administered with a strong CYP2D6 inhibitor or 
given to CYP2D6 PM patients [23, 36]. This means that depending on the maturation half-life and the 
activity difference between PM and EM of a specific CYP enzyme, the polymorphic status is only 
becoming apparent some time after birth. 
When normalizing the clearance per kg bodyweight, an increased clearance capacity of toddlers versus 
adults is often identified [23, 38, 39]. This phenomenon implies that the dose needed, expressed as 
mg/kg, is higher for toddlers compared to adults. To date there has been no compelling evidence 
suggesting increased drug metabolizing enzyme activity. Two possible theories are now postulated. The 
first theory attributes this phenomenon to the ratio of the liver to the total body weight, which is higher 
in children between 2 to 4 years of age [40]. The second theory originates from the allometric principle. 
When dosing mg/kg, in essence a linear scaling is applied to predict a child’s drug dose from adults. 
However, it is well accepted that metabolic weight (BWT0.75) is recommended for extrapolating adult 
drug doses to children [38]. This principle holds true for the different pediatric age categories, except 
for neonates and infants due to ontogeny-related aspects [41]. Dosing issues related to this finding may 
go two directions. On the one hand, underexposure has been reported for the anti-HIV drug efavirenz, 
which was dosed to children on a per kg basis from adult doses. After some years, a PK assessment 
revealed that no less than 40% of efavirenz levels were subtherapeutic for children, dosed following the 
initial WHO guidelines [23]. On the other hand, increased activity of CYP enzymes (CYP3A and CYP1A2) 
may increase the formation of potentially toxic metabolites. This scenario would occur if an increased 
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bioactivation is not accompanied by a corresponding increase in detoxifying capacity (typically 
glutathione conjugation) [39].  
 
2.4 EXCRETION 
An important organ, involved in the excretion of many endogenous compounds and xenobiotics is the 
kidney. Kidney function too is not fully mature at birth and displays a distinct maturation profile. 
Nephrogenesis starts in the embryo at week 5–6 of gestation and is completed at week 36. 
Hemodynamic changes at birth lead to a rapidly rising GFR during the first weeks of life. The adult GFR 
is approached at approximately 6–12 months of age (per unit of body surface area). Maturation in GFR 
has been studied for a long time (e.g. Rubin in 1949), with the most recent effort by De Cock et al. [42]. 
In this study, maturation in GFR was derived from in vivo data in neonates with a model-based approach 
using amikacin as probe substrate. This semi-physiological GFR maturation function was further 
investigated using probe substrates gentamicin, tobramycin and vancomycin [43]. In line with what was 
described in the metabolism section, the renal clearance, expressed as clearance per kg body weight, is 
much higher in toddlers than adults. Consequently, drugs that are primarily renally excreted need a 
higher dose, in mg/kg [44] 
In addition, the active tubular transport process, measured by para-aminohippuric acid (PAH), also 
matures in the first months after birth. This mainly depends on renal blood flow and ontogeny of organic 
anion transporters. There is consensus that maturation of OAT transporters is slower than the GFR 
maturation and reaches adult values around 7 months of age, though the relative contribution of tubular 
secretion might be higher in children aged 3-12 years compared to adults. P-glycoprotein expression 
and function seems to follow maturation in GFR [11, 13]. The third process involved in the renal 
elimination is the tubular reabsorption, which mainly acts as a passive process for xenobiotics, 
determined by their physicochemical properties. In neonatal life, urinary pH is typically lower and may 
influence the reabsorption of acids and bases [45]. It is documented that extreme situations (i.e. 
undernutrition, energy excess, and sustained stress) during perinatal life increase the chances of 
developing chronic kidney disease, hypertension, diabetes mellitus, obesity, and atherosclerosis later 
on in life [46].  
Biliary excretion is a major elimination pathway in which intact drug or glucuronidated metabolites are 
actively transported from hepatocyte into the bile canaliculus. Once released in the intestines, the drug 
may undergo enterohepatic recirculation. Measuring biliary excretion is not often done, since it is 
difficult to do and experimental procedures are often invasive. Therefore, age-related changes are not 
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well documented for this elimination route and it is highly unlikely that this situation would change in 
the near future [47, 48]. Key transporters involved in the transport of drugs from hepatocytes in to the 
bile canaliculus, are P-glycoprotein (P-gp), multidrug resistance–associated protein 2 (MRP2), and breast 
cancer resistance protein (BCRP). The abundance of transporter proteins appears to be lower compared 
to adults [19, 49], although the impact on biliary excretion remains uncertain. However, a very recent 
study from Johnson et al [48] applied a ‘bottom-up’ approach to assess the maturation of these key 
transporters, using ‘top-down’ data from dedicated probe substrates. In general, biliary excretion 
appears to develop rapidly and reaches adult capacities soon after birth. The authors conclude that this 
finding is in line with recent reports on transporter ontogeny in humans, although a lot of contradictory 
information is present as well. 
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3 CURRENT TECHNOLOGIES USED IN PEDIATRIC DRUG RESEARCH 
The challenges and limitations associated with determining the correct dose for pediatric use, together 
with the scarcity of clinical studies supporting pediatric indications and labeling, created a public 
awareness that safe and efficacious drug therapy for children is largely lacking. By the different 
regulatory authorities in the U.S. and E.U., legislative frameworks as well as financial incentives were 
adopted to push pediatric drug development forward. Parallel to the increased interest in pediatric 
research, pharmaceutical industry committed to implement model-based drug development in its drug 
development programs. Modelling and simulation are two different techniques but are always 
mentioned in conjunction (as M&S), since they are always combined in model-based drug development. 
‘Modelling’ comprises the mathematical description of the behavior of a biological process or system 
under consideration. ‘Simulation’ indicates the application of the constructed model to explore other 
situations, initially not used to build the model. M&S aligns hypotheses and experimental observations 
while transitioning from a pharmacotherapeutic problem to its solution (Figure 6). It fulfills, as Sheiner 
stated [50], a so-called ‘learn-confirm’ paradigm and by consequence, offers a way to transcend 
empiricism in drug research. [51-53]. The modelling approaches used in pediatric model-based drug 
development can be divided into two distinct but complimentary domains: a ‘top-down’ and a ‘bottom-
up’ approach. 
 
 
 
 
 
 
 
 
 
 
FIGURE 6: TRANSITING FROM PHARMACOTHERAPEUTIC PROBLEM TO SOLUTION BY THEORETICAL REASONING AND CLINICAL EXPERIMENTS, 
INTERCONNENCTED BY MODELLING & SIMULATION [51] 
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3.1 TOP-DOWN APPROACH 
3.1.1 BACKGROUND 
The top-down approach has the longest track record in PKPD drug development. Based on observed 
data (e.g. plasma or biomarker concentrations, clinical signs, …) from actual healthy volunteers or 
patients, the modeler takes an assumption in the form of a mathematical description (model) that is 
fitted to the data. The most common top-down approach is the compartmental pharmacokinetic 
analysis. The description of how the drug is absorbed and distributed in the human body is simplified in 
terms of a number of hypothetical or ‘lumped’ compartments (Figure 7). They mostly have no 
physiological meaning but are appropriate to describe the evolution of plasma concentrations as a 
function of time after dosing [54] . 
 
 
 
 
 
 
In compartmental pharmacokinetics, there are mainly 2 approaches: the standard two-stage (STS) 
approach and the population pharmacokinetic (popPK) approach. In the STS approach, individual PK 
parameters are estimated subject-by-subject and then summarized as means with their associated 
spread. A weakness of this approach is that it needs intense sampling in all subjects and the observed 
variability cannot be assigned to either inter-individual variability (IIV) or residual unexplained variability 
(RUV). IIV is the true variability originating from differences in PK parameters between different subjects, 
while RUV is the random noise that consists of variability within one subject, measurement error, 
bioanalytical error, or model misspecification. In population PKPD models, the structural model 
component (i.e. the compartmental model) is supplemented with a stochastic, and a covariate model 
component. The stochastic model describes the variability (or random effects) in the observed data and 
allows to distinguish the IIV on different PK parameters from the RUV. Finally, in the covariate model, 
FIGURE 7: REPRESENTATION OF A SIMPLE TWO-COMPARTMENTAL MODEL. DRUG IS ASSUMED ABSORBED INTO THE CENTRAL 
COMPARTMENT, REVERSIBLY DISTRIBUTED TO THE PERIPHERAL COMPARTMENT AND ELIMINATED (METABOLISED AND/OR EXCRETED) FROM 
THE CENTRAL COMPARTMENT, ADAPTED FROM ROWLAND TOZER [45] 
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the IIV on some estimated PK parameters might be explained by variables, related to the studied 
subjects, e.g. weight, height, age, sex, race, genotype (the fixed effects) [55, 56]. In essence, population 
PKPD models are non-linear mixed-effects models that attempt to assign observed variability in the 
observations to random effects (IIV and RUV) and fixed effects (covariates). In pediatric research, ethical 
and practical constraints limit the volume and number of PK samples that one can draw, often leaving 
no choice but sparse, unbalanced, and fragmented sampling schemes. However, the population 
approach is a data-driven approach and is based on a simultaneous analysis of all data of the entire 
population, while still accounting for the fact that different observations come from different patients. 
Therefore, it is the method of choice for analyzing pediatric pharmacokinetic data [57, 58]. 
3.1.2 CLEARANCE ESTIMATION IN PEDIATRICS 
Drug clearance may be seen as the most important pharmacokinetic parameter determining 
pharmacological response [26, 27]. It determines the exposure after a single intravenous dose, as well 
as the steady-state plasma concentration after i.v. infusion/multiple i.v. doses. Given the importance of 
this parameter, it is often used to extrapolate the dose in the pediatric age range [59]. 
In defining appropriate functions to describe clearance maturation across the pediatric age range, 
mainly 3 different approaches are distinguished: allometric scaling, allometric scaling with maturation 
functions, and systematic covariate analysis. Allometry, in biology, is a concept that links size to a 
physiological process (e.g. metabolic rate, GFR, cardiac output). In PK, it is used to estimate or predict 
the evolution of a certain PK parameter with bodyweight. In population PK, an allometric relationship is 
built into the model using the following equation : 
𝜃𝑖 = 𝜃𝑠𝑡𝑑 ∗ (
𝐵𝑊𝑖
𝐵𝑊𝑠𝑡𝑑
)
𝑒𝑥𝑝
 
EQUATION 1 
 Where  is a PK parameter of interest (e.g. clearance (CL), volume of distribution (Vd), or half-
life) for the individual i. The individual PK parameter is assumed to be related to the standardized 
population parameter (std) multiplied with the ratio of individual (BWi) and standardized bodyweight 
(BWstd, i.e. 70 kg). The exponent of this ratio (exp) may be fixed, based on theoretical principles, or 
estimated directly from the data. For scaling drug clearance from adults to children, the fixed exponent 
is assumed to be 0.67 or 0.75, based on the universal relationship between basal metabolic rate and 
body surface area or bodyweight, respectively [59, 60]. The estimation of the allometric exponent 
directly from the data, which may change across the age range, is more data-driven and does not 
assume an a priori value for the allometric exponent. Some authors reported on issues regarding 
pediatric extrapolation for drug clearance using a single fixed exponent for the complete pediatric age 
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range, especially in neonates and infants [61, 62]. In their vision, when using a fixed or single allometric 
exponent for BW, an additional age-related exponential or sigmoidal maturation function is required 
that accounts for the maturation in early life. Here again some issues have arisen with the predictive 
performance of these models, and the inclusion of 2 collinear covariates (BW and age) in the model 
structure [63, 64]. In a systematic covariate analysis, no a priori relationship between a covariate and 
the drug clearance is assumed. It is a much cleaner data-driven approach in which empirical Bayes 
estimates (the individual parameter estimates in non-linear mixed effects are estimated using Bayesian 
methodology) are plotted against different covariates (if shrinkage allows), in order to obtain the most 
appropriate covariate relationship for drug clearance. There is some evidence that the covariate 
relationships, estimated this way, would be applicable across drugs sharing the same metabolic 
pathways [65]. This finding, however, still does not make allometry the method of choice for clearance 
extrapolations to children. 
3.2 BOTTOM-UP APPROACH 
3.2.1 BACKGROUND 
The bottom-up approach is relatively new to this specific area, but has gained a lot of interest from 
regulators, academia and industry [66]. The general concept is to mathematically describe the relevant 
underlying physiological, physicochemical, and biochemical processes that explain the observed 
pharmacokinetic behavior in clinical studies. In order to do so, bottom-up physiologically-based 
pharmacokinetic (PBPK) models make an a priori distinction between the properties of the organism or 
‘system’ and those of the drug. Regarding the system’s properties, the anatomical structure of a human 
body is represented by physiologically relevant compartments that are interconnected via the blood 
circulation (Figure 8)  
Every tissue is represented by a single compartment, supplied by the arterial blood and debouching in 
the venous blood pool. Only the lung is an exception, which is supplied by the venous blood. The 
differential equations describing (reversible) drug (mass) transfer from and to the tissues are derived 
from the law of mass action. In specific organs (by default liver, kidney, and intestines), the drug may be 
eliminated from the tissue, hence an extra term in the differential equation should account for the 
disappearance of mass over time. The differential equations below exemplify the mass balance principle 
from plasma to a perfusion rate-limited tissue without (equation 2) and with (equation 3) elimination 
[67, 68]. 
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𝑉𝑡 ∗
𝑑𝐶𝑡
𝑑𝑡
= 𝑄 ∗ (𝐶𝑎𝑟𝑡 −
𝐶𝑡
𝐾𝑝
) 
EQUATION 2 
𝑉𝑡 ∗
𝑑𝐶𝑡
𝑑𝑡
= 𝑄 ∗ 𝐶𝑎𝑟𝑡 − 𝑄 ∗
𝐶𝑡
𝐾𝑝
− 𝐶𝑙𝑖𝑛𝑡𝑢 ∗
𝐶𝑡 ∗ 𝑓𝑢𝑝
𝐾𝑝
 
EQUATION 3 
 Where Vt is the tissue volume, dCt/dt the change of the tissue concentration over time, Q the 
tissue perfusion, Cart the arterial concentration, Ct the tissue concentration, Kp the tissue-plasma 
partition coefficient, fup the unbound fraction in plasma, and CLintu the unbound intrinsic clearance. 
FIGURE 8: GENERIC PBPK MODEL STRUCTURE 
THAT REPRESENTS EVERY TISSUE AS A SINGLE 
COMPARTMENT. COMPARTMENTS IN RED ARE 
INVOLVED IN ORAL DRUG ABSORPTION, AND IN 
BLUE THE COMPARTMENT INVOLVED IN BILIARY 
EXCRETION TO THE SMALL INTESTINE 
(ENTEROHEPATIC RECIRCULATION). ALL 
COMPARTMENTS (BLACK, RED, BLUE) ARE 
INVOLVED IN DISTRIBUTION. ELIMINATION MAY 
OCCUR FROM THE SMALL AND LARGE 
INTESTINE, LIVER AND KIDNEY COMPARTMENTS. 
FIGURE ADOPTED FROM WILLMANN ET AL. [69] 
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On top of the anatomical structure depicted in Figure 8, tissues are provided with tissue-specific 
properties derived from physiological knowledge pertaining to e.g. tissue volumes and composition, 
cardiac output to the tissues, surface area, intracellular pH, etc. Tissues may even be divided into cellular 
and subcellular spaces, as far as the physiological knowledge is available to do so and depending on the 
level of detail required to get reliable bottom-up predictions. This is often done for liver tissue as a drug’s 
(sub)cellular location may influence its transport or elimination [67, 69]. 
In parallel, drug-specific properties should be provided, which create a molecular fingerprint for in silico 
bottom-up simulation of the expected PK behaviour. Table 2 provides an overview of drug-specific 
parameters, necessary for bottom-up predictions. Some parameters may be obtained from in vitro 
assays, e.g. permeability from Caco-2 or Vmax/Km from metabolism assays [70, 71]. Others may be 
predicted in silico from published models, e.g. microsomal binding from physicochemistry [72, 73].  
TABLE 2: DRUG-SPECIFIC PARAMETERS THAT ARE USED AS DRUG-RELATED INPUT FOR PBPK MODELLING AND SIMULATION PLATFORM 
Drug-specific parameter Description 
B:P Blood-to-plasma ratio 
fup Fraction unbound in plasma 
KD Dissociation constant from binding proteins 
P*SA Permeability-Surface Area product 
logP Lipophilicity 
MW Molecular Weight 
pKa Acid dissociation constant 
S Solubility in reference medium 
CLint Intrinsic elimination clearance 
Km Vmax Michaelis-Menten kinetic constants 
 
In the next step, information on the ‘system’ and the ‘drug’ is integrated into a very specific set of models 
that yield essential parameters, which represent the interaction of the drug with the system. These 
parameters are incorporated in the differential equations and govern the disposition of the drug in the 
in silico organism. Tissue-to-plasma partition coefficients (Kp) are calculated based on the compound’s 
physicochemistry and the tissue’ composition. Kp’s determine the extent of distribution to each tissue, 
as illustrated in equations 2 and 3, and may be derived using a variety of published methodologies by 
e.g. Rodgers [74, 75], Poulin [76], Schmitt [77]. The choice of method depends on the compound’s 
physicochemical properties and the assumptions underlying these models. For example, the Rodgers 
and Rowland distribution model was well-suited to predicted tramadol volume of distribution, since it 
1 
 24 
takes into account the electrostatic interactions of positively-charged basic amines and negatively-
charged phospholipids in biological membranes. The intrinsic liver clearance (CLintH) is calculated based 
on the drug’s in vitro metabolism parameters (Km, Vmax, CLint), the in vivo abundance of the 
responsible liver enzymes and the overall liver architecture. CLintH is the determinant of liver clearance 
and, as illustrated in equation 3, determines the loss of mass from the system [78]. More information 
on how to obtain in vitro metabolism parameters from in vitro assays is provided in the section ‘In vitro-
to-in vivo extrapolation’. 
Although drug distribution and elimination are strictly separate processes, their prediction depends on 
a given set of physiological parameters. Given the naturally occurring variation in the physiological 
parameters, e.g. organ volumes, blood flows, enzyme abundances, etc. in a given population, this 
information can be used to create physiologically plausible variability in the bottom-up predictions of 
drug distribution and elimination. The most attractive concept of the bottom-up approach is, that it 
allows to predict changes in drug PK that are due to physiological variation. Therefore, with the 
increasing availability of physiological information for specific subpopulations, such as pediatrics, 
geriatrics, cirrhotic or renally impaired patients, PBPK creates a scientific platform and stimulates 
integrated research in these populations. It enables the mechanistic exploration of the effect of 
physiology on drug disposition and allows to simulate any ‘what-if’ scenarios to anticipate the drug’s 
behavior in vulnerable patient populations. In the context of pediatrics, PBPK is ideally positioned to 
integrate the a priori known physiological and biochemical changes occurring in childhood into a 
meaningful model to predict ADME changes with age. PBPK makes pediatric clinical trials ‘confirmatory’ 
rather than ‘exploratory’ [79-81]. 
3.2.2 IN VITRO-TO-IN VIVO EXTRAPOLATION OF DRUG CLEARANCE 
In order to assess the rate at which a drug compound is metabolized in vitro and to identify the 
responsible enzymes involved, metabolism parameters CLint/Vmax/Km can be estimated from in vitro 
studies mainly using human liver microsomes, hepatocytes or recombinantly expressed enzymes. 
Human hepatocytes are regarded as the gold standard for the prediction of human drug clearance, since 
they possess the whole armamentarium of enzymes and transporters participating in the hepatic 
clearance of most drugs and represent the most relevant system physiologically. However, given the 
low enzyme selectivity of this in vitro model, human liver microsomes (HLM) or human recombinantly 
expressed enzyme systems (rhCYP) may be used instead. HLM are obtained by differential 
centrifugation of liver homogenate and only contain enzymes present in the endoplasmic reticulum, i.e. 
CYPs, Flavin monooxygenases (FMO) and UDP-glucuronosyltransferases (UGT). Recombinant enzyme 
systems are microsomes prepared from systems (mostly insect cells) infected with a virus (baculovirus) 
engineered to express a specific CYP enzyme. Although these subcellular systems may add to the 
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uncertainty of extrapolation to the in vivo situation, the system’s complexity is lower and the enzyme 
selectivity higher. Therefore, these systems allow a more accurate assessment of a particular enzyme’s 
involvement [70, 82, 83]. 
Michaelis-Menten parameters Km and Vmax may be estimated by fitting a non-linear regression model 
to the in vitro clearance rate (metabolite formation or substrate depletion) as a function of the substrate 
concentration (equation 4). Alternatively, the intrinsic clearance (CLint) may be estimated at substrate 
concentrations well below the Km (equation 5). This is often done in high-throughput analyses when 
only one low substrate concentration is incubated to provide an estimate of the maximal enzyme 
efficiency (CLint). In this setting, data do not allow to estimate Km and no information is available 
regarding when the substrate concentration will start to saturate the enzyme under study [80].  
𝐶𝐿𝑖𝑛𝑣𝑖𝑡𝑟𝑜 =
𝑉𝑚𝑎𝑥
𝐾𝑚 + [𝑆]
 
EQUATION 4 
𝐶𝐿𝑖𝑛𝑡 =
𝑉𝑚𝑎𝑥
𝐾𝑚
      𝑖𝑓 [𝑆] ≪ 𝐾𝑚 
EQUATION 5 
Subsequently, in vitro metabolism parameters may be extrapolated to an in vivo hepatic clearance by 
multiplication with the total abundance of each enzyme in the liver, the so-called in vitro-to-in vivo 
extrapolation (IVIVE). It is important to correct the Km for microsomal drug binding using the unbound 
fraction in the assay (fumic), since only the unbound drug can be metabolized. equation 6 and 7 represent 
the calculation of the unbound hepatic intrinsic clearance (CLintH,u) from in vitro estimated Vmax/Km 
values in HLM and rhCYP, respectively. 
𝐶𝐿𝑖𝑛𝑡𝐻,𝑢 = [∑ (
𝑉𝑚𝑎𝑥
𝐾𝑚 ∗ 𝑓𝑢𝑚𝑖𝑐
∗ 𝐶𝑌𝑃𝑗 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒)
𝑛
𝑗=1
] ∗ 𝑀𝑃𝑃𝐺𝐿 ∗ 𝑙𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 
EQUATION 6 
𝐶𝐿𝑖𝑛𝑡𝐻,𝑢 = [∑ (𝐼𝑆𝐸𝐹𝑗 ∗
𝑉𝑚𝑎𝑥
𝐾𝑚 ∗ 𝑓𝑢𝑚𝑖𝑐
∗ 𝐶𝑌𝑃𝑗 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒)
𝑛
𝑗=1
] ∗ 𝑀𝑃𝑃𝐺𝐿 ∗ 𝑙𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 
EQUATION 7 
 Where j represents each of the n CYPs, CYPj abundance the in vivo abundance of each of the n 
CYP enzymes, the MPPGL the microsomal protein per gram liver, and the ISEF the inter-system 
1 
 26 
extrapolation factor; a scaling factor that compensates for any difference in the activity per unit of 
enzyme between recombinant systems and hepatic enzymes. The resulting hepatic intrinsic clearance 
is now ready to be implemented in the differential equations from the PBPK model. The liver may be 
considered to act as a well-stirred compartment interacting with parameters describing liver blood flow 
and fraction unbound in plasma (dynamic well-stirred liver model). The static form of the well stirred 
liver model is well-known and is represented in equation 8 [84-86].  
𝐶𝐿𝐻 =
𝑄𝐻 ∗ 𝑓𝑢𝑝 ∗ 𝐶𝐿𝑖𝑛𝑡𝐻,𝑢
𝑄𝐻 + 𝑓𝑢𝑝 ∗
𝐶𝐿𝑖𝑛𝑡𝐻,𝑢
𝐵: 𝑃
 
EQUATION 8 
 Where QH represents hepatic blood flow, fup the unbound fraction in plasma, CLintH,u the 
unbound hepatic intrinsic clearance, and B:P the blood-to-plasma ratio. Alternatively, the parallel tube 
or dispersion model for the liver may be used, although their mathematical complexity is higher. 
Moreover, the difference between the well-stirred and the other hepatic liver models is only apparent 
for intermediate to high extraction compounds [82, 87]. 
3.2.3 CLEARANCE PREDICTION IN PEDIATRICS 
In the bottom-up prediction of drug clearance, the knowledge of physiological changes occurring in 
childhood is essential in the prediction of the clearance evolution across the pediatric age span. In 
predicting the drug clearance within the context of PBPK modelling and simulation, a rigorous workflow 
should be followed for the successful construction of an adequate pediatric PBPK model (Figure 9). First, 
an adult PBPK model needs to be developed, and then iteratively verified and refined. Verification of 
the model predictions is accomplished by using the results from in vitro ADME experiments and clinical 
studies. In this model, the different relevant drug disposition pathways need to be captured and sources 
of variability understood even before this model is to be used for pediatric predictions. In the next step, 
the pediatric drug clearance is predicted by the PBPK platform by using the drug-specific information, 
which has been verified in adults in the first step, and the pediatric physiology in an integrated, 
mechanistic framework. Then, the pediatric PBPK model should be verified and refined using the 
available pediatric data. Verification may be obtained i) by comparing PK parameters from top-down (in 
vivo) and bottom-up (PBPK) methodologies, or ii) by comparing observed and predicted plasma 
concentration-time profiles. Depending on the age group, one or the other approach may be used (e.g. 
sparsely sampled infants may provide popPK-estimated PK parameters which can be compared to PBPK-
predicted ones). In adequate pediatric microdosing studies, PK parameters are informative about the 
drug’s disposition at therapeutic doses [88]. Possible mismatches between PBPK-predicted and 
estimated in vivo clearances may guide subsequent experiments, i.e. the ‘learning-confirming’ paradigm 
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should be followed. Relevant pathways, specific to pediatrics, may be identified or 
anatomical/physiological variables carrying a high degree of uncertainty in the pediatric population may 
be adjusted to match the observed data. Additional drug-specific PBPK investigations may then confirm 
these anatomical/physiological variables [3, 71]. The incorporation of pediatric, and by extension any 
subpopulation’s physiological information in such PBPK M&S platforms is a time and resource-costly 
task. However, once created, this population library can be used repeatedly for any drug under any 
study design. Moreover, libraries can be updated and expanded as the knowledge of the system 
improves [89].  
 
FIGURE 9: RIGOROUS WORKFLOW TO SET UP A PEDIATRIC PBPK MODEL. FIRST, THE PBPK MODEL NEEDS TO BE DEVELOPED, VERIFIED AND 
REFINED IN ADULTS. IN THE NEXT STEP, THIS VERIFIED PBPK MODEL IS USED TO MECHANISTICALLY PREDICT PEDIATRIC PK. VERIFICATION OF 
THE PEDIATRIC PBPK PREDICTIONS WITH OBSERVED PEDIATRIC DATA IS NECESSARY. THE FURTHER REFINEMENT OF THIS MODEL MAY BE 
NECESSARY IN THE SIMULATION OF CLINICAL TRIALS OR DIFFERENT DOSING SCENARIOS, ADAPTED FROM LEONG ET AL. [3] 
 
To date, there are several PBPK M&S platforms commercially available (Simcyp® by Certara, PK-Sim® by 
Bayer, Gastroplus® by SimulationsPlus) that allow end-users (PKPD scientists) to put in experimentally 
determined drug-specific data and simulate the PK(PD) for a given drug in virtual patient populations 
that are built from system-specific information. These tools are provided as platforms on which a user-
defined PBPK model can be constructed by combining building blocks in an appealing graphical user 
interface.  
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4 STATE-OF-ART BOTTOM-UP CLEARANCE PREDICTION IN CHILDREN AND FOCUS 
OF THIS DISSERTATION 
The area in which PBPK models may really provide added value is for children below 2 years of age, i.e. 
neonates/infants. Typically in the first 2 years of life, processes ‘maturation’ and ‘growth’ occur side-by-
side, impacting drug clearance in such a way that a single allometric exponent is no longer appropriate 
[59]. Given their physiological nature, PBPK models predict the changing elimination capacity based on 
the knowledge of the changing biology/physiology in these early years. PBPK models that successfully 
predict changes in the pediatric clearance for several drugs from very early life to adulthood, were 
published. Influential publications were provided by Johnson et al. [90] for 11 drugs (midazolam, 
caffeine, carbamazepine, cisapride, theophylline, diclofenac, omeprazole, S-warfarin, phenytoin, 
gentamicin, and vancomycin) and Edginton [81] for a training set of 8 (gentamicin, isepamicin, alfentanil, 
midazolam, caffeine, ropivacaine, morphine, lorazepam) and a test set of 6 drugs (fentanyl, theophylline, 
acetaminophen, ciprofloxacin, lidocaine, buprenorphine) after i.v. administration. Although both 
publications contrast bottom-up clearance predictions with observed pediatric clearances, both share 
a similar weakness. Predicted and observed total clearances are compared, even if the compounds were 
eliminated by different pathways. Hence, biases in pathway-specific contributions may cancel out in the 
predicted total clearance. The consequence is that if these models are to be used for situations in which 
the renal or metabolic route is impaired, the predicted clearance may be completely erroneous since 
the underlying contributions could be incorrect. Therefore, an in-depth analysis of different pathways 
involved in the bottom-up prediction and top-down estimation of the clearance is provided in this work. 
To this end, tramadol was used as the model compound. Tramadol is an excellent probe substrate 
because of 3 reasons. First, tramadol is clinically implemented as an analgesic drug, used over the entire 
pediatric age range from premature neonates to adults. Moreover, relatively much data is available 
coming from tramadol’s clinical use in the pediatric population. The analgesic effect of tramadol is 
mediated through noradrenaline re-uptake inhibition, increased release of serotonin, and decreased re-
uptake of serotonin in the spinal cord [91]. Concerning the opioid effect, tramadol itself has weak -
opioid activity (~6000 times weaker than morphine), but the CYP2D6 metabolite, O-desmethyltramadol, 
has a -opioid-receptor affinity approximately 300 times larger than tramadol [92]. Consequently, 
CYP2D6 poor metabolizer status is highly correlated with an increased non-response rate to pain 
medication, making individualized treatment highly necessary [93]. Second, the different pathways 
involved in the disposition of tramadol include a renal component, as well as CYP enzymes CYP2D6, 
CYP3A4, and CYP2B6. As was already outlined in the section on pediatric ADME, these are relevant 
disposition routes for the majority of drugs. By investigating the ontogeny and activity of tramadol’s 
disposition routes in a PBPK-M&S environment, indirectly the prediction of many drugs, eliminated by 
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at least one of these disposition routes, will be enhanced. Third, given the low hepatic extraction of 
tramadol, its in vivo hepatic clearance is sensitive to changes in the activity of the involved CYP enzymes. 
Any alterations in CYP activity will be reflected in the hepatic clearance, e.g. immature clearance in 
pediatrics, and CYP2D6 poor-extensive metabolizers. Taken all together, tramadol is well-suited to 
investigate pediatric bottom-up clearance maturation, particularly focusing on children below 2 years 
of age.   
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5  PKPD OF TRAMADOL 
5.1 INTRODUCTION 
In this PhD dissertation, tramadol is the model compound that allowed us to investigate the maturation 
of CYP2D6 and renal clearance from birth to adulthood. Tramadol is a centrally acting analgesic drug, 
which is structurally related to morphine and codeine. It is known to exhibit enantioselective 
metabolism and pharmacodynamics properties. Tramadol has weak µ-opioid activity and inhibits 
serotonin and norepinephrine reuptake, thereby inhibiting pain transmission in the spinal cord. O-
desmethyltramadol, the CYP2D6 metabolite of tramadol, has a µ-opioid activity 300-times higher than 
that of tramadol. It was first registered as analgesic drug in Germany in 1977, and later on in the UK 
(1994) and US (1995) with many other countries to follow. Given the unique PD profile of this drug, it 
has been classified as a nontraditional centrally acting analgesic by the FDA. This section aims to provide 
a brief overview of the PKPD properties of this drug and its clinical implementation, with a focus on 
pediatrics. The reason why tramadol was chosen as a model compound is discussed in section 4 “State-
of-art bottom-up clearance prediction in children and focus of this dissertation”.  
5.2 PHYSICOCHEMICAL INFORMATION 
Tramadol, or (1RS,2RS)- 2-[(dimethylamino)methyl]- 1 -(3-methoxyphenyl)- cyclohexanol has a 
molecular weight of 263.4 g/mol and is depicted alongside its metabolites in Figure 10. It is a weak base 
with a pKa of 9.41, which makes that tramadol is ionized and caries a positive charge on its amine residue 
at physiological pH. The logP-value is 1.35, showing a moderate tendency of tramadol towards the lipid 
phase. Tramadol has 2 chiral centers and is formulated as racemic mixture, mostly as the tramadol 
hydrochloride salt [94]. 
5.3 PHARMACOKINETICS 
5.3.1 ABSORPTION  
Tramadol is formulated as a solution for injection, immediate and sustained release capsules, drops, 
and suppositories for different administration routes (intravenous, intramuscular, subcutaneous, and 
per os). After a single oral dose, tramadol attains a bioavailability of 70%, and is subject to first-pass 
metabolism. Upon multiple administration the bioavailability reaches 90-100%, probably due to 
saturation of first-pass metabolism. Plasma concentrations and AUC increase linearly over a dose range 
of 50-400 mg. No food effect was observed in tramadol’s PK. Bioavailability of tramadol in drops with 
or without ethanol, remains similar. After rectal administration, absolute bioavailability is higher, 
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probably due to (partial) avoidance of first-pass. Intramuscular injection and infusion are bio-equivalent 
[92, 95-97]. 
 
 
 
 
 
FIGURE 10: MOLECULAR STRUCTURE OF TRAMADOL AND ITS PRIMARY PHASE I METABOLITES O-DESMETHYLTRAMADOL (ODT), N-
DESMETHYLTRAMADOL (NDT), AND THE SECONDARY NODT (N,O-DIDESMETHYLTRAMADOL). 
 
5.3.2 DISTRIBUTION 
Tramadol displays extensive tissue distribution and distributes widely throughout the body, especially 
in the lungs, spleen, liver, kidneys and brain. This is readily observed by the initial drop in tramadol 
plasma concentrations after an i.v. bolus dose (Figure 11), leading to a typical two-compartmental 
pharmacokinetic profile. The volume of distribution is estimated at 210 L for a 70 kg individual. Due to 
the fact that tramadol is a weak base, many charge-charge interactions are possible between tramadol 
and the constituents of biological membranes, i.e. acidic phospholipids. In addition, weak bases tend to 
accumulate intracellularly (and in lysosomes in particular) because of the more acidic pH at the 
intracellular side of the cell membrane.  
Plasma protein binding for tramadol is reported to be 20% of the total tramadol plasma concentration 
and typical plasma concentrations are in the region of 5 to 10 µM (1.3 to 2.6 µg/mL). In addition, in vitro 
studies indicate that tramadol and its metabolite, O-desmethyltramadol (ODT), are substrates for OCT 
transporters. However, tramadol plasma concentrations in vivo are unaffected by the OCT1-genotype, 
while ODT concentrations are [92, 98]. 
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FIGURE 11: SEMILOGARITHMIC PLOTS OF TRAMADOL, ODT, AND NDT MEAN PLASMA CONCENTRATION VS. TIME PROFILES AFTER A 
100MG RACEMIC TRAMADOL I.V. DOSE, ADAPTED FROM GARCIA QUETGLASS, ET AL. [99]. 
 
5.3.3 EXCRETION 
Ninety percent of a tramadol dose (unchanged tramadol and metabolites) may be traced back in urine, 
while only 10% is excreted via the faeces. The kidney accounts for 25% of the tramadol plasma clearance 
that is mainly governed by glomerular filtration. Tramadol has an extensive metabolite profile (23 
metabolites from phase I & II reactions have been identified in man) but is considered a low clearance 
drug [100]. The plasma clearance is 30 L/h, of which 75% is hepatically cleared. The metabolism of 
tramadol to its primary metabolites, ODT and N-desmethyltramadol (NDT), is governed by CYP enzymes. 
In vitro metabolism studies of tramadol indicated that CYP2D6, CYP3A4 and CYP2B6 are mainly 
responsible for tramadol phase I metabolism. As indicated in Figure 10, Tramadol metabolism to ODT is 
mainly governed by CYP2D6, while the N-demethylation to NDT is governed by CYP2B6 and CYP3A4. 
There is a common secondary metabolite as well, N,O-didesmethyltramadol (NODT), although its 
formation is believed to be mainly driven by CYP2D6 from NDT [100-102]. The formation of ODT is slow 
in vivo, with reported Tmax values of 1.4h later than tramadol Tmax. The half-lives of the metabolites 
ODT and NDT are similar to the one of tramadol, making the metabolites kinetics formation-rate 
dependent [92]. 
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CYP2D6 is an enzyme known to exhibit genetic polymorphisms, leading to different phenotypes in the 
patient population. Poor metabolizers have two null-alleles leading to a non-functional CYP2D6 protein, 
while intermediate and extensive metabolizers have at least one allele that leads to functional CYP2D6. 
Ultra-rapid metabolizers even have more than two alleles. This phenotypic variation does not only lead 
to a difference in tramadol clearance in the population, it also results in pharmacodynamic variation 
since the CYP2D6 metabolite has stronger opioid activity than tramadol itself (see later) [25, 93].  
In addition, tramadol displays stereoselective metabolism. The O-demethylation appeared to be 2-fold 
greater for (-)-tramadol than for (+)-tramadol. On the other hand, N-demethylation occurs faster for the  
(+)-enantiomer. The kidney preferably eliminates (-)-tramadol and (+)-ODT. In terms of total exposure, 
the AUC for (+)-tramadol and (+)-NDT is greater than the AUC for their (-)-enantiomers [92].  
5.4 PHARMACODYNAMICS 
Tramadol possesses a moderate affinity for the µ-opioid receptor. Compared to morphine and codeine, 
tramadol’s affinity is respectively 6000- and 10-times lower. In a way, tramadol may be considered a 
prodrug since the metabolic reaction via CYP2D6 releases the ODT metabolite that has 300-times more 
affinity for the µ-opioid receptor than tramadol itself. The CYP2D6-polymorphism has led to the 
observation that treatment efficacy in vivo is associated with CYP2D6 genotype [93]. In addition, 
tramadol also inhibits the neuronal reuptake of norepinephrine and serotonin, neurotransmitters 
involved in antinociceptive effects of the descending inhibitory pathways of the central nervous system. 
This dual mode of action provides tramadol its status of nontraditional centrally acting analgesic. 
Stereoselectivity is also observed in tramadol’s mechanism of action. (+)-Tramadol binds to the µ-opioid 
receptor with a 20-fold higher affinity than (-)-tramadol. In addition, (+)-tramadol mainly blocks 
serotonin reuptake, while (-)-tramadol is the main blocker for norepinephrine reuptake [92, 103]. 
5.5 TRAMADOL CLINICAL USE 
Tramadol is mainly used in patients, suffering from postoperative pain. It is effective in providing 
adequate analgesia in acute pain, being superior to placebo in many studies. In some cases however, 
tramadol’s analgesic effects are not distinguishable from placebo, depending on the baseline pain 
intensity. Therefore, tramadol may be combined with other analgesics (e.g. paracetamol, or dipyrone) 
to broaden its clinical applications [92, 104]. Oral or intravenous tramadol administration may be 
preferred, since intramuscular injection is painful and the absorption may delay Tmax, thereby 
hampering fast pain relief. Tramadol shares some common features of opioids as typical adverse events 
include nausea and vomiting. However, a major advantage of tramadol over opioids is that it minimally 
affects respiratory function, making it an often-used analgesic drug in children for moderate to severe 
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pain. In addition, given the pathways involved in its elimination, impairment of one route will not directly 
lead to safety concerns, as the others take over. However, in patients suffering from severe liver 
cirrhosis or renal failure, the drug dose should be adapted.  
5.6 TRAMADOL PKPD IN PEDIATRICS 
Earlier reports claiming there is no age-dependency in tramadol’s PK [92, 105] are contradicted by new 
insights in the field. A study by Allegaert et al [106] pooled the available pediatric and adult studies that 
describe tramadol disposition after i.v. administration. The raw data from different individual authors 
was gathered and used to construct a population PK model. Differences in pediatric tramadol and ODT 
PK vs. adults are mainly explained by weight and age differences, requiring the use of an allometric 
exponent when extrapolating from adult data. The tramadol clearance that is attributable to CYP2D6, is 
even considered to mature in very early life and reaches 50% of the adult-normalized value at 39.8 
weeks PMA, i.e. shortly before term birth. Thereafter, mainly the increase in body weight explains the 
increasing clearance of tramadol. The maturation in renal function occurs slower (50% of adult-
normalized activity at 47.7 weeks), so that clearance of the ODT metabolite as well as tramadol urinary 
excretion is delayed in early life as compared to the CYP2D6 maturation. In the Allegaert study, it could 
be estimated that in subjects with low CYP2D6 activity, the formation clearance of ODT was 19.4% of 
that in extensive metabolizers at the population level. In this analysis, not more than two phenotypic 
groups could be identified, i.e. poor and extensive metabolizers. It should be noted, however, that the 
formation and elimination of ODT in this analysis is considered to be the result of CYP2D6 activity and 
renal filtration. Information regarding the influence of organic cationic transporter (OCT1)-activity on 
ODT disposition still is lacking and should be supplemented to better understand the disposition of this 
metabolite. The volume of distribution can be scaled from children to adults based solely on weight. 
Looking at the dosing protocols that are used in children (table 2 from the reference article), it stands 
out that different loading and maintenance doses are provided to these children in different studies. 
Since this popPK analysis determines how the clearance changes with age, a consensus should be made 
on the appropriate dosing regimen, which is to be used in the clinic for tramadol use in pediatrics. In 
addition, it needs mentioning that tramadol still is used off-label in the pediatric population because of 
the risk for respiratory depression. FDA is currently investigating the use of tramadol in pediatrics and 
will communicate their findings upon completion of the review [107].    
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An often used phrase in pediatric pharmacology is that “children are not small adults”. Hence, the 
pediatric drug dose is often not a miniature adult dose, but should be tailored to this specific population 
in order to obtain the adequate exposure, ensuring acceptable efficacy/safety profiles in children. In 
drug development as well as in the clinic,  children’s drug doses are typically calculated based on several 
scaling approaches, using easily accessible covariates. These include the scaling of the adult drug dose 
(or clearance & volume) using bodyweight, body surface area, or some empirically-derived exponent to 
the pediatric dose [1]. Any of these methods failed to reliably predict the drug dose that should be given 
over the complete pediatric age range for certain classes of compounds. The main problem is that these 
approaches do not consistently take into account organ maturation, changes in body composition, and 
the ontogeny of drug elimination pathways across the pediatric life span. Because these changes are 
often non-linear, a simple linear or exponential model frequently fails to predict an adequate pediatric 
drug dose, especially in children below 2 years of age. The population pharmacokinetic (popPK) 
approach is a ‘top-down’ model-based approach in which the changes in pharmacokinetic parameters 
(mainly clearance or volume of distribution) and their variability are assessed over the pediatric life span, 
based on measured plasma-concentration time profiles. These models may provide a much better 
quantitative description of the changes in drug disposition that affect the drug plasma concentration. A 
disadvantage, however, is that they remain drug-dependent per se, which limits their extrapolatibility, 
although some groups are putting efforts in circumventing these constraints [2]. 
An approach in which physiological changes occurring in early life implicitly affect the prediction of a 
drug’s pharmacokinetic (PK) profile, is physiologically-based pharmacokinetic modelling and simulation 
(PBPK-M&S). This makes the method very attractive and appropriate to predict drug clearance over the 
complete human life span, since it assimilates the physiological knowledge in each particular age stage 
to predict changes in a drug’s PK (bottom-up). Additionally, these models may also be applied to 
anticipate or explain a drug’s behavior in pathophysiological conditions, e.g. liver cirrhosis [3], or drug-
drug interactions [4]. The fact that PBPK models are drug-independent, allows ‘extrapolatibility’ of many 
drugs to many (virtual) clinical situations [5]. Practically, however, there are some limitations in the 
approach that need further evaluation and optimization in order to better predict the pediatric 
clearance. The emphasis of this work is on drug clearance since it is the most important pharmacokinetic 
parameter determining pharmacological response [1, 6, 7]. 
The main aim of this PhD project was twofold: 
I. Evaluate the PBPK approach for a reliable bottom-up clearance prediction in pediatric life, and 
II. Identify the gaps that underlie prediction inaccuracies.  
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In this light, tramadol was used as a model compound to compare the bottom-up to the top-down 
clearance maturation function across pediatric life, with a particular focus on neonates/infants. The top-
down clearance maturation was estimated from a population PK investigation in a pooled data set, 
ranging from neonates to adults. In order to achieve the main aim of this project, four objectives were 
defined as separate subprojects:  
1. Investigate tramadol in vitro metabolism and investigate in vitro-to-in vivo extrapolation of CYP 
enzyme activity [Chapter 3 & 4] 
2. Construct and qualify the tramadol adult i.v. PBPK clearance model in terms of absolute total 
clearance, and CYP2D6 and renal contributions [Chapter 5] 
3. Use the adult model to mechanistically predict pediatric clearance (bottom-up) and evaluate 
against in vivo pediatric data (top-down) [Chapter 5] 
4. Construct the adult model in different commercially available PBPK software tools,  
mechanistically predict pediatric clearance (bottom-up) for each and evaluate their strengths/ 
weaknesses against in vivo pediatric data (top-down) [Chapter 6] 
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1 ABSTRACT 
Objective 
To predict the tramadol in vivo pharmacokinetics in adults by using in vitro metabolism data and an in 
vitro-in vivo extrapolation (IVIVE)-linked physiologically-based pharmacokinetic (PBPK) modeling and 
simulation approach (Simcyp®). 
Methods 
Tramadol metabolism data was gathered using metabolite formation in human liver microsomes (HLM) 
and recombinant enzyme systems (rhCYP). Hepatic intrinsic clearance (CLintH) was (i) estimated from 
HLM corrected for specific CYP contributions from a chemical inhibition assay (model 1); (ii) obtained in 
rhCYP and corrected for specific CYP contributions by study-specific intersystem extrapolation factor 
(ISEF) values (model 2); and (iii) scaled back from in vivo observed clearance values (model 3). The 
model-predicted clearances of these 3 models were evaluated against observed clearance values in 
terms of relative difference of their geometric means, the fold difference of their coefficients of 
variation, and relative CYP2D6 contribution. 
Results 
Model 1 underpredicted, while model 2 overpredicted the total tramadol clearance by -27% and +22%, 
respectively. The CYP2D6 contribution was underestimated in both models 1 and 2. Also, the variability 
on the clearance of those models was slightly underpredicted. Additionally, blood-to-plasma ratio and 
hepatic uptake factor were identified as most influential factors in the prediction of the hepatic 
clearance using a sensitivity analysis. 
Conclusion 
IVIVE-PBPK proved to be a useful tool in combining tramadol’s low turnover in vitro metabolism data 
with system-specific physiological information to come up with reliable PK predictions in adults. 
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2 INTRODUCTION 
Tramadol is a centrally acting analgesic drug with weak opioid activity and has an established use in the 
clinical setting [1]. Tramadol is metabolized by different cytochrome P450 enzymes (CYP), of which 
CYP3A4 and CYP2D6 are deemed to be the most important ones [2, 3] (Figure 1). CYP3A4 governs the 
metabolism of about 50% of clinically used drugs and is characterized by large interindividual variability 
[4]. Also for CYP2D6 genetic polymorphisms have been described that can lead to large interindividual 
variation in substrate  pharmacokinetics [5]. Tramadol, which inhibits neuronal uptake of 
norepinephrine and serotonine, is bio-activated by CYP2D6 to its O-demethylated metabolite that has 
300 times more affinity for the -opioid receptor than tramadol [1]. Therefore, CYP2D6 activity and 
metabolizer status may have implications on the pharmacokinetics and on the extent of -opioid effect 
after administration of this drug [6, 7]. The above described metabolism properties make this drug an 
interesting compound to study the performance of bottom-up physiologically-based pharmacokinetic 
(PBPK) modeling, relying on in vitro drug metabolism kinetics to predict in vivo pharmacokinetics. 
 
In the past, the use of PBPK models was limited due to their complexity and high computational 
requirements. Therefore, simpler, empirical methods such as sums of exponentials and compartmental 
models, were commonly chosen to ‘describe’ the (plasma) concentration-time profiles [8]. PBPK models 
represent the studied organism as a closed circulatory system in which organs and different tissues 
make up the physiologically relevant compartments, interconnected by the blood circulation, 
independent of the drug under investigation [9]. In order to make compound-specific PBPK predictions, 
compound-specific information, such as molecular descriptors logP, pKa, molecular weight (Mw), and 
in vitro measured values intrinsic clearance (CLint), Km, Vmax, blood-plasma ratio, fraction unbound in 
plasma have to be provided [10]. The mechanistic extrapolation of in vitro pharmacokinetic data to in 
vivo is the so-called bottom-up IVIVE-linked PBPK approach and allows to predict first-in-man 
FIGURE 1: TRAMADOL CYP METABOLISM PATHWAYS (O-DESMETHYLTRAMADOL 
(ODT); N-DESMETHYLTRAMADOL (NDT); NODT (N,O-DIDESMETHYLTRAMADOL)) 
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pharmacokinetic exposure, anticipate major drug-drug interactions, and predict drug clearance in 
subject populations at risk (e.g. renal/hepatic impaired, pediatric populations) [11, 12]. Furthermore, 
this bottom-up PBPK approach is able to a priori identify disposition covariates of a new drug candidate 
through in vitro investigation, and can provide mechanistic insight in the observed absorption, 
distribution, metabolism, and excretion properties of the studied compound. Nevertheless, the classical 
‘top-down’ approach will remain a vital complementary tool to adequately describe the observed data 
obtained in clinical studies [13]. 
In IVIVE, it is extremely important that the metabolic enzyme kinetic data are obtained under optimal 
conditions to build a robust quantitative PBPK model. Intrinsic metabolic drug clearance values can be 
determined by using metabolite formation or substrate depletion assays. In substrate depletion assays, 
the in vitro half-life of the drug is determined [14] and at least 20% compound turnover is required for 
analytical reasons. In such assays, especially for low clearance drugs, long incubation times and relatively 
high protein concentrations are needed. This may lead to issues such as loss in enzyme activity over 
time, end product inhibition, and binding problems, thus preventing reliable prediction of drug 
clearance. However, other methods (such as the hepatocyte relay method) are now available that allow 
accurate and precise measurement of compounds with low in vitro turnover [15]. Metabolite formation 
assays use initial rates, enabling the use of shorter incubation times and lower protein concentrations. 
However, reference standards for metabolites are needed for the bioanalysis. Underprediction of 
clearance can occur if not all metabolic pathways are accounted for [16]. As an alternative, formation 
of all metabolites originating from a parent compound can be studied by using a radiolabel in the 
incubation experiments. 
In this manuscript we present an extended case study on the IVIVE-PBPK prediction of tramadol. The 
hepatic intrinsic clearance (CLintH) was estimated using 3 different clearance models: CLintH from human 
liver microsomal (HLM) metabolism data corrected for specific CYP contributions from a chemical 
inhibition assay (model 1, HLM model); CLintH obtained from recombinant enzyme systems corrected 
for specific CYP contributions by study-specific intersystem extrapolation factor (ISEF) values (model 2, 
rhCYP model); and CLintH scaled back from in vivo observed clearance values (model 3, retrograde 
model). Besides, we highlight a number of essential aspects regarding the design of the in vitro enzyme 
kinetic experiments and discuss the role of PBPK in the bottom-up scaling of these data to in vivo PK.  
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3 MATERIALS AND METHODS 
3.1 CHEMICALS AND MATERIALS 
All chemicals and reagents used were of the highest available grade: Na2HPO4, KH2PO4, KCl, MgCl2, NADP, 
HCl (Merck, Darmstadt, Germany), glucose-6-phosphate, glucose-6-phosphate dehydrogenase (Roche 
Diagnostics GmbH, Manheim, Germany), Tramadol (TRC inc, Toronto, Canada), O-desmethyltramadol 
(ODT) (TRC inc, Toronto, Canada), N-desmethyltramadol (NDT) (LGC GmbH, Luckenwalde, Germany), 
N,O-didesmethyltramadol (NODT) (TRC inc, Toronto, Canada), O-desmethyltramadol-D6 (TRC inc, 
Toronto, Canada), 14C-tramadol (Isotope Synthesis, Janssen, Beerse, Belgium). 
3.2 INCUBATIONS WITH HUMAN LIVER MICROSOMES 
A human liver microsomal pool (BD Biosciences, Woburn, USA), used for tramadol enzyme kinetics 
investigation, consisted of 50 adult donors and was stored at -80°C in an Ultra Freezer (New Brunswick 
scientific, Rotselaar, Belgium). Incubation mixtures (total volume 600 µl) consisted of 297 µl microsomal 
protein, 3 µl of a tramadol solution, and 300 µl cofactor mix containing an NADPH-regenerating system 
consisting of 1 mg of glucose-6-phosphate, 0.50 units of glucose-6-phosphate dehydrogenase, 0.25 mg 
of NADP and 1 mg of MgCl2.6H2O in 1 ml of 0.5 M Na,K-phosphate buffer pH 7.4. Final microsomal 
protein concentrations ranged from 0.5 to 2 mg protein/ml. A preincubation with cofactor mix was done 
for 5 minutes in a shaking water bath at 37°C (100 oscillations/min) (Thermo, Waltham, USA). 
Incubations were started by adding 3 µl of a tramadol solution (in water), resulting in a final 
concentration of 0.5, 1, 5, 20, 50, 100, 150, and 200 µM. Reactions were stopped at 2, 5, 7, 10, 20, and 
30 min by transferring 100 µl aliquots  into 96-well plates containing 10 µl ice-cold 4N HCl and 10 µl of 
internal standard (O-desmethyltramadol-D6, 6 ng/ml in DMSO). For each substrate and protein 
concentration level, samples were incubated in duplicate or triplicate and boiled control incubates were 
run in parallel to correct for non-enzymatic degradation. 96-well plates were then stored at -20°C 
waiting to be analyzed by UPLC-MS/MS. 
3.3 INHIBITION ASSAYS WITH HUMAN LIVER MICROSOMES 
Incubation mixtures were essentially the same as described above but relative volumes differed due to 
the addition of inhibitors, and contained 294 µl of microsomal protein, 300 µl of cofactor mix, 3 µl of 
inhibitor, and 3 µl of a tramadol solution. The final concentration of microsomal protein and tramadol 
in the incubations was 0.5 mg/ml and 1 µM, respectively. Inhibitors, which were dissolved in methanol 
in order to minimize solvent effects (0.5%), were ketoconazole (CYP3A inhibitor, 1 µM), SR-9186 
(CYP3A4 inhibitor, 2.5 µM), quinidine (CYP2D6 inhibitor, 1 µM), and thioTEPA (CYP2B6 inhibitor, 10 µM). 
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Incubations with the mechanism-based inhibitors SR-9186 (TRC inc, Toronto, Canada) and N,N',N''-
triethylenethiophosphoramide (thioTEPA; Sigma Aldrich, Overijse, Belgium) were equilibrated in a 
shaking water bath at 37°C (100 oscillations/min) (Thermo, Waltham, USA) for 5 and 15 min, 
respectively, and were then started by the addition of tramadol. A 5 min equilibration time was used 
for the reversible inhibitors ketoconazole and quinidine. All samples were stopped at 10 min in 96-well 
plates, containing 10 µl ice-cold 4N HCl and 10 µl of internal standard. Linearity controls (incubation 
mixtures without inhibitors; tramadol 1 µM, 0.5 mg protein/ml, 10 min) as well as boiled controls were 
run in parallel to allow determination of the inhibited fraction and to correct for background, 
respectively. 96-well plates were then stored at -20°C waiting to be analyzed by UPLC-MS/MS. 
3.4 INCUBATIONS WITH RECOMBINANT CYP ENZYMES 
Supersomes™ are membrane fractions derived from baculovirus infected insect cells expressing a 
specific (selection of) drug metabolizing enzyme(s), i.e. CYP enzymes with or without NADPH 
cytochrome P450 reductase and cytochrome b5. Supersomes™ (BD Biosciences, Woburn, USA) were 
used in order to investigate the enzyme kinetic behavior of tramadol for the isolated CYPs. Incubation 
mixtures contained 297 µl of a given recombinant isoform at a final 100 pmol/ml (CYP isoform) 
concentration, together with 300 µl of the cofactor mix containing an NADPH-regenerating system 
(composition cfr Materials and Methods 2nd paragraph). These mixtures were preincubated in a shaking 
water bath at 37°C (100 oscillations/min) (Thermo, Waltham, USA) for 5 min and incubations were 
started by adding 3 µl of a tramadol solution. Tramadol final test concentrations were 1, 5, 150, and 250 
µM. Reactions were stopped at 2, 5, 7, and 10 min by transferring 100 µl aliquots into 96-well plates 
containing 10 µl ice-cold 4N HCl and 10 µl of internal standard. For each substrate and each recombinant 
isoform, samples were incubated in duplicate and SupersomeTM insect controls, consisting of membrane 
fractions containing all proteins from the insect cell line except the CYP component, were run in parallel 
to correct for background. 96-well plates were then stored at -20°C waiting to be analyzed by UPLC-
MS/MS. 
3.5 BIOANALYSIS 
Tramadol’s main metabolites O-desmethyl tramadol (ODT, M1),N-desmethyl tramadol (NDT, M2), and 
N,O-didesmethyl tramadol (NODT, M5) [1] were quantified by a sensitive UPLC-MS/MS method. The 
Nexera UHPLC system (Shimadzu, Kyoto, Japan), consisting of a RackChanger II, SIL-30AC autosampler, 
CTO-30A column oven, and LC30AD pump units was linked via a Valco switching valve to an API 4000 
QTRAP (AB Sciex, Toronto, Canada) equipped with a Turbo VTM ion source in ESI+ mode. For the 
chromatographic separation, a gradient was run -with solvents A (0.025M ammonium acetate, pH 8.5) 
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and B (acetonitrile:methanol 80:20, v/v)- from 5% to 50% B in 3 min, to 100% B in an immediate step 
gradient, held for 0.3 min, and back to 5% B, allowing 2 min re-equilibration, at a flow rate of 0.6 ml/min. 
The column was an Acquity UPLC BEH C18 1.7µm 50x2.1mm column (Waters, Milford, USA) packed with 
1.7 µm particles and maintained at 60°C. 
Metabolite formation was quantified by use of a calibrator set and quality control samples that were 
prepared by spiking 25 µl of reference standard solutions N-desmethyl tramadol (NDT), O-desmethyl 
tramadol (ODT), N,O-didesmethyl tramadol (NODT) containing O-desmethyltramadol-D6 as internal 
standard (6 ng/ml) to a mixture of 250 µl microsomal matrix and stopped with 25 µl 4N HCl. Depending 
on the expected extent of metabolite formation 10 calibrator levels (ranging 200-fold) and 3 QC levels 
(low, medium, high; made in duplicate) were selected for each analytical batch. Runs were accepted 
based on recommendations from the FDA’s “Guidance for Industry– Bioanalytical Method Validation”. 
An overview of the specific criteria that were used for run acceptance are provided as an Appendix to 
this chapter. At least 4 out of 6 QC samples were within 15% of their nominal value, for the calibration 
curve simple linear regression was applied with a weighting factor 1/x. Standards deviated not more 
than 15% from the nominal concentration, except for the LLOQ where 20% deviation was allowed. 
Samples in 96-well plates were thawed while shaking, submersed in an ultrasone bath, and centrifuged 
using an AllegraTM 25R ultracentrifuge (Beckman Coulter, Suarlée, Belgium). Depending on the expected 
degree of metabolite formation, between 1 and 10 µl supernatant was directly injected onto the column 
to assess concentrations of ODT, NDT, and NODT in the incubation samples. 
3.6 TRAMADOL ENZYME KINETICS AND IVIVE 
Concentrations of metabolites in the incubation samples were corrected for protein concentration (mg 
microsomal protein/ml), reaction time (min), and initial substrate concentration (µM) in order to 
calculate the apparent in vitro clearance (CLapp) for every metabolite. CLapp was plotted vs. tramadol 
incubation concentration and a nonlinear model –with the model structure provided in equation 1-  was 
fitted to the data, using the R statistics program [17]. Models were evaluated by visually inspecting 
residual plots for bias. In  equation 1 CLapp is the apparent in vitro clearance, expressed as µl/min/mg 
microsomal protein, vo is the initial rate of metabolite formation in the incubate (pmol/min/mg protein), 
[S] is tramadol concentration (µM), Km and Vmax are the Michaelis-Menten constant (µM) and 
maximum velocity (pmol/min/mg protein), respectively. This equation allowed estimation of the 
parameters Km and Vmax, and hence the calculation of CLint. 
𝐶𝐿𝑎𝑝𝑝 =
𝑣𝑜
[𝑆]
=
𝑉𝑚𝑎𝑥
𝐾𝑚 + [𝑆]
 
EQUATION 1 
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When the substrate concentration in the incubate is substantially below the Km (in practice [S]< Km/10), 
the intrinsic clearance (CLint) can be approximated from the ratio of Vmax/Km. When the substrate 
concentration is at Km, the CLapp approximates the half maximal CLint. 
Tramadol incubation concentrations (0.5 to 250 µM) were chosen to be near the therapeutic plasma 
concentrations observed in vivo (Cmax 2.25 µM [1]) in order to define the enzyme kinetic parameters of 
tramadol at a therapeutically relevant concentration test range. An unbound fraction in microsomes 
(fumic) of  ~0.96 was estimated in silico using the prediction toolbox in Simcyp® V12.1 [18]. 
By scaling up an in vitro obtained (unbound) intrinsic clearance (CLintu) with mechanistic information on 
the liver abundance of each CYP, the amount of microsomal protein per gram liver (MPPGL), and liver 
weight, a determination of the in vivo hepatic intrinsic clearance (CLintH) can be obtained. Additionally, 
known variability in demographic and biological components is incorporated in order to predict drug 
disposition in relevant individuals with realistic variability. Additionally, for the scaling from recombinant 
systems, an intersystem extrapolation factor (ISEF) corrects for the inherent activity difference between 
recombinant systems and HLM [19, 20].  
Equations 2 and 3 are used for the mechanistic scaling of unbound intrinsic clearance to hepatic intrinsic 
clearance , obtained from HLM and recombinant systems, respectively. For scaling up HLM unbound 
CLint, the amount of microsomal protein per gram liver (MPPGL), and liver weight are needed to provide 
an estimate of the in vivo hepatic intrinsic clearance (CLintH) (equation 2). For scaling up the unbound 
CLint determined from rhCYP systems, the CYP isoform abundance in vivo and the ISEF value are 
additional factors needed to calculate the hepatic CLint (equation 3) [19].  
𝐶𝐿𝑖𝑛𝑡𝐻 = 𝐶𝐿𝑖𝑛𝑡𝑢,𝐻𝐿𝑀 ∗ 𝑀𝑃𝑃𝐺𝐿 ∗ 𝑔 𝑙𝑖𝑣𝑒𝑟 
EQUATION 2 
 
𝐶𝐿𝑖𝑛𝑡𝐻 = 𝐶𝐿𝑖𝑛𝑡𝑢,𝑟𝐶𝑌𝑃 ∗ 𝐼𝑆𝐸𝐹 ∗ [𝑖𝑠𝑜𝑓𝑜𝑟𝑚]𝑖𝑛 𝑣𝑖𝑣𝑜 ∗ 𝑀𝑃𝑃𝐺𝐿 ∗ 𝑔 𝑙𝑖𝑣𝑒𝑟 
EQUATION 3 
Subsequently, the hepatic intrinsic clearance (CLintH) is integrated with the fraction unbound in plasma 
(fup), blood-to-plasma ratio (B:P) and the hepatic blood flow (QH) in the commonly used well-stirred liver 
model in order to obtain an estimate of the hepatic plasma clearance (CLH), as illustrated in equation 4: 
𝐶𝐿𝐻 =
𝑄𝐻 ∗ 𝑓𝑢𝑝 ∗ 𝐶𝑙𝑖𝑛𝑡H
𝑄𝐻 + 𝑓𝑢𝑝 ∗ 𝐶𝐿𝑖𝑛𝑡H/𝐵: 𝑃
 
EQUATION 4 
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3.7 BLOOD DISTRIBUTION 
The blood distribution of tramadol was investigated by incubating a tramadol concentration range (0.1 
– 10 µM) in whole blood. Fresh whole blood was collected from 3 healthy male volunteers in EDTA-
coated tubes to which 14C-tramadol was spiked (no organic solvents were used). Spiked whole blood 
was left to equilibrate for 30 min in a shaking water bath Grant (type OLS200) (Grant instruments, 
Cambridge, UK) at 37°C and was gently homogenized every 10 min. After 30 min, 3 homogenous aliquots 
of 100 µl were pipetted to oxidation cups and the rest of the whole blood sample was centrifuged for 
10 min at 1700g in a Hettich Rotixa (type 50S) (Hettich AG, Tuttlingen, Germany). 2 aliquots of 100 µl 
plasma were placed in counting vials together with scintillation fluid Ultima Gold (PerkinElmer, Waltham, 
USA) and were counted by liquid scintillation counting (LSC) in a Tri-carb® 2900 TR  (PerkinElmer, 
Waltham, USA). Whole blood samples were combusted in a Packard Sample Oxidizer 307 (PerkinElmer, 
Waltham, USA), released 14CO2 was trapped with Carbosorb and mixed with scintillation fluid, and 
submitted to LSC. The radioactivity was measured in an aliquot of whole blood as well as in plasma from 
the same sample in order to assess the ratio of the whole blood concentration vs. the plasma 
concentration (blood-to-plasma or B:P ratio). 
3.8 SIMULATIONS 
An intravenous full PBPK model was selected in the Simcyp® Simulator V12.1 (Sheffield, UK) to predict 
pharmacokinetics as a function of time. In order to verify the simulations, PK parameters were 
compared to in vivo data [21-24]. 
The virtual clinical trial design was set to capture the pharmacokinetics as a function of time for a 100 
mg tramadol i.v. bolus up to 24h post-dose, in line with the in vivo observed AUC’s which were also 
obtained from 0 to 24h. Following molecular descriptors were extracted from literature and used as 
input for the PBPK model: molecular weight 264.4; logP 1.35; pKa 9.41; B:P ratio 1.09 (own experiments); 
fup 0.8. 
The virtual population was set to mimic the reference population in terms of the proportion male-
female (30% female), the age range (23-57 years), and CYP2D6 metabolizer status (8.2% PM – 86.5% 
EM – 5.3% UM). 
The distribution component of the PBPK model was represented by the Rodgers & Rowland model 
(method 2 in Simcyp®). The Rodgers and Rowland equation was used since this equation, in contrast to 
the Poulin and Theil equation (method 1 in Simcyp®), takes into account a tissue’s acidic phospholipid 
fraction and takes explicit account of the extent of ionization of a compound at the pH of the 
compartment concerned. Since tramadol is almost completely ionized at pH 7.4, the Rodgers and 
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Rowland equation will assume that binding to acidic phospholipids controls the distribution within the 
body [25]. The elimination component of the PBPK model involved a renal and a hepatic clearance part. 
The renal plasma clearance was mechanistically predicted at 6.6 L/h (110 ml/min) using the 
permeability-limited mechanistic kidney model. Since this value was in good agreement with in vivo 
observations the renal clearance was fixed at 6.6 L/h for further simulations. The hepatic plasma 
clearance was investigated by means of an IVIVE-linked elimination model using kinetic data from in 
vitro experiments, further elaborated hereunder in the section “Hepatic clearance investigation”. In 
addition, a sensitivity analysis was conducted to assess model robustness to changing input parameters 
other than CLint values, as well as a population simulation comparing the geometric means of clearance 
and volume of distribution and their associated variabilities with the reference data set used in this 
study [21-24]. 
3.8.1 HEPATIC CLEARANCE INVESTIGATION 
The CYP-isoform specific CLint values that were used in the 3 different clearance modeling approaches, 
described hereunder, can be found in Table 1. A factor of 1.58 was used to account for hepatic 
accumulation of the basic amine tramadol (see discussion for details). 
The HLM model (model 1) represents input from intrinsic clearance values obtained in HLM for the two 
main tramadol CYP-mediated metabolites ODT and NDT (Table 2). The contribution of different CYP 
enzymes to the total intrinsic clearance per metabolite is estimated based on the effect of different 
chemical inhibitors (Table 1). The rhCYP model (model 2) consists of intrinsic clearance values obtained 
in isolated recombinant enzyme systems CYP3A4, 2D6, and 2B6 for the two main tramadol CYP-
mediated metabolites ODT and NDT (Table 1). ISEF values for CYP3A4 and CYP2D6 were determined for 
scaling up tramadol rhCYP kinetic data using probe substrates midazolam and dextromethorphan, 
respectively. CLint values for both probes were obtained in HLM as well as in rhCYP systems, and specific 
CYP abundances of 137 and 8 pmol/mg microsomal protein were used to calculate the ISEF values for 
CYP3A4 and CYP2D6 (Table 1), respectively [26, 27]. For CYP2B6, an ISEF-value of 0.43 was used as 
provided by Simcyp® V12.1. The retrograde model (model 3) calculates a retrograde hepatic intrinsic 
clearance per CYP isoform based on apparent in vivo CYP contributions in the total metabolism (Table 
1). Therefore, it can serve as a reference model next to the 2 other models in evaluating the prediction 
of the population clearance. Simulations were performed using a study design and healthy volunteer 
population that resembled the study design and covariate characteristics of the reference study, 
respectively [21-24]. The simulations were executed using virtual populations of 1000 subjects 
The CYP2D6 contribution in the current clearance models was assessed by comparing the fold increase 
in hepatic clearance between PM and EM with observed data from a study conducted by Pedersen et 
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al. [28]. Patients from this study were genotyped as *1/*1 (EM; n=8) and *4/*4 (n=7) or *4/*6 (PM) 
(n=1). The PBPK trial design was set to resemble the actual trial design as closely as possible by taking 
into account the actual age range, administered dose, proportion of male-female, and metabolizer 
phenotype in the 2 groups. One thousand virtual patients were simulated for every run. 
3.8.2 POPULATION SIMULATION 
In Simcyp®, known covariates or correlations of different specifications of the population as well as the 
observed variability associated with each parameter involved in the bottom-up approach is considered 
to generate virtual subjects representative of those in the real world [10]. Therefore, a population 
simulation was set up to investigate how well the 3 IVIVE-linked PBPK models could predict the 
population values of the clearance (CL) and volume of distribution (Vss) as well as their associated 
variability. In that respect the relative difference of the predicted and observed geometric means, 
calculated as (predicted-observed)/observed*100%, was used to compare the population values of CL 
and Vss. To compare the predicted and observed variability in the population, the fold difference of the 
predicted and observed coefficients of variation (CV) was used, assuming that these PK parameters 
follow log-normal distributions (Table 3). Evaluation was based on visual inspection of observed and 
predicted 95% prediction intervals, calculated as suggested by Johnson et al (29). The simulated virtual 
population consisted of 1000 patients that mimicked the dosage, age range and male-female proportion 
of the reference studies[21-24]. 
3.8.3 SENSITIVITY ANALYSIS 
A sensitivity analysis was undertaken in order to define to what extent other input parameters than 
intrinsic clearance would influence the prediction of clearance (CL) using the clearance model 1 (based 
on HLM values) and volume of distribution (Vss) using the distribution model based on the Rodgers 
equations [25]. Five input parameters of interest (logP, pKa, fraction unbound in plasma (fu), B:P ratio 
(BP), drug accumulation in hepatocyte (ACC)) were varied within the PBPK model (full factorial design 
(25)), using the Simcyp® Batch processor, between the lowest and the highest value published in 
literature or own experimental results. Following values (low level – high level) were used as input to 
the PBPK model: logP (1.35- 2.41), pKa (9.14 – 9.44), fu (0.74 – 0.80), BP (1.09 – 1.20), ACC (1.5 – 3). The 
reason for varying the ACC factor 2-fold can be found in the discussion. PBPK simulations were 
performed using a healthy volunteer population that resembled the study population of the reference 
studies [21-24]. One hundred virtual patients were simulated for every run. The prediction results were 
interpreted by means of a generalized linear model (glm) that was fitted to the PBPK prediction results, 
so as to disentangle the effects of the input parameters and their interactions on the prediction of CL 
and Vss.   
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FIGURE 2: THE OBSERVED IN VITRO CLEARANCE (µL/MIN/MG MICROSOMAL PROTEIN) IN RELATION TO THE INCUBATION CONCENTRATIONS 
(µM) OF TRAMADOL FOR ODT (A) AND NDT (B). FOR ODT THE PLATEAU OF INTRINSIC CLEARANCE (CLINT) IS REACHED AT 0.80 µL/MIN/MG 
PROTEIN, AND FOR NDT THE CLINT WAS ESTIMATED AT 1.63 µL/MIN/MG PROTEIN. 
4 RESULTS 
4.1 IN VITRO RESULTS 
4.1.1 CLINT FROM HLM ASSAYS 
The metabolism kinetics of 0.5 µM to 250 µM tramadol to its two primary metabolites O-desmethyl 
tramadol (ODT) and N-desmethyl tramadol (NDT) was determined in pooled human liver microsomes. 
The secondary metabolite N,O-didesmethyl tramadol (NODT) was always about 1% and < 3% of the 
amount of NDT and ODT formed, respectively, implying negligible underestimation of enzyme kinetic 
parameters due to secondary metabolism. Furthermore, preliminary experiments using 14C-tramadol 
(data not shown) it was demonstrated that no other metabolites were formed than the ones described 
in this paper. The aim was to identify the intrinsic clearance for both metabolites at concentrations well 
below Km values, previously reported by Subrahmanyam et al. [29] (KmODT 116 µM; KmNDT 1021 µM). 
Linearity of metabolite formation to ODT and NDT in relation to time and protein content was 
investigated at 0.5 µM tramadol, and seemed to be linear up to 10 min and up to 1 mg of microsomal 
protein per ml.  
Considering only linear kinetic data (initial velocities), the CLapp was calculated, as described in the 
previous section. The intrinsic clearance (CLint) is the apparent in vitro clearance that is maximal and 
constant at the lower end of the substrate concentration test range (illustrated for ODT and NDT in 
Figure 2). Estimated enzyme kinetic parameters Km, Vmax, CLint are presented in Table 2 with their 95% 
confidence intervals. 
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TABLE 1: OVERALL SUMMARY OF THE CLINT VALUES OBTAINED IN KINETIC EXPERIMENTS THAT WERE USED AS INPUT FOR PBPK. 
SPECIFIC CYP ISOFORM CONTRIBUTION IS INCORPORATED THROUGH CHEMICAL INHIBITION (MODEL 1, HLM) OR ISEF VALUES (MODEL 2, 
RHCYP) OR BACK-CALCULATED FROM IN VIVO (MODEL 3, RG) FOR ODT AND NDT. 
Model Formula CYP isoform CLint ODTa  CLint NDTa  
1 HLM b 
 
CLintHLM 
(CLintODT/NDT * %CYP by chemical inhibition data) 
3A4 0.12 
(0.80*15%) 
1.06 
(1.63*65%) 
2D6 0.64 
(0.80*80%) 
0.08 
(1.63*5%) 
2B6 0.04 
(0.80*5%) 
0.5 
(1.63*30%) 
2 rhCYP c 
 
CLintrhCYP * ISEF 3A4 0.00   *0.23 0.11   *0.23 
2D6 0.57   *0.45 0.054 *0.45 
2B6  0.018 *0.43 0.20   *0.43 
3 RGd Retrograde model 2D6 48% of HepCL 
3A4+2B6 52% of HepCL 
a CLint values for model 1 are expressed as µl/min/mg protein, whereas for model 2 CLint is expressed as 
µl/min/pmol CYP 
b reported CLint values are obtained by multiplication of the CLintHLM values with % CYP isoform contribution 
calculated from inhibition assay data 
c CLintrhCYP obtained from recombinant enzyme systems, are presented with their specific ISEFs 
d Retrograde model allows the user to set specific CYP contributions based on in vivo data in CYP2D6 PM and EM 
 
 
TABLE 2: OVERVIEW OF ENZYME KINETIC PARAMETERS KM, VMAX AND CLINT AND THEIR ASSOCIATED 95% CONFIDENCE INTERVALS FOR 
TRAMADOL’S TWO MAIN METABOLITES ODT AND NDT IN POOLED HLM 
 ODT NDT 
Km [95% CI]      (µM) 57.5 [47.0 ; 71.1] 242 [174 ; 353] 
Vmax [95% CI]  (pmol/min/mg protein) 46.4 [38.9 ; 56.1] 395 [290 ; 565] 
CLint [95% CI]   (µl/min/mg protein) 0.80 [0.78 ; 0.84] 1.63 [1.57 ; 1.69] 
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4.1.2 HLM INHIBITION ASSAYS 
Tramadol metabolism to ODT (Figure 3, Table 1) was found to be primarily inhibited (80%) by 1 µM 
quinidine, which causes a selective inhibition of CYP2D6 [30]. Inhibition of another major CYP enzyme, 
CYP3A and CYP3A4 by ketoconazole and SR-9186 [31], respectively was derived to be approximately 
15%. The rest of the ODT formation (5%) seemed to be mediated by CYP2B6 as indicated by the thioTEPA 
inhibitory effect. 
Tramadol N-demethylation, displayed in Figure 3 and Table 1, is mainly mediated by CYP3A4 because 
about 60% of the metabolism to NDT is blocked by chemical inhibition with ketoconazole (1 µM) and 
SR-9186 (2.5 µM). The inhibitory effect of thioTEPA (10 µM) is believed to result from a dual effect on 
CYP3A4 and CYP2B6. This cross-reactivity was investigated by co-incubating tramadol with the 2 
inhibitors. Knowing that SR-9186 causes selective inhibition of CYP3A4, the real contribution of CYP2B6 
in the NDT formation can be estimated at 30% by subtracting the inhibition of SR-9186 alone from the 
inhibition with SR-9186 + thioTEPA, thereby correcting for thioTEPA’s inhibitory effect on CYP3A4.  
4.1.3 CLINT FROM RHCYP ASSAYS 
The kinetics of 1 µM to 250 µM tramadol to metabolites ODT and NDT was determined in recombinantly 
expressed enzyme systems containing CYP3A4, CYP2D6, CYP2B6, and insect controls (Supersomes™). 
Linear conditions were determined for both metabolites in relation to time per recombinant isoform at 
100 pmol/ml. Enzymatic rates were linear up to 5 or 7 min, depending on the isoform under 
investigation. Only linear data should be used for calculation of the CLapp, yielding a plateau of CLint at 
tramadol concentrations well below Km (Figure 4). CLint values that were used as input for hepatic 
clearance model 2, the rhCYP model, can be found in Table 1. 
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FIGURE 3: THE INHIBITION PLOTS REPRESENT REST FRACTIONS OF METABOLITE ODT (LEFT) AND NDT (RIGHT) IN RELATION TO INHIBITOR(S) 
PRESENT. A LINEAR CONTROL WAS ALWAYS RUN IN PARALLEL TO THE INHIBITION ASSAYS TO DETERMINE 100% ODT AND NDT FORMATION. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4: THE APPARENT IN VITRO CLEARANCE (µL/MIN/PMOL CYP) FOR ODT AND NDT IN RELATION TO THE INCUBATION CONCENTRATIONS 
(µM) OF TRAMADOL, FOR EVERY RECOMBINANT ENZYME CYP3A4, 2D6 AND 2B6. 
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4.1.4 BLOOD DISTRIBUTION 
The blood distribution of tramadol appeared to be concentration independent within the test range of 
0.1 to 10 µM tramadol and the blood-to-plasma ratio was determined at 1.09 (sd 0.02). 
4.2 SIMULATION RESULTS 
4.2.1 HEPATIC CLEARANCE INVESTIGATION AND POPULATION SIMULATION 
The involvement of the hepatic clearance in the total tramadol clearance was investigated by using the 
input from two distinct IVIVE-linked PBPK clearance models (HLM and rhCYP model) and the retrograde 
clearance model as reference model. The results of this analysis are presented in figures 5, 6, and Table 
3. Input details for every clearance model are provided in the section Materials and Methods- 
Simulations. 
 
The HLM model as well as the rhCYP model (models 1 and 2) are predicted within 2 fold of the observed 
geometric mean clearance, and the retrograde model, as a reference model, coincides with the 
geometric mean clearance (Figure 5). From Table 3 it is apparent that the geometric mean clearance is 
slightly underpredicted in the HLM model but is somewhat overpredicted in the rhCYP model. The 
variability in every model seems to be slightly underpredicted when compared to the observed 
variability. The CYP2D6 contribution, as illustrated by the fold increase of the hepatic clearance in PM 
FIGURE 5: THE PREDICTION OF THE TOTAL CLEARANCE PER CLEARANCE MODEL. BLACK DOTS ARE PREDICTED GEOMETRIC MEAN CLEARANCE 
AND ERROR BARS REPRESENT THE STANDARD DEVIATIONS. DASHED AND DOTTED LINES REPRESENT THE OBSERVED GEOMETRIC MEAN AND 
THEIR 2 FOLD BOUNDARIES, RESPECTIVELY. HLM MODEL: HEPATIC CLEARANCE MODEL FROM HUMAN LIVER MICROSOMES; RHCYP MODEL: 
HEPATIC CLEARANCE MODEL FROM RECOMBINANT HUMAN ENZYMES; RETROGRADE MODEL: HEPATIC CLEARANCE MODEL FROM IN VIVO 
OBSERVED CLEARANCE DATA 
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vs EM (Table 3), is underpredicted by both the HLM and the rhCYP model, compared to the retrograde 
model and the observed data [28]. 
 
TABLE 3: HEPATIC CLEARANCE INVESTIGATION BY COMPARISON OF 3 PBPK MODELS. 
FIRST, THE 3 MODELS ARE PRESENTED WITH THEIR RENAL, HEPATIC AND 2D6 INVOLVEMENT, RELATIVE TO THE TOTAL CLEARANCE. SECOND, 
THE 3 MODELS ARE COMPARED BY THEIR RELATIVE DIFFERENCE IN GEOMETRIC MEAN AND FOLD OF COEFFICIENTS OF VARIATION (CV) VERSUS 
OBSERVED DATA. FURTHERMORE, THE INCREASE IN HEPATIC CLEARANCE BETWEEN CYP2D6 PM AND EM IS A MEASURE OF CYP2D6 
CONTRIBUTION, INDICATING AN UNDERINVOLVEMENT OF CYP2D6 IN BOTH THE HLM AND THE RHCYP MODEL 
 HLM model 1 rhCYP model 2 Retrograde model 3 
Renal involvement (%) 43 24 29 
Hepatic involvement (%) 57 76 71 
2D6 involvement in 
hepatic clearance (%) 
29 29 44 
2D6 involvement in total 
clearance (%) 
17 22 31 
Comparison of geometric mean and coefficient of variation 
Relative difference in 
geometric Mean 
-27% +22% +1% 
Fold difference in CV 0.73 0.89 0.85 
Hepatic clearance fold increase 
HepCL fold increase for 
CYP2D6 PM to EM 
1.39 1.33 1.73a 
 a observed hepatic clearance increase was calculated at 1.74 [28] 
 
The steady-state volume of distribution was mechanistically predicted using the Rodgers and Rowland 
model. Preliminary simulations with the Poulin & Theil distribution model [32] resulted in a clear 
underprediction of the volume of distribution (data not shown). This is in line with previous reports on 
the better performing Rodgers & Rowland model, accounting for membrane interaction of ionized basic 
drugs [25, 33], such as tramadol. 
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In Figure 6 the 3 plots visualize the output from the simulation results by overlaying the in vivo observed 
clearances and PBPK predicted clearances in a plot per considered model. Circles represent data from 
in vivo studies by Lintz et al. and Quetglas et al. [21-24] with the dashed line being their overall geometric 
mean and the dotted line their 95% prediction interval as calculated by Johnson [34]. Y-axis represents 
total clearance for the predictions and observations, while the x-axis represents an index for the 
observations only -sorted per individual (Lintz data [21-23]) or per study population (Quetglas data [24])-. 
The greyed area represents the 95% prediction interval on the total clearance of the virtual population 
with its geometric mean as solid black line. Visually, the 95% prediction intervals for the rhCYP and the 
retrograde model are more in line with the observed interval than for the HLM model, where an 
underestimation is present. In addition, Figure 7 displays the observed and predicted values of Vss. 
Although some underprediction of the geometric mean Vss in this case is apparent, the predicted 
variability is in line with the observed one as can be concluded visually from the 95% prediction intervals. 
 
FIGURE 6: POPULATION SIMULATION RESULTS FOR TOTAL CLEARANCE BY THE 3 MODELS CONSIDERED IN THIS PAPER. OPEN CIRCLES (LINTZ 
DATA [21-23)) AND BLACK CIRCLE (MEAN +- 2*SD) (QUETGLAS DATA [24]) REPRESENT DATA FROM IN VIVO STUDIES WITH THE DASHED LINE 
BEING THEIR OVERALL GEOMETRIC MEAN AND THE DOTTED LINE THEIR 95% PREDICTION INTERVAL. THE GREYED AREA REPRESENTS THE 95% 
PREDICTION INTERVAL OF THE SIMULATED POPULATION WITH ITS GEOMETRIC MEAN AS SOLID BLACK LINE 
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4.2.2 SENSITIVITY ANALYSIS 
In order to identify those input parameters that significantly affected the PBPK prediction of total 
clearance (CL) and steady-state volume of distribution (Vss), a generalized linear model (glm) was fitted 
to the PBPK prediction outcomes. In this sensitivity analysis, effects of input parameters logP, pKa, 
fraction unbound in plasma (fu), blood:plasma ratio (B:P), and hepatic accumulation (ACC) on PBPK 
predicted CL and Vss were determined. Isolated effects and interaction effects were distinguished in 
order to obtain meaningful parameter estimates (Table 4). It is worth noting that CL values were 
calculated as dose/AUC from Simcyp® output sheets. This means that the predictions of CL in this case 
(PK profiles mode) are not independent from the prediction of Vss, because we record AUCs over the 
24h period post dose. In short, if input parameters that have an impact on the elimination or distribution 
of the drug are changed, plasma concentrations change, AUC0-24h changes, and hence CL (=D/AUC0-24h). 
The “(Intercept)” from the glm output displays the predicted total clearance (19.31 L/h) and volume of 
distribution (2.77 L/kg) when all five input parameters are at their lower level. Increasing the logP, fu, 
B:P and ACC to their higher level, increases the predicted total clearance, while increasing pKa has a 
small but significantly lowering effect on the total clearance. An increase in logP and B:P increases the 
predicted Vss, while increasing pKa and fu decreases the prediction of Vss. A simultaneous increase in 
both fu and ACC results in a higher predicted CL than what is to be expected from their isolated effects. 
 
FIGURE 7: POPULATION SIMULATION RESULTS FOR VOLUME OF DISTRIBUTION (VSS). SINCE WE ONLY CONSIDERED 1 DISTRIBUTION MODEL, 
ONLY 1 PLOT IS PRESENTED. OPEN CIRCLES (LINTZ DATA [21-23]) AND BLACK CIRCLE (MEAN +- 2*SD) (QUETGLAS DATA [24]) REPRESENT DATA 
FROM IN VIVO STUDIES WITH THE DASHED LINE BEING THEIR OVERALL GEOMETRIC MEAN AND THE DOTTED LINE THEIR 95% PREDICTION 
INTERVAL. THE GREYED AREA REPRESENTS THE 95%PREDICTION INTERVAL OF THE SIMULATED POPULATION WITH ITS GEOMETRIC MEAN AS 
SOLID BLACK LINE. 
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TABLE 4: SENSITIVITY ANALYSIS BY A GENERALIZED LINEAR MODEL (GLM). 
THE ISOLATED AND INTERACTION EFFECTS OF INPUT PARAMETERS ON THE GEOMETRIC MEAN TOTAL CLEARANCE (CL) AND VOLUME OF 
DISTRIBUTION (VSS) ARE DISPLAYED WITH SIGNIFICANCE LEVEL. (INTERCEPT) HAS THE VALUE OF THE CL OR VSS WHEN ALL VARIABLES ARE AT 
THEIR LOWER INPUT LEVEL. THE ESTIMATE FOR A SPECIFIC VARIABLE REPRESENTS THE INCREASE/DECREASE IN CL OR VSS WHEN THIS 
VARIABLE IS CHANGED TO THE HIGHER INPUT LEVEL 
 Input level Coefficients for CL (L/h)a Coefficients for Vss (L/kg)a 
 low – high Estimate Significance Estimate Significance 
(Intercept)  19.31 *** 2.77 *** 
logP 1.35 – 2.41 +0.19 *** +0.070 *** 
pKa 9.13 – 9.44 -0.020 ** -0.0075 *** 
fu 0.74 – 0.80 +0.025 ** -0.23 *** 
BP 1.09 – 1.20 +2.84 *** +1.12 *** 
ACC 1.5 – 3 +6.32 *** - -  
logP:pKa9.44  -0.098 *** -0.040 *** 
logP:fu0.8  -  -  +0.010 *** 
fu:BP1.2  -0.13 *** -  -  
fu:ACC3  +0.49 *** -  -  
BP:ACC3  -0.17 *** -  -  
pKa:fu0.8  -  -  -0.0050 ** 
pKa:BP1.2  -  -  -0.0050 ** 
a Signif. codes  ‘***’ 0 ; ‘**’ 0.001 ;  ‘-’ coefficient for this variable did not contribute significantly to the model 
 
It can be concluded from the results in Table 4 that based on the values for these 5 input parameters 
encountered in the literature or derived from own experimental work, the B:P ratio (BP) and the hepatic 
accumulation factor (ACC) influenced the prediction of the total clearance most, while mainly the B:P 
ratio (BP) and the unbound fraction in plasma (fu) seemed to be affecting the value of Vss.  
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5 DISCUSSION 
In this paper, we investigated the contribution of the hepatic clearance and the different CYP isoforms 
in the total clearance of tramadol by considering 3 different clearance models. Model 1 (HLM model) is 
based on data from HLM systems with specific CYP contributions via a chemical inhibition assay, while 
model 2 (rhCYP model) uses recombinant in vitro clearance data with ad hoc determined ISEF values. 
Finally, model 3 (retrograde model) was included as a reference model, based on hepatic intrinsic 
clearances scaled back from in vivo hepatic clearance. For every model prediction not only the 
geometric mean of the total clearance but also the associated variability was evaluated. The difference 
in total clearance between these models is solely due to their hepatic component since renal clearance 
was fixed at 6.6 L/h. Apparently, the HLM model underpredicted the total clearance by -27%, while the 
rhCYP model overpredicted the total clearance by +22% due to the fact that the hepatic clearance is 
increased in the rhCYP model vs the HLM model (cfr Figure 6 and Table 3). The involvement of CYP2D6 
still is underestimated in the HLM model and rhCYP model, as can be concluded from the lower values 
for hepatic fold increase in Table 3 compared to the retrograde model. Although a large pool of human 
liver microsomes was used for the experiments, it has been previously shown that CYP2D6 is not the 
most stable isoform as could be derived from in vitro metabolism studies [35], and hence an 
underestimation of CYP2D6 activity as measured in this HLM batch could be a plausible explanation. 
Despite the fact that the rhCYP model, based on study-specific ISEFs, somewhat overpredicts hepatic 
involvement, the CYP2D6 contribution is quite analogous to the one in the HLM model. Although an 
underprediction of -27% (HLM model) and an overprediction of +22% (rhCYP model) of the total 
clearance is apparent, the question can be raised how much more accurate these bottom-up clearance 
models need to be. Are we only and unconditionally satisfied when the model predictions fall within the 
2 fold prediction error margins? In our opinion, although our clearance model predictions clearly fall 
within these boundaries, there is undoubtedly room for improvement since a suboptimal CYP2D6 
involvement in our clearance models prevails. Additional research should enable us to fine-tune these 
models further in their relative CYP contributions. 
In the evaluation of the population simulations we found that the variability in all three models tends to 
be underpredicted, as is readily observed from the CV fold values being smaller than 1 in Table 3. Upon 
visual inspection of Figure 6 the variability of the rhCYP model predictions seems larger than that of the 
HLM model predictions. However, when comparing the fold differences of CV between the two models, 
it is noticed that the difference between the fold differences (0.73 vs 0.89, Table 3) is smaller than what 
would have been expected based on comparison of the 95% prediction intervals from the plots in Figure 
6. This indicates that variability, incorporated in the PBPK predictions, assumes a constant CV model. 
Having a good prior estimate of the variability associated with the clearance through the use of PBPK 
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modeling and simulation would definitely facilitate the prospective design and power calculations of an 
upcoming clinical trial. 
In establishing in vitro intrinsic clearance values, using whatever in vitro system, it is well known that 
data should be linear with respect to time and protein concentration [36]. Drug-specific HLM and 
recombinant enzyme kinetic data on tramadol are available in the literature [29]. The data, however, 
are based on experiments using pools from 5 livers in which linearity was not investigated at the lowest 
in vitro test concentration. Moreover, the experiments were conducted at concentrations beyond those 
ever reached in vivo (intrahepatically). We therefore redesigned these experiments, in order to obtain 
physiologically relevant in vitro enzyme kinetic parameters. From the literature it was anticipated that 
tramadol would have a very low turnover in vitro [37], and our data equally substantiated that after 10 
min incubation with 1 mg microsomal protein/ml, only 1% of tramadol at [S] < Km/10 was converted to 
its respective metabolites. By using appropriate, physiologically relevant incubation conditions, we were 
able to achieve quantitative estimates for the intrinsic clearances for both metabolites. Additionally, 
next to CYP2D6 and CYP3A4, a role for CYP2B6 of about 30% in the HLM metabolism of tramadol to NDT 
could be identified. This contribution however may be overemphasized due to the lower CYP2D6 activity 
present in this HLM batch. Nevertheless, in the case of CYP2D6 poor metabolizers e.g., the contribution 
of CYP2B6 and its expected associated variability [38] may become important covariates in the tramadol 
disposition. 
An appealing feature of IVIVE-linked PBPK modeling and simulation is the learning-confirming principle, 
and consequently, the fact that mechanistic insights into the observed pharmacokinetics can be 
obtained [39]. In that respect, the sensitivity analysis conducted in this case study clearly revealed that 
the B:P ratio and hepatic accumulation were factors most influential for the prediction of clearance, 
while the B:P ratio and fraction unbound in plasma strongly influenced the prediction of steady-state 
volume of distribution. While it is obvious why e.g. the hepatic accumulation and unbound fraction in 
plasma determine the prediction of the clearance and volume, respectively, it is not directly evident 
why the B:P ratio has such a marked effect, while logP and pKa hardly have any effect on the prediction 
of the tramadol clearance (Table 4). It has to be kept in mind however, that all predictions are based on 
kinetics as a function of time after a single i.v. dose, recording plasma concentrations up to 24h post 
dose. Because B:P ratio, logP, and pKa all influence the prediction of the volume of distribution, and 
hence plasma concentrations, this has a rebound effect on the calculation of the clearance, calculated 
as dose/AUC0-24h. The influence of the B:P ratio on the Vss was anticipated considering its role in the 
Rodgers & Rowland model for the prediction of tissue distribution [25]. Therefore, a blood distribution 
experiment was conducted to ascertain the value of this B:P ratio in the model. Also, the positive effect 
of hepatic accumulation on the prediction of the hepatic clearance value proved to be a very influential 
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factor in this PBPK model, which is to be expected for low clearance drugs. Tramadol, as basic amine, is 
expected to accumulate inside the hepatocyte, solely driven by the existing pH gradient from 7.4 outside 
the cell, over 7.2 in the cytosol, to 5 in lysosomes [40]. No transporters are thought to be involved in 
this process [7], which is in line with tramadol’s BCS class I. An important issue in this matter is to 
establish which fraction of drug is available to the CYP enzyme system. The CLint, as determined in vitro 
in hepatocyte suspensions, should provide an indirect measure of the accumulation of unbound drug 
inside the hepatocyte, that is readily available for biotransformation. Nevertheless, a substantial 
underestimation of the CLint using hepatocyte incubations is a recognized problem [41, 42] and 
questions concerning the presence of a comparable pH gradient in such an in vitro setup have arisen 
[43, 44]. Additionally, Poulin and co-workers also stated that the unbound drug fraction inside the 
hepatocyte could be greater than the unbound fraction in plasma because of binding effects of albumin 
on the hepatocyte cell surface in vivo on the one hand, and the aforementioned pH difference for 
ionizable compounds on the other hand. Consequently, by using in vitro systems in which these effects 
are unaccounted for, the CLint could be underestimated [45]. Because of the inability to determine this 
uptake, a hepatic accumulation value of 1.58 [40] was used in all clearance models, based on the pH 
difference between the hepatocyte’s outer (7.4) and inner (7.2) environment. To be able to put this into 
context, quite recently, equations were published by Berezhkovskiy et al. [44, 46] that can be used to 
calculate an ionization factor, describing a drug’s trapping behavior based on the drug’s pKa and the pH 
difference over the hepatocyte membrane. These equations revealed that for tramadol by varying the 
intracellular pH between 7.0 and 7.2, the ionization factor takes on values of 1.67 and 2.5, respectively. 
In analogy, varying the hepatic accumulation factor 2-fold (from 1.5 to 3) in our sensitivity analysis 
increased prediction of the clearance with 33%. This indicates that small changes in pH can introduce 
significant changes in tissue-to-plasma concentration ratios. A better characterization of the relevant 
processes at hand could improve clearance prediction accuracy from an IVIVE perspective.  
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6 CONCLUSION 
In conclusion, based on this work, we document that for quantitative PBPK modeling & simulation, all 
experiments to determine enzyme kinetic parameters should be performed with concentrations 
mimicking the in vivo obtained concentrations as closely as possible, while at the same time carefully 
scrutinizing reaction linearity. Tramadol as such displays a low turnover in hepatic in vitro systems, but 
using the physiological integration features of IVIVE-PBPK, i.e. the combination with a high fraction 
unbound in plasma (80%) and the hepatic accumulation (1.58 fold) of tramadol, leads to a simulation 
result corresponding with the quite extensive metabolism (approximately 80% of dose) observed in vivo. 
Three distinct clearance models were described in this paper. The HLM model slightly underpredicted, 
while the rhCYP model slightly overpredicted the geometric mean clearance. The CYP2D6 contribution 
was underpredicted in both cases. Although the variability also suffered from some underpredicition, 
the predicted coefficients of variation were in line with observed ones. We clearly illustrated that the 
use of a retrograde model as reference model facilitates the bottom-up PBPK model building process. 
The IVIVE-linked PBPK approach has proven to be a very useful tool in integrating available in vitro, in 
silico, and in vivo data on tramadol to successfully predict the in vivo PK and gain mechanistic insight in 
relevant disposition covariates at hand. 
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8 APPENDIX 
The bioanalytical runs were accepted based on the criteria, which are described hereunder. For these 
criteria, the FDA Guidance document was followed. 
 
• The calibration curve consisted of 10 calibrators. QC samples were present on 3 levels (low, mid, 
and high), and were made in duplicate. Calibrators and QC samples were always made from dry 
powder for every new run 
• Linearity of the calibration curve was checked. Simple linear regression was applied with a 
weighting factor 1/x. The coefficient of determination (R²) was 0.99 or more. 
• At least 4 out of 6 QC samples were within 15% of their nominal value. Standards deviated not 
more than 15% from the nominal concentration, except for the LLOQ where 20% deviation was 
allowed. 
• Within run accuracy and precision was assessed on the three QC levels (n=4) for the different 
metabolites that were measured in the analysis (as tabulated hereunder).  
 ODT NDT NODT 
Level 
Conc 
ng/mL 
ACC 
(PREC) 
Conc 
ng/mL 
ACC 
(PREC) 
Conc 
ng/mL 
ACC 
(PREC) 
LQC 3.65 
98% 
(9.4%) 
3.95 
95% 
(5.1%) 
3.20 
96% 
(5.4%) 
MQC 85.17 
105% 
(1.3%) 
92.17 
107% 
(2.6%) 
74.67 
101% 
(7.2%) 
HQC 851.67 
102% 
(0.1%) 
921.67 
104% 
(2.5%) 
746.67 
97% 
(0.7%) 
 
• Between-run accuracy and precision was assessed at the LLOQ level (n=4) for the different 
metabolites that were measured in the analysis (as tabulated hereunder). 
 ODT NDT NODT 
Level 
Conc 
ng/mL 
ACC 
(PREC) 
Conc 
ng/mL 
ACC 
(PREC) 
Conc 
ng/mL 
ACC 
(PREC) 
LLOQ 1.04 
99% 
(6.2%) 
1.19 
110% 
(2.4%) 
0.24 
107% 
(9.6%) 
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CHAPTER 4 
 
 
 
 
 
 
 
 
 
STRATEGIES FOR DETERMINING CORRECT CYTOCHROME 
P450 CONTRIBUTIONS IN HEPATIC CLEARANCE 
PREDICTIONS: IN VITRO-IN VIVO EXTRAPOLATION AS 
MODELLING APPROACH AND TRAMADOL AS PROOF-OF 
CONCEPT COMPOUND 
 
 
 
 
 
This chapter is based on: 
T’jollyn H, Snoeys J, Van Bocxlaer J, De Bock L, Annaert P, Van Peer A, et al. Strategies for Determining 
Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro–In Vivo Extrapolation 
as Modelling Approach and Tramadol as Proof-of Concept Compound. European Journal of Drug 
Metabolism and Pharmacokinetics. 2016//:1-7 (AOP)  
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1 ABSTRACT 
Background and Objective 
Although the measurement of cytochrome P450 (CYP) contributions in metabolism assays is 
straightforward, determination of actual in vivo contributions might be challenging. How representative 
are in vitro for in vivo CYP contributions? This article proposes an improved strategy for the 
determination of in vivo CYP enzyme-specific metabolic contributions, based on in vitro data, using an 
in vitro-in vivo extrapolation (IVIVE) approach. Approaches are exemplified using tramadol as model 
compound, and CYP2D6 and CYP3A4 as involved enzymes. 
Methods 
Metabolism data for tramadol and for the probe substrates midazolam (CYP3A4) and 
dextromethorphan (CYP2D6) were gathered in human liver microsomes (HLM) and recombinant human 
enzyme systems (rhCYP). From these probe substrates, an activity-adjustment factor (AAF) was 
calculated per CYP enzyme, for the determination of correct hepatic clearance contributions. As a 
reference, tramadol CYP contributions were scaled-back from in vivo data (retrograde approach) and 
were compared with the ones derived in vitro. In this view, the AAF is an enzyme-specific factor, 
calculated from reference probe activity measurements in vitro and in vivo, that allows appropriate 
scaling of a test drug’s in vitro activity to the ‘healthy volunteer’ population level. Calculation of an AAF 
thus accounts for any ‘experimental’ or ‘batch-specific’ activity difference between in vitro HLM and in 
vivo derived activity. 
Results 
In this specific HLM batch, for CYP3A4 and CYP2D6, an AAF of 0.91 and 1.97 was calculated, respectively. 
This implies that, in this batch, the in vitro CYP3A4 activity is 1.10-fold higher and the CYP2D6 activity 
1.97-fold lower, compared to in vivo-derived CYP activities. 
Conclusion 
This study shows that, in cases where the HLM pool does not represent the typical mean population 
CYP activities, AAF correction of in vitro metabolism data, optimizes CYP contributions in the prediction 
of hepatic clearance. Therefore, in vitro parameters for any test compound, obtained in a particular 
batch, should be corrected with the AAF for the respective enzymes. In the current study, especially the 
CYP2D6 contribution was found to better reflect the average in vivo situation. It is recommended that 
this novel approach is further evaluated using a broader range of compounds.  
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2 INTRODUCTION 
In setting up a physiologically relevant in vitro-in vivo extrapolated physiologically-based 
pharmacokinetic (IVIVE-PBPK) model, not only must the total clearance be captured well, also the 
relevant Cytochrome P450 (CYP) contributions used in the model should be representative of the in vivo 
situation [1, 2]. This IVIVE approach assumes that the CYP contributions measured in vitro (pooled 
human liver microsomes (HLM)) are the same as the ones observed in vivo. However, in vitro activities 
might not represent healthy adult activity due to e.g. the source of the liver tissue (often diseased 
patients) [3] or binding competition of the compound under study with free fatty acids [4]. Therefore, 
methods are needed that ensure this predictability. In the current work, the use of an activity-
adjustment factor (AAF) is presented as an alternative method and evaluated against the conventional 
(uncorrected) approach. The conventional approach consists of IVIVE from HLM and human 
recombinant (rhCYP) enzyme kinetic data, including determination of the preferred inter-system 
extrapolation factor (ISEF) [5]. Tramadol is used as a proof-of-concept compound since it is metabolized 
by different and clinically important CYP enzymes (i.e. CYP3A4, CYP2D6 and CYP2B6) [6]. Besides, clinical 
data is available concerning the effect of (i) CYP2D6 polymorphisms, and (ii) rifampicin induction on 
tramadol’s clearance. In the current work, the main focus is on the CYP2D6-CYP3A4 interplay, and less 
on CYP2B6. This is because the initial focus of this project was on the most relevant CYP enzymes and 
because CYP2B6 plays a minor role in tramadol metabolism, as indicated in the discussion section.   
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3 MATERIALS AND METHODS 
3.1 CHEMICALS AND MATERIALS 
All chemicals and reagents used were of the highest available grade: Na2HPO4, KH2PO4, KCl, MgCl2, NADP, 
HCl (Merck, Darmstadt, Germany), glucose-6-phosphate, glucose-6-phosphate dehydrogenase (Roche 
Diagnostics GmbH, Mannheim, Germany), midazolam, dextromethorphan, 1-OH midazolam, 
dextrorphan, deuterated 1-OH midazolam (TRC inc, Toronto, Canada), chlorpropamide (Sigma Aldrich, 
St. Louis, USA). Human liver microsomal pool (BD Biosciences, Woburn, USA) consisted of 50 adult 
donors (mixed gender). 
3.2 INCUBATIONS IN HLM AND RHCYP OF MIDAZOLAM, DEXTROMETHORPHAN, AND 
TRAMADOL 
For midazolam/dextromethorphan, the incubation mixture consisted of 120 µL diluted microsomes, 100 
µL cofactor mix for NADPH regeneration system, and 5 µL test compound (0.5% MeOH in final 
incubation mixture) for both HLM as well as rhCYP systems. After a preincubation period of 5 min at 
37°C and 100 oscillations/min, NADP was added to the preincubation mixture to a final volume of 250 
µL to initiate the reaction. Midazolam was incubated in the range of 0.1-16 µM at 0.15 mg protein/mL 
(HLM) and 10 pmol CYP3A4/mL (rhCYP). The reaction was stopped after 10 min with 250 µL DMSO 
containing deuterated 1-OH midazolam as the internal standard (0.1 µg/mL). Dextromethorphan was 
incubated in the range of 0.5-16 µM at 0.3 mg protein/mL (HLM) and 4 pmol CYP2D6*1/mL (rhCYP). 
The reaction was stopped after 10 min with 250 µL DMSO containing chlorpropamide as the internal 
standard (0.22 µg/mL). Although these conditions differ from the ones used in the Walsky and Obach 
paper [7], linearity as a function of time and protein concentration for these probe substrates was 
demonstrated (data on file). Samples were centrifuged for 10 min at 1711g and the supernatant 
introduced to the UPLC-MS method. The intrinsic clearance was calculated in the Enzyme Kinetics 
module of Sigma Plot. For tramadol linearity experiments, incubations, and phenotyping experiments in 
pooled HLM and rhCYP systems, we refer to our previous publication [8]. The unbound fraction in the 
incubates for probe substrates midazolam and dextromethorpan was calculated from reported 
literature values [9, 10]. Details on the determination of these fu values are provided in the Appendix. 
3.3 BIOANALYSIS 
The midazolam metabolite, 1-OH midazolam, was analyzed using a Waters Acquity UPLC system coupled 
to a Thermo LTQ mass spectrometer (Thermo Fisher Scientific, San Jose, U.S.)  in APCI +. The column 
was an Acquity UPLC BEH C18 (1.7µm) 50 x 2.1 mm held at 60°C with mobile phase constituents 0.1% 
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HCOOH in ULC water and 0.1% HCOOH in CH3CN in a linear gradient. Run time was 3 min and flow rate 
0.6 mL/min. Mass transitions for 1-OH midazolam and deuterated 1-OH midazolam (internal standard) 
using a collision energy (CE) of 30 eV were 342>325, and 346>328, respectively. Calibration curves were 
always made in the same microsomal matrix as the incubates using at least 8 calibrator levels and 3 QC 
levels for the calibration curve. The dextromethorphan metabolite, dextrorphan, was analyzed using a 
Waters Acquity UPLC system coupled to a Micromass Quattro Ultima triple quadrupole, operating in ESI 
+. The column was an Acquity UPLC BEH C18 (1.7µm) 50 x 2.1 mm at 35°C with mobile phase 
constituents 0.1% HCOOH in ULC water and 0.1% HCOOH in CH3CN in a linear gradient. Run time was 
5.25 min and flow rate 0.4 mL/min. Mass transitions for dextrorphan and chlorpropamide using a CE of 
28 and 25 eV were 258>157, and 277>275. Details about the dextromethorphan and tramadol 
bioanalysis methods, can be found in De Bock et al, 2012 [11] and T’jollyn et al., 2015 [8], respectively. 
3.4 CALCULATION OF ISEF AND ACTIVITY-ADJUSTMENT FACTORS USING PROBE SUBSTRATES 
ISEF values were calculated for CYP3A4 (midazolam) and CYP2D6 (dextromethorphan) using the formula 
below (equation 1). 
𝐼𝑆𝐸𝐹= 
𝐶𝐿𝑖𝑛𝑡𝑢,𝐻𝐿𝑀
𝐶𝐿𝑖𝑛𝑡𝑢,𝑟ℎ𝐶𝑌𝑃∗[𝐶𝑌𝑃]𝐻𝐿𝑀
 
EQUATION 1 
CLintu,HLM and CLintu,rhCYP are the unbound intrinsic clearances (determined via metabolite formation) of 
a specific probe substrate in HLM and rhCYP systems, respectively. [CYP]HLM represents the typical 
enzyme abundance values of 137 and 8 pmol CYP/mg used for CYP3A4 and CYP2D6, respectively [5, 12].  
The activity-adjustment factor (AAF) is calculated as the ratio of the (unbound) in vivo back-calculated 
hepatic CLint and the unbound in vitro HLM CLint for a specific enzyme using the specific probe substrate 
(equation 2 and Table 1). 
 
𝐴𝐴𝐹𝐶𝑌𝑃=
𝐶𝐿𝑖𝑛𝑡𝑢,𝑖𝑛𝑣𝑖𝑣𝑜,𝐶𝑌𝑃
𝐶𝐿𝑖𝑛𝑡𝑢,𝐻𝐿𝑀,𝐶𝑌𝑃
 
EQUATION 2 
Then, the AAF, which is calculated for each CYP isozyme, is multiplied with the relevant parameter 
involved in the IVIVE (i.e. either CLintu,HLM,CYP or ISEFCYP. This yields the CLintaa,u,HLM,CYP for HLM data and 
ISEFaa,CYP, for rhCYP data (equation 3 and Table A1 in Appendix). 
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𝐶𝐿𝑖𝑛𝑡𝑎𝑎,𝑢,𝐻𝐿𝑀,𝐶𝑌𝑃=𝐶𝐿𝑖𝑛𝑡𝑢,𝐻𝐿𝑀,𝐶𝑌𝑃 ∗ 𝐴𝐴𝐹𝐶𝑌𝑃
𝐼𝑆𝐸𝐹𝑎𝑎,𝐶𝑌𝑃= 𝐼𝑆𝐸𝐹𝐶𝑌𝑃 ∗𝐴𝐴𝐹𝐶𝑌𝑃 
  
EQUATION 3 
3.5 IVIVE-PBPK MODEL DEVELOPMENT 
The unbound intrinsic clearance calculated per in vitro system with/without correction (see previous 
section), is used in the well-stirred liver approach in Simcyp® (v12.1, Certara, Sheffield, UK) to come up 
with an in vivo hepatic clearance. The AAF-corrected hepatic clearance predictions are compared to 
their uncorrected counterparts, as described in Chapter 3. In the HLM and HLMaa models, CLint values 
Table A1  in Appendix, columns 1 & 2) were provided in the enzyme kinetics tab of the Simcyp® 
Simulation platform, whereas in the rhCYP and rhCYPaa models, both CLint and ISEF values (Table A1, 
columns 3 & 4) were provided. In the retrograde model, CLint values were calculated from in vivo data, 
as described below (Table A1, column 5).  
3.6 RETROGRADE METHOD: INDIVIDUAL CYP CONTRIBUTIONS FROM TRAMADOL IN VIVO DATA 
The retrograde-scaled approach calculates a hepatic intrinsic clearance per CYP enzyme based on in vivo 
hepatic clearance values and apparent in vivo CYP contributions in the total metabolism. Two different 
approaches were used to quantitatively define CYP2D6, CYP2B6 and CYP3A4 involvement using 
tramadol in vivo data. For details about the CYP2D6 contribution, we refer to Chapter 3. The CYP2B6-
CYP3A4 contribution was assessed by performing a clinical trial simulation in which a tramadol-
rifampicin drug-drug interaction (DDI) was considered. To this end, the study population and study 
design as described by Saarikoski, et al. [13] was matched in a PBPK modelling environment. The 
rifampicin drug-specific parameters that were used in the PBPK model and that describe its PK and 
induction effects on CYP2B6 and CYP3A4, are described elsewhere [14]. They were proven to be capable 
to describe rifampicin’s DDI potential. While keeping the CYP2D6 contribution in the tramadol 
retrograde (RG) model fixed, the CYP2B6 contribution was varied between 0 and 30% at the expense of 
the CYP3A4 contribution. Simulation results were expressed as the geometric mean ratio of the 
AUCcontrol/AUCinduced for 100 simulated trials and compared to the observed geometric mean ratio from 
the actual in vivo DDI study between tramadol and rifampicin [13].   
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4 RESULTS 
For the calculation of the AAF, the back-calculation of the CYP3A4 CLintu,invivo (probe substrate 
midazolam) involved a well-stirred liver model and its value is based on 31 investigational midazolam 
PK studies [15]. This CYP3A4 -specific contribution was assessed by accounting for the conversion 
midazolam -> 1-OH midazolam, representing 74% of the in vivo derived hepatic CLint (Simcyp® 
midazolam compound file, v12.1) (see Appendix). Next, the AAF3A4 was calculated and had a value of 
0.91 (Table 1). In order to calculate the AAF2D6, the CYP2D6 CLintu,invivo (probe substrate 
dextromethorphan) was collected from one study [16], using a parallel tube model. In addition, a factor 
of 1.56 accounts for dextromethorphan’s accumulation in the hepatocyte’s cytosol [17](see Appendix). 
Next, the AAF2D6 was calculated and had a value of 1.97 (Table 1). Final metabolism parameters used in 
the IVIVE are displayed in Table A1 (Appendix). In addition, Table 1 reports ISEF values per CYP enzyme. 
Based on midazolam and dextromethorphan metabolism data, an ISEF of 0.23 and 0.45 could be 
calculated for CYP3A4 and CYP2D6, respectively. 
 
 
TABLE 1: OVERVIEW OF PROBE SUBSTRATE DATA 
THESE VALUES WERE OBTAINED FOR THE PROBE SUBSTRATES MIDAZOLAM (CYP3A4) AND DEXTROMETHORPHAN (CYP2D6). AAF WAS 
CALCULATED FROM THE RATIO OF THE CLINT VALUES IN THIS TABLE AS DESCRIBED IN THE METHODS SECTION. ISEF WAS CALCULATED PER 
PROBE SUBSTRATE FROM THE RATIO OF THE CLINTS OBTAINED IN HLM AND RHCYP SYSTEMS. 
CYP Enzyme (probe) CYP3A4 (midazolam) CYP2D6 (dextromethorphan) 
CLintu,in vivo,CYP (µL/min/mg) 336 a 58.9 b 
CLintu,HLM,CYP (µL/min/mg) 369 29.9 
AAF 0.91 1.97 
ISEF 0.23 0.45 
a [15] ; b [16] 
CLint: intrinsic clearance; CLintu,in vivo,CYP: the unbound in vivo CLint for a specific CYP enzyme; 
CLintu,HLM,CYP : the unbound HLM CLint for a specific CYP enzyme: AAF: activity-adjustment factor; ISEF: 
inter-system extrapolation factor 
 
The different hepatic clearance models were evaluated based on prediction errors (calculated as (CLobs-
CLpred)/CLobsx100%) and the different CYP enzyme contributions (Table 2). Tramadol’s in vitro CYP 
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contributions (with and without AAF correction) were compared with the ones calculated from the RG 
method. Tramadol’s CYP contributions from activity-adjusted models (HLMaa and rhCYPaa model; Table 
2) agree well with those from the tramadol retrograde-scaled clearance approach (RG model, Table 2), 
although the absolute values of total clearance display some prediction bias (indicated by the prediction 
error). The CYP2D6 contribution (HLMaa 45%; rhCYPaa 44.6%; RG 45.6%) corresponds very well between 
the AAF models and is more accurate as compared to the HLM and rhCYP models without AAF. The 
contributions of CYP3A4 (HLMaa 39.2%; rhCYPaa 39.9%; RG 45.1%) and CYP2B6 (HLMaa 15.8%; rhCYPaa 
15.5%; RG 9.3%) differ by maximum 5% with the RG approach. 
 
TABLE 2: MODEL PERFORMANCE AND CHARACTERISTICS PRESENTED PER CLEARANCE MODEL. 
THE HLM AND RHCYP MODELS ARE BUILT-UP FROM IN VITRO DATA IN HLM AND RHCYP SYSTEMS, RESPECTIVELY. THE HLMAA AND RHCYPAA 
MODELS ARE CORRECTED WITH THE AAF. THE RETROGRADE MODEL CAN BE CONSIDERED THE REFERENCE MODEL IN TERMS OF TOTAL 
CLEARANCE AND CYP CONTRIBUTIONS IN THE HEPATIC CLEARANCE. 
 prediction 
error (%) 
% hepatic 
clearance 
% CYP2D6 
in hep CL 
% CYP3A4  
in hep CL 
% CYP2B6 
in hep CL 
HLM model - 27% 56.9% 29.1% 51.9% 19.0% 
HLMaa model - 19% 61.3% 45.0% 39.2% 15.8% 
rhCYP model + 22% 75.9% 29.2% 51.8% 19.0% 
rhCYPaa model + 39% 78.7% 44.6% 39.9% 15.5% 
Retrograde model + 2% 70.5% 45.6% 45.1% 9.3% 
HLM: human liver microsomes; rhCYP: human recombinant CYP enzymes; AAF: activity-adjustment 
factor; HLMaa: the activity-adjusted HLM model; rhCYPaa: the activity-adjusted rhCYP model 
 
In the tramadol RG model, the CYP2D6 contribution was estimated using the dataset from [18] by 
determining which percentage of the hepatic clearance (48%, Table A1) is required to increase it 1.74-
fold between poor and extensive metabolizers. Next, the CYP2B6-CYP3A4 involvement was estimated 
by comparing geometric mean AUC ratios from a DDI clinical trial simulation approach. The resulting 
geometric mean AUC ratio with 90% confidence intervals was compared to the observed geometric 
mean AUC ratio (Figure 1). Only with a CYP2B6 contribution of less than 10% and a CYP3A4 contribution 
of more than 42% (Table A1), the observed geometric mean AUC ratio fell within the 90% confidence 
interval of the trial simulations (Figure 1). The main driver of this rifampicin-tramadol DDI is CYP3A4, in 
view of its important role in tramadol’s metabolism. The steady-state rifampicin induction increases 
CYP2B6’s contribution with only 2%, whereas CYP3A4’s contribution is increased with 31% (data not 
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shown). The CYP2B6 contribution was calculated to be maximally 10% of tramadol’s hepatic intrinsic 
clearance (Table A1). 
 
 
 
  
FIGURE 1: DDI CLINICAL TRIAL SIMULATION OF TRAMADOL AND RIFAMPICIN TO ASSESS THE CONTRIBUTION OF CYP2B6 AND CYP3A4. THE FIGURE 
DEPICTS THE RESULTS OF 100 TRIAL SIMULATIONS MIMICKING THE ORIGINAL TRIAL, WHEN CYP2B6 AND CYP3A4 CONTRIBUTIONS ARE ASSUMED 
TO BE 10 AND 42%, RESPECTIVELY. BLACK HORIZONTAL LINES REPRESENT THE IN VIVO OBSERVED RATIO OF AUC GEOMETRIC MEANS (SOLID) 
AND 90% CONFIDENCE LIMITS (DASHED). THE RED DOTS REPRESENT THE GEOMETRIC MEANS OF EACH TRIAL SIMULATION (AND ERROR BARS 
REPRESENT THE 90 CONFIDENCE INTERVAL). THE SOLID RED LINE REPRESENTS THE AVERAGE RATIO OF SIMULATED AUC GEOMETRIC MEANS. 
THE SOLID BLACK LINE IS IN THE 95% CONFIDENCE REGION (GREYED AREA) ONLY IF THE CYP2B6 CONTRIBUTION IS LESS THAN OR EQUAL TO 
10%.  DDI: DRUG-DRUG INTERACTION; AUC: AREA UNDER THE CURVE 
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5 DISCUSSION 
Whenever pooled HLM activities are measured, the assumption is that every enzyme represents the 
population average activity. If this is not the case, the activity-adjustment factor (AAF) provides a way 
to correct for the difference between in vitro and in vivo activities. The AAF (equation 2 and Appendix) 
is an enzyme-specific factor, calculated from reference probe activity measurements in vitro and in vivo 
that allows appropriate scaling of a test drug’s in vitro activity to the ‘healthy volunteer’ population level. 
The AAF for CYP3A4 in this study is 0.91 (Table 1) (1 represents no activity adjustment is needed). This 
implies that the CYP3A4 activity in the pooled HLM batch at hand, is nearly identical to that derived from 
the midazolam CLint, which was back-calculated from in vivo clearance values. Consequently, CYP3A4 
activity measurements in this batch will be representative for the average population CYP3A4 activity. 
However, for CYP2D6, the AAF was computed at 1.97 (Table 1). This indicates that the CYP2D6 in vitro 
activity in this batch is about 2-fold below the typical ‘healthy volunteer’ population CYP2D6 activity. 
Calculation of an AAF thus accounts for any ‘experimental’ or ‘batch-specific’ activity difference 
between in vitro HLM and in vivo derived activity. The importance of using the AAF concept is illustrated 
by integrating it in the IVIVE of tramadol metabolism to its two primary metabolites O-desmethyl 
tramadol (ODT) and N-desmethyl tramadol (NDT). The metabolism parameters used in the IVIVE are 
displayed in Table A1 (Appendix). 
Although the retrograde-scaled approach is an attractive way to calculate CYP contributions based on 
in vivo data, it also depends on the quality of these in vivo data. The 10% involvement threshold for 
CYP2B6 in the retrograde model should be viewed as an approximate value for two reasons: (i) for 
CYP2B6, an AAF could not be calculated since CYP2B6 in vitro probe data were not available (see Table 
2), and (ii) the design of the rifampicin-tramadol in vivo DDI study allowed only a partial differentiation 
of the CYP2B6 and CYP3A4 contributions. In essence, since for CYPD6 the different data elements were 
all available, the CYP2D6 approach could serve as proof of concept for the proposed methodology. The 
activity-adjusted CYP2D6 contribution turned out to be very similar to the one estimated from in vivo 
clearance data (RG approach), and shows a large improvement versus its contribution calculated in non-
activity adjusted models (Table 2). This finding underscores the method’s potential benefit.  
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6 CONCLUSION 
Taken together, the AAF (i) provides compound-independent information about specific enzyme 
activities that should be incorporated whenever in vitro HLM activities are measured for a test drug, and 
(ii) allows to accurately calculate CYP contributions in vivo, even before clinical data of the test drug is 
available. In view of the increasing role of IVIVE-PBPK in drug development programs, it is important to 
determine the actual enzyme contributions in the hepatic clearance as early as possible. This way, 
clinical trial designs and clinically important drug-drug interactions may be better anticipated. In the 
current work, tramadol was used as a proof-of-concept compound, but more work is needed to 
extensively validate the proposed approach across a broader range of compounds.  
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8 APPENDIX 
TABLE A1: REPRESENTATION OF ALL CLINT AND ISEF VALUES THAT WERE USED PER HEPATIC CLEARANCE MODEL AS INPUT PARAMETERS FOR 
THE ENZYME KINETICS TAB IN THE SIMCYP® SIMULATOR. 
                Model 
 
Reaction 
HLM model 
CLintHLM 
(µL/min/mg) 
HLMaa model 
CLintaa,HLM 
(µL/min/mg) 
rhCYP model 
CLint [ISEF] 
(µL/min/pmol P450) 
rhCYPaa model 
CLint [ISEFaa] 
(µL/min/pmol P450) 
RG model 
CLintRG 
(µL/min/pmol P450) 
3A4-ODT 0.120 
0.1092 
(AAF3A4= 0.91) 
0.000 [0.23] 
0.000 [0.21] 
(AAF3A4= 0.91) 0.0154 
(42% HepCL) 
3A4-NDT 1.060 
0.9646 
(AAF3A4= 0.91) 
0.110 [0.23] 
0.110 [0.21] 
(AAF3A4= 0.91) 
2D6-ODT 0.640 
1.261 
(AAF2D6= 1.97) 
0.57 [0.45] 
0.57 [0.89] 
(AAF2D6= 1.97) 0.301 
(48% HepCL) 
2D6-NDT 0.080 
0.158 
(AAF2D6= 1.97) 
0.054 [0.45] 
0.054 [0.89] 
(AAF2D6= 1.97) 
2B6-ODT1 0.040 
0.040 
(AAF2B6= 1) 
0.018 [0.43] 
0.018 [0.43] 
(AAF2B6= 1) 0.0295 
(10% HepCL) 
2B6-NDT1 0.500 
0.500 
(AAF2B6= 1) 
0.200 [0.43] 
0.200 [0.43] 
(AAF2B6= 1) 
1 The CYP2B6 ISEF was not measured in these experiments and so (i) the standard Simcyp® ISEF of 0.43 was used, 
and (ii) the AAF is considered to be 1= no activity adjustment. 
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Calculation of the AAF and ISEF for CYP3A4 and CYP2D6 
CYP3A4 (Midazolam) 
1. Calculation of total hepatic CLint from in vivo data [15] 
CLintH (mL/min) = 440 mL/min/kg x 70 kg = 30800 mL/min 
CLintH (µL/min/mg MP) = 30800 mL/min / 1718 g / 39.5 MPPGL= 454 µL/min/mg MP 
Via the Simcyp® midazolam compound file (V12.1, PK profiles, n=1000) it was calculated that CYP3A4 is 
involved for (only) 74% in the above midazolam CLintH. Therefore:  
CLintu,invivo,3A4 (µL/min/mg MP) = 454 µL/min/mg MP x 0.74 = 336 µL/min/mg MP 
 
2. Calculation of the AAF for CYP3A4 in pooled HLM 
CLintu,invivo,3A4 = unbound CYP3A4 CLint calculated from in vivo data = 336 µL/min/mg MP 
CLintu,HLM,3A4 = Batch-specific unbound CLint calculated from HLM midazolam activity (369 µL/min/mg 
MP) 
 CLint HLM,3A4 = 358 µL/min/mg MP, determined experimentally, with conditions provided 
in the materials and methods section 
 FumicMDZ = 0.97 at 0.15 mg MP/mL. This value is derived from the fumicMDZ of 0.83 in 
the presence of 0.5 mg MP/mL [9] and the formula fu2 = [C2/C1*((1-fu1)/fu1) + 1]-1, which allows 
calculation of fumic for different protein concentrations 
AAF = CLintu,invivo,3A4 / CLintu,HLM,3A4 = 336 / 369 = 0.91 
 
3. Calculation of the ISEF for CYP3A4 
CLintu,HLM,3A4 = Batch-specific unbound CLint calculated from in vitro HLM midazolam activity = 369 
µL/min/mg MP 
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CLintu,rh3A4 = Batch-specific unbound CLint calculated from rh3A4 midazolam activity = 11.53 
µL/min/pmol rh3A4 
[CYP3A4]invivo = CYP3A4 abundance in vivo = 137 pmol/mg MP [12] 
ISEF = CLintu,HLM,3A4 / (CLintu,rh3A4 x [CYP3A4]invivo) = 0.23 
 
 
CYP2D6 (Dextromethorphan) 
1. Calculation of CYP2D6 hepatic CLint from in vivo data [16] 
CLintH,2D6 (µL/min/g liver) = 3900 µL/min/mL liver / 1.08 mL/g = 3611 µL/min/g liver 
CLintH,2D6 (µL/min/mg MP) = 3611 µL/min/g liver / 39.5 MPPGL / 1.56 = 58.60 µL/min/mg MP 
 
 Why division by 1.56? 
Dextromethorphan behaves as a lipophilic weak base concerning its distribution at the hepatocellular 
level. Because the pH in hepatocytes is somewhat lower (pH=7.0 – 7.2) than in plasma (7.4), an ion 
trapping phenomenon can be observed resulting in higher concentrations of dextromethorphan in the 
cytosolic space of the hepatocyte than expected [17]. For dextromethorphan, a hepatic uptake factor 
of 1.56 is considered. 
 
2. Calculation of the AAF for CYP2D6 in pooled HLM 
CLintu,invivo,2D6 = unbound CYP2D6 CLint calculated from in vivo data = 58.90 µL/min/mg MP 
CLintu,HLM,2D6 = Batch-specific unbound CLint calculated from HLM dextromethorphan activity (29.87 
µL/min/mg MP) 
 CLint HLM,2D6 = 29.27 µL/min/mg MP, determined experimentally, with conditions 
provided in the materials and methods section 
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 FumicDEX = 0.98 at 0.3 mg MP/mL. This value is derived from the fumicDEX of 0.96 in the 
presence of 0.5 mg MP/mL (Witherow & Houston, 1999 JPET) and the formula fu2 = [C2/C1*((1-
fu1)/fu1) + 1]-1, which allows calculation of fumic for different protein concentrations 
AAF = CLintu,invivo,2D6 / CLintu,HLM,2D6 = 58.90 / 29.87 = 1.97 
 
3. Calculation of the ISEF for CYP2D6 
CLintu,HLM,2D6 = Batch-specific unbound CLint calculated from HLM dextromethorphan activity = 29.87 
µL/min/mg MP 
CLintu,rh2D6 = Batch-specific unbound CLint calculated from rh2D6 dextromethorphan activity = 4.56 
µL/min/pmol rh2D6 
[CYP2D6]invivo = CYP2D6 abundance in vivo = 8 pmol/mg MP [12] 
ISEF = CLintu,HLM,2D6 / (CLintu,rh2D6 x [CYP2D6]invivo) =  0.45 
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CHAPTER 5 
 
 
 
 
 
 
 
 
 
PHYSIOLOGICALLY-BASED PHARMACOKINETIC 
PREDICTIONS OF TRAMADOL EXPOSURE THROUGHOUT 
PEDIATRIC LIFE: AN ANALYSIS OF THE DIFFERENT 
CLEARANCE CONTRIBUTORS WITH EMPHASIS ON 
CYP2D6 MATURATION 
 
 
 
 
This chapter is based on: 
T’jollyn, Huybrecht; Snoeys, Jan; Vermeulen, An; Michelet, Robin; Cuyckens, Filip; Mannens, Geert; Van 
Peer, Achiel; Annaert, Pieter; Allegaert, Karel; Van Bocxlaer, Jan & Boussery, Koen. Physiologically Based 
Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the 
Different Clearance Contributors with Emphasis on CYP2D6 Maturation. AAPS J. 2015 Nov; 17(6):1376-
87  
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1 ABSTRACT 
Background & Objective 
This paper focuses on the retrospective evaluation of PBPK techniques used to mechanistically predict 
clearance throughout pediatric life. The objective was to evaluate the bottom-up predictions of the 
clearance against top-down clearance predictions in pediatrics, with a focus on neonates and infants. 
Methods 
An intravenous tramadol retrograde PBPK model was set up in Simcyp® using adult clearance values, 
qualified for CYP2D6, CYP3A4, CYP2B6, and renal contributions. Subsequently, the model was evaluated 
for mechanistic prediction of total, CYP2D6-related, and renal clearance predictions in very early life. In 
2 in vitro pediatric HLM batches (1 and 3 months), O-desmethyltramadol and N-desmethyltramadol 
formation rates were compared with CYP2D6 and CYP3A4 activity, respectively. Additionally, the 
clearance maturation of the PBPK model predictions was compared to two in vivo maturation models 
(Hill and exponential) based on plasma concentration data, and to clearance estimations from a 
WinNonlin® fit of plasma concentration and urinary excretion data.  
Results 
O-desmethyltramadol formation in vitro was mediated only by CYP2D6, while N-desmethyltramadol was 
mediated in part by CYP3A4. Concerning the bottom-up predictions, in early life maturation of renal and 
CYP2D6 clearance is captured well in the PBPK model predictions, although CYP2D6 clearance was 
underpredicted from 2 years of age. The total tramadol clearance is underpredicted over the complete 
lifespan. The most pronounced underprediction of total and CYP2D6-mediated clearance was observed 
in the age range of 2-13 years. 
Conclusion 
In conclusion, the PBPK technique showed to be a powerful mechanistic tool capable of predicting 
maturation of CYP2D6 and renal tramadol clearance in early infancy, although some underprediction 
occurs between 2-13 years for total and CYP2D6-mediated tramadol clearance. 
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2 INTRODUCTION 
The present study focuses on the mechanistic prediction of tramadol clearance over the pediatric 
lifespan, since this parameter drives the total exposure to the drug and is key in titrating to the right 
drug dosage. Physiologically-based pharmacokinetic (PBPK) modeling enables pediatric pharmacological 
research to proceed to the next level, by guiding dose finding studies and the formulation design for the 
different stages in pediatric life [1-4]. The stronghold of PBPK models is that they separate intrinsic from 
extrinsic patient factors i.e., drug-independent (system) factors versus drug-dependent factors and 
study design, so that a physiologically plausible generic human model structure can be applied for any 
drug under various study conditions [3, 5]. In addition, a PBPK model, which incorporates demographical, 
physiological, and biochemical data elements, can be adjusted depending on a specific subpopulation 
of interest in order to make mechanistic PK predictions. In pediatrics, these models account for the 
ontogeny of different enzymes, changing tissue volumes and composition, as well as blood flows to 
these organs [6]. At this time, research into the ontogeny of transporters [7, 8] lags behind that of 
hepatic enzymes. 
Tramadol is a centrally acting analgesic drug mediating its effect through noradrenaline re-uptake 
inhibition, increased release of serotonin, and decreased re-uptake of serotonin in the spinal cord. 
Although in healthy volunteers tramadol is excreted unchanged in urine for about 25%, the greater part 
is metabolized [9]. Tramadol is oxidized to an active metabolite O-desmethyltramadol (ODT) via CYP2D6, 
having a µ-opioid activity 300 times that of the parent drug. Additionally, tramadol is inactivated to N-
desmethyltramadol (NDT) by CYP3A4 and CYP2B6. Secondary metabolism involves further oxidation and 
phase 2 conjugative reactions [10]. In early life, however, these primary metabolic pathways mature 
differently, and as a consequence not only the absolute value of the clearance but also relative 
contributions of the different eliminating pathways may change over time. Therefore, tramadol serves 
as a model drug in our PBPK study to evaluate whether maturation of the clearance is adequately 
predicted over the pediatric lifespan. In order to make mechanistically sound pediatric tramadol 
exposure predictions, different elimination pathways in the tramadol clearance should first be validated 
in an adult PBPK model previous to predicting pediatric exposure [11]. In the application of this 
methodology these limitations/assumptions should be considered: (i) clearance pathways in children 
are the same as those observed in adults, (ii) enzyme kinetics of metabolic contributors are first order, 
(iii) clearance models are perfusion limited (well-stirred), and (i.v.) no transporters are involved for 
which ontogeny information is unknown. These assumptions should always be checked since they are 
key in the mechanistic prediction of pediatric PK from adult data. Violation of these assumptions may 
result in clearance under- or overprediction if the clearance pathways differ between children and 
adults [12], if enzyme processes become saturated or enzyme affinities decrease (e.g. due to the 
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presence of free fatty acids or bilirubin), and if liver/kidney perfusion is altered (e.g. in the case of 
cirrhosis). Neglecting important transporter involvements might substantially over- or underpredict the 
clearance, depending on the specific transport mechanism at hand [13]. In the case of tramadol, 
although no OCT1-transport is involved [14], a minor contribution of proton dependent efflux pumps 
could not be ruled out [15]. 
In this work, first, an adequate intravenous adult PBPK model was set up in the Simcyp Simulator that 
accurately describes the total adult clearance, as well as the different CYP contributions (CYP2D6, 
CYP2B6, CYP3A4), and the renal elimination part, composing this clearance. Second, system specific 
parameters were adjusted to represent the physiological and biochemical changes occurring during 
childhood. The mechanistic prediction of the formation clearance to ODT and NDT in pediatrics has to 
take into account (i) ontogenic profiles of the CYP isoforms 2D6, 3A4, and 2B6 [16], as well as changes 
in (ii) amount of microsomal proteins per gram of liver, (iii) liver size, (iv) liver blood flow, and (v) plasma 
protein binding [17, 18]. Third, on the one hand, CYP maturation functions for CYP2D6 [17] and CYP3A4 
[18] were compared to experimentally determined human liver microsomal (HLM) activities of tramadol 
(together with the activity of CYP-specific probe substrates dextromethorphan (DEX for CYP2D6) and 
midazolam (MDZ for CYP3A4)) in two pediatric batches of 1 and 3 months of age. On the other hand, 
the pediatric PBPK in vivo clearance predictions were compared to popPK-derived maturation functions 
[19, 20].  
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3 MATERIALS AND METHODS 
3.1 CHEMICALS AND REAGENTS 
All chemicals and reagents used were of the highest available grade: Na2HPO4, KH2PO4, KCl, MgCl2, NADP, 
HCl (Merck, Darmstadt, Germany), glucose-6-phosphate, glucose-6-phosphate dehydrogenase (Roche 
Diagnostics GmbH, Mannheim, Germany), tramadol, midazolam (MDZ), dextromethorphan (DEX), O-
desmethyltramadol (ODT), N,O-didesmethyltramadol (NODT), 1-OH midazolam, dextrorphan, O-
desmethyltramadol-D6, and deuterated 1-OH midazolam (TRC inc, Toronto, Canada), N-
desmethyltramadol (NDT) (LGC GmbH, Luckenwalde, Germany), chlorpropamide (Sigma Aldrich, St. 
Louis, USA). 
3.2 ADULT VS PEDIATRIC IN VITRO METABOLISM OF TRAMADOL AND PROBE SUBSTRATES MDZ 
AND DEX 
3.2.1 TRAMADOL HLM INCUBATION CONDITIONS 
One pooled adult batch and two pediatric human liver microsomal (HLM) batches (BD Biosciences, 
Woburn, USA) were used in this study, collected from children aged 1 (male, Caucasian, head trauma) 
and 3 months (male, Hispanic, anoxia), and stored at -80°C in an Ultra Freezer (New Brunswick scientific, 
Rotselaar, Belgium). Incubation mixtures (total volume 600 µL) consisted of 297 µL microsomal protein, 
3 µL of a tramadol dissolved in MeOH, and 300 µL cofactor mix containing an NADPH-regenerating 
system consisting of 1 mg of glucose-6-phosphate, 0.50 units of glucose-6-phosphate dehydrogenase, 
0.25 mg of NADP and 1 mg of MgCl2.6H2O in 1 mL of 0.5 M Na,K-phosphate buffer pH 7.4. A 
preincubation with cofactor mix was done for 5 minutes in a shaking water bath at 37°C (100 
oscillations/min) (Thermo, Waltham, USA). Incubations were started by adding 3 µL of a substrate 
solution, and stopped by transferring 100 µL aliquots into 96-well plates containing 10 µL ice-cold 4N 
HCl and 10 µL of internal standard (O-desmethyltramadol-D6, 6 ng/mL). 
Linearity of tramadol metabolite formation was assessed as a function of time and protein 
concentration at the lowest in vitro substrate concentration in the adult HLM batch. The formation rate 
was linear up to 10 min and 1 mg protein/mL (data not shown). The enzyme kinetic parameters of 
tramadol in pediatric HLM were assessed by using a range of incubation concentrations (0.5, 1, 5, 20, 
50, 100, 150, 250, 300 and 500 µM). For each substrate and protein concentration level, samples were 
incubated in duplicate or triplicate and boiled control incubates were run in parallel to correct for non-
enzymatic degradation. 96-well plates were then stored at -20°C awaiting to be analyzed by UPLC-
MS/MS. 
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3.2.2 MDZ AND DEX HLM INCUBATION CONDITIONS 
MDZ/DEX incubation materials and methods were essentially the same as those for the tramadol 
metabolism assays. The incubation mixture consisted of 120 µL diluted microsomes, 100 µL cofactor 
mix for NADPH regeneration system, and 5 µL test compound. After a preincubation period of 5 min at 
37°C and 100 oscillations/min, NADP was added to the preincubation mixture to a final volume of 250 
µL to initiate the reaction. Midazolam was incubated at 0.2 µM and 0.05 mg protein/mL. The reaction 
was stopped after 10 min with 250 µL DMSO containing deuterated 1-OH midazolam as the internal 
standard (0.1 µg/mL). Dextromethorphan was incubated at 0.5 µM and 0.3 mg protein/mL. The reaction 
was stopped after 10 min with 250 µL DMSO containing chlorpropamide as the internal standard (0.22 
µg/mL). Samples were centrifuged for 10 min at 1711g and the supernatans introduced to the UPLC-MS 
system. The intrinsic clearance was calculated in the Enzyme Kinetics module of Sigma Plot. 
3.2.3 BIOANALYSIS 
Tramadol’s main metabolites O-desmethyltramadol (ODT, M1), N-desmethyltramadol (NDT, M2), and 
N,O-didesmethyltramadol (NODT, M5) were quantified by a sensitive UPLC-MS/MS method. A Nexera 
UHPLC system (Shimadzu, Kyoto, Japan) was coupled to an API 4000 QTRAP (AB Sciex, Toronto, Canada) 
equipped with a Turbo VTM ion source in ESI+ mode. For the chromatographic separation, a gradient 
was run - with solvents A (0.025M ammonium acetate, pH 8.5) and B (acetonitrile:methanol 80:20, v/v) 
- from 5% to 50% B in 3 min, to 100% B in an immediate step gradient, held for 0.3 min, and back to 5% 
B, allowing 2 min re-equilibration, at a flow rate of 0.6 mL/min. The column was an Acquity UPLC BEH 
C18 (1.7µm) 50 x 2.1 mm column (Waters, Milford, USA), maintained at 60°C. More details about this 
method were published earlier by our group in T’jollyn et al., 2015 [16] and are described in Chapter 3, 
hence they will not be repeated here. 
The MDZ metabolite, 1-OH midazolam, was analyzed using a Waters Acquity UPLC system coupled to a 
Thermo LTQ mass spectrometer (Thermo Fisher Scientific, San Jose, U.S.)  in APCI +. The column was an 
Acquity UPLC BEH C18 (1.7µm) 50 x 2.1 mm held at 60°C with mobile phase constituents 0.1% HCOOH 
in ULC water and 0.1% HCOOH in CH3CN in a linear gradient. Run time was 3 min and flow rate 0.6 
mL/min. Mass transitions for 1-OH midazolam and deuterated 1-OH midazolam (internal standard) 
using a collision energy (CE) of 30 eV were 342>325, and 346>328, respectively. Calibration curves were 
always made in the same microsomal matrix as the incubates using at least 8 calibrator levels and 3 QC 
levels for the calibration curve. The DEX metabolite, dextrorphan, was analyzed using a Waters Acquity 
UPLC system coupled to a Micromass Quattro Ultima triple quadrupole, operating in ESI +. The column 
was an Acquity UPLC BEH C18 (1.7µm) 50 x 2.1 mm at 35°C with mobile phase constituents 0.1% HCOOH 
in ULC water and 0.1% HCOOH in CH3CN in a linear gradient. Run time was 5.25 min and flow rate 0.4 
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mL/min. Mass transitions for dextrorphan and chlorpropamide using a CE of 28 and 25 eV were 258>157, 
and 277>275 [21], respectively. 
3.2.4 ENZYME KINETIC DATA ANALYSIS 
Concentrations of metabolites in the incubation samples were corrected for protein concentration (mg 
microsomal protein/mL), reaction time (min), and initial substrate concentration (µM) in order to 
calculate the apparent in vitro clearance (CLapp) for every metabolite. For tramadol, CLapp was plotted vs. 
tramadol incubation concentration and a nonlinear model –with the model structure provided in 
equation 1- was fitted to the data, using R v3.1.1 [22]. Models were evaluated by visually inspecting 
residual plots for bias. In equation 1, CLapp is the apparent in vitro clearance, vo is the initial rate of 
metabolite formation in the incubate, [S] is the tramadol concentration (µM), Km is the Michaelis-
Menten constant (µM) and Vmax the maximum velocity. This equation allowed estimation of the 
parameters Km and Vmax, and hence the calculation of CLint. An unbound fraction in microsomes (fumic) 
of ~0.96 was estimated in silico using the prediction toolbox in Simcyp® v13 [23]. 
𝐶𝐿𝑎𝑝𝑝 =
𝑣𝑜
[𝑆]
=
𝑉𝑚𝑎𝑥
𝐾𝑚 + [𝑆]
 
EQUATION 1 
 
3.3 DEVELOPMENT OF THE ADULT TRAMADOL PBPK MODEL 
An intravenous adult PBPK model was set up, using the retrograde calculator available in the Simcyp® 
Simulator (v13, Sheffield, UK), by extracting in vivo hepatic and renal clearance values from publications 
available in the scientific literature [24-28]. In this retrograde calculator, hepatic intrinsic clearances per 
CYP isoform are calculated, based on hepatic plasma clearance and apparent in vivo CYP contributions, 
using the well-stirred liver model [29, 30].  Table A1 with final numerical values for different parameters 
is provided in the supplementary data. Following approaches were used to define the contribution of 
CYP2D6, CYP2B6 and CYP3A4 in the adult hepatic clearance of tramadol. 
3.3.1 CYP2D6 CONTRIBUTION 
The CYP2D6 contribution in the tramadol hepatic clearance was assessed by comparing the hepatic 
clearance increase between poor and extensive metabolizers in observations and predictions. 
Observations were extracted from a study conducted by Pedersen et al. [31]. Patients from this study 
were genotyped as *1/*1 (EM; n=8) and *4/*4 (n=7) or *4/*6 (PM) (n=1). By taking into account the 
actual age range, administered dose, and proportion of males and females in the PBPK trial design, we 
mimicked the actual clinical trial in our predictions. Virtual populations are generated in the Simcyp® 
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Simulator by using a correlated Monte Carlo approach. For a more detailed description, we redirect the 
interest reader to Jamei et al, 2009[32]. 
3.3.2 CYP2B6-CYP3A4 CONTRIBUTION 
Although CYP2B6 seems to be a minor contributor to the total clearance, the CYP2B6 contribution apart 
from the CYP3A4 involvement was assessed by performing a tramadol-rifampicin drug-drug interaction 
(DDI) simulation and by comparison of predicted with observed AUCs. Using information of the study 
population and design by Saarikoski, et al. [33], 100 virtual trials were simulated with 12 subjects each 
receiving six doses of 600 mg oral rifampicin (RIF) every 24h were simulated. Twelve hours after the last 
rifampicin dose, 50 mg tramadol was administered and the change in AUC reported. Subjects ranged 
from 18 to 30 years of age and the female proportion was set to 0.42. Drug-specific parameters for 
rifampicin (elimination and induction effects on CYP2B6 and CYP3A4), described elsewhere [34], were 
used in this simulation. While keeping the CYP2D6 contribution in the tramadol adult PBPK model fixed, 
the CYP2B6 contribution was increased from 0 to 30% while the CYP3A4 contribution was (in parallel) 
decreased from 52 to 22%. The sum of the contributions of CYP2D6 and CYP2B6-3A4 always added up 
to 100% of the hepatic intrinsic clearance. Results for the 100 simulated trials were expressed as the 
geometric mean ratio of the AUCcontrol/AUCinduced and were compared to the observed geometric mean 
ratio from the actual in vivo DDI study [33]. 
3.4 PREDICTION OF PEDIATRIC CLEARANCE WITH THE DEVELOPED TRAMADOL PBPK MODEL  
The developed PBPK model was used to predict the clearance (total, CYP2D6, and renal component) 
over the pediatric lifespan, using the pediatric module of the Simcyp® Simulator. This module contains 
ontogeny information for the different CYP enzymes considered in this work (CYP2D6 and CY2B6 
ontogeny functions are described by Johnson et al. in [17], whereas CYP3A4 ontogeny information is 
described by Salem et al. in [35]). Additionally, the changes in  tissue volumes (i.e. liver, kidney), tissue 
composition (lipids vs. water content), and blood flows (i.e. QH, GFR), also described in [17], all vary as 
a function of age and determine the extent of the clearance in a specific pediatric subject. 
3.5 MODEL EVALUATION 
On the in vitro level, theoretical CYP maturation functions for CYP2D6 [17] and CYP3A4 [18] were 
compared to experimentally determined human liver microsomal (HLM) activities of tramadol (together 
with the activity of CYP-specific probe substrates dextromethorphan (DEX for CYP2D6) and midazolam 
(MDZ for CYP3A4)) in two pediatric batches of 1 and 3 months of age. On the in vivo level, pediatric PBPK 
model predictions (from a full term 40 weeks PMA onwards) were visually compared to in vivo clearance 
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maturation models, in terms of total, CYP2D6, and renal tramadol clearance, published in literature and 
described in more detail in the previous section “Available pediatric in vivo reference data”. 
3.6 AVAILABLE PEDIATRIC IN VIVO REFERENCE DATA 
Clearance maturation parameter estimates were collected from publications in the scientific literature 
[19, 20]. The overall maturation function (maturation + size function) was applied to predict individual 
clearance values for extensive CYP2D6 metabolizers only, given the subjects’ age (post-menstrual age; 
PMA) and weight (kg). Besides, the raw clinical data of a subset of 57 neonates and young infants, used 
for estimating total, CYP2D6 and renal clearance parameters, were available.  
3.6.1 EXPONENTIAL MATURATION FUNCTION 
The first published maturation function for total and CYP2D6 mediated tramadol clearance originates 
from a publication by Allegaert et al.[20]. This resulting maturation curve for the total clearance is 
obtained by summation of ‘CYP2D6’ and ‘non-CYP2D6’ clearance maturation, both taking on following 
form: 
𝐶𝐿𝑖 = 𝐶𝐿𝑠𝑡𝑑 ∗ 𝐹𝑠𝑖𝑧𝑒 ∗ exp{𝑆𝐿𝑃𝐶𝐿 ∗ (𝑃𝑀𝐴 − 40)} 
EQUATION 2 
 in which CLstd is the standardized clearance, Fsize is the factor taking into account the size effect 
(WTi/WTstd)**0.75, SLPCL (slope of clearance) is the exponent of the maturation function centered 
around a term age of 40 weeks PMA. Numerical values for these parameters are provided in Table A2 
in the Appendix. 
3.6.2 HILL MATURATION FUNCTION 
The second maturation function was derived from a pooled popPK analysis [19] in pediatric and adult 
subjects in which the maturation of ‘CYP2D6’ and ‘non-CYP2D6’ tramadol clearance was described by a 
Hill function, as follows: 
𝐶𝐿𝑖 = 𝐶𝐿𝑠𝑡𝑑 ∗ 𝐹𝑠𝑖𝑧𝑒 ∗
1
1 +
𝑃𝑀𝐴
𝑇𝑀50
−𝐻𝑖𝑙𝑙
 
EQUATION 3 
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 in which TM50 is the age (PMA) at 50% of maturation, and Hill is the Hill coefficient describing 
the steepness of the maturation function. Numerical values for these parameters are provided in Table 
A2 in the Appendix. Both modelling attempts assume a 2-compartmental, linear disposition model for 
tramadol with 1st order elimination, consisting of different clearance pathways, based on plasma 
observations of parent tramadol and ODT metabolite. The major difference between these 2 models 
lies in how the PK of the metabolite is described. In the first model, the metabolite volume is fixed to 
224 L/70kg and metabolite clearance is estimated to exponentially increase with PMA [20]. In the 
second model, the metabolite volume is estimated by applying allometric principles to an observed 
metabolite volume in dogs. Metabolite clearance is fixed by a Hill function assuming a maturation of the 
glomerular filtration rate [19].  
 
3.6.3 WINNONLIN® FITTING OF SUBJECTS WITH RICH SAMPLING 
In addition to the previously described popPK models, which are solely based on plasma observations, 
we performed a one-by-one fitting procedure in WinNonlin®, taking into account not only plasma 
observations but also urinary excretion data of parent and metabolite [36]. These were available for 9 
out of 57 neonates and young infants from the original dataset, which were richly sampled. The 
compartmental model depicted in Figure 1 was used to estimate the different clearance parameters. 
Pharmacokinetic analysis for the one-by-one fitting was performed by WinNonlin® Professional version 
5.2.1. (Pharsight, St-Louis, MI, USA). Plasma and urinary concentrations of parent and metabolite were 
simultaneously modeled, applying a user-written differential equation model. Both plasma and urine 
FIGURE 1: A ONE-COMPARTMENT LINEAR DISPOSITION MODEL WAS USED TO FIT THE PARENT DRUG. AN ADDITIONAL COMPARTMENT FOR THE 
ODT METABOLITE WAS LINKED TO THE CENTRAL COMPARTMENT BY ITS FORMATION CLEARANCE (CLP2M). URINARY EXCRETION OF TRAMADOL 
(CLPR) WAS ESTIMATED BASED ON THE TOTAL AMOUNT OF TRAMADOL FOUND IN URINE (UR). ODT MOIETY-RELATED CLEARANCE (CLM) AND 
VOLUME (VM) WERE ESTIMATED BASED ON THE ODT PLASMA CONCENTRATIONS AND TOTAL ODT AMOUNT FOUND IN URINE (UR); CLPO OTHER 
CLEARANCE PARENT 
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concentrations were modeled using the 1/Y weight, and the Gauss-Newton (Levenberg and Hartley) 
algorithm with 50 iterations. A 1-compartment model for tramadol was retained on the basis of visual 
inspection of the fitted plasma concentration-time profiles and standard errors of the estimated PK 
parameters. Tramadol was cleared by renal excretion (CLPR), CYP2D6 clearance (CLP2M), and other 
clearance routes (CLPO). For the CYP2D6 metabolite, ODT, a 1-compartment model was used with 
formation clearance (CLP2M), ODT moiety-related clearance (CLM) and volume (VM). The metabolite 
clearance (CLM) is a hybrid clearance parameter describing the total mass outflux of ODT, since ODT 
concentrations measured in urine are the sum of unchanged as well as conjugated ODT [36]. 
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4 RESULTS 
4.1 QUALIFICATION OF TRAMADOL ADULT PBPK MODEL 
By scaling back intravenous tramadol in vivo adult clearance data, the tramadol adult PBPK model is 
provided with information on the CYP2D6 involvement by comparing hepatic clearances between 
different CYP2D6 metabolizer statuses [31], and the CYP2B6-CYP3A4 involvement by comparing AUC 
ratios after induction of tramadol metabolism by rifampicin [33] (Table 1). CYP2D6 was calculated to be 
involved for 48% in the hepatic clearance, based on an in vivo observed 1.74-fold hepatic clearance 
increase from CYP2D6 poor metabolizer (PM, no remaining CYP2D6 activity) to extensive metabolizers 
(EM). The DDI clinical trial simulation of tramadol and rifampicin was used to calculate the relative 
CYP2B6-3A4 involvement. The observed geometric mean AUC ratio (induced/control) fell within the 90% 
confidence interval around the predicted geometric mean AUC ratio, based on 100 virtual trials 
mimicking the actual in vivo trial (Figure 2), only if the CYP2B6 contribution in the hepatic intrinsic 
clearance was less than 10% and the CYP3A4 contribution not below 42%. Therefore, the percentage 
CYP2B6 involvement in hepatic tramadol metabolism was estimated to be not more than 10%. As a 
consequence, the CYP3A4 contribution was estimated to constitute between 42 and 52% of tramadol 
hepatic metabolism (Table 1). 
 
TABLE 1: CRITERIA BY WHICH CYP CONTRIBUTIONS IN THE RETROGRADE MODEL ARE ASSESSED. CYP2D6 INVOLVEMENT WAS ESTIMATED BY 
COMPARING HEPATIC CLEARANCE FOLD INCREASE FROM PM TO EM BETWEEN PREDICTIONS AND IN VIVO. CYP2B6-CYP3A4 INVOLVEMENT 
WAS ESTIMATED BY COMPARING AUCINDUCED/AUCCONTROL RATIOS BETWEEN PREDICTIONS AND OBSERVATIONS. 
PM/EM= POOR OR EXTENSIVE METABOLIZER; RG= RETROGRADE; DDI= DRUG-DRUG INTERACTION 
The retrograde model for CYP involvement in tramadol metabolism 
 criterion in vivo observation RG PBPK model 
prediction 
% involvement in 
Hep CL 
CYP2D6 Hepatic CL fold increase 
from PM to EM 
1.74 a 1.73 48% CYP2D6 
CYP2B6 
CYP3A4 
AUCInd/AUCcontrol in 
Rifampicin-Tramadol DDI 
clinical trial simulation 
0.58 b 0.61->0.62 0->10% CYP2B6 
52->42% CYP3A4 
a [31]; b [33] 
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4.2 ADULT VS PEDIATRIC IN VITRO METABOLISM OF TRAMADOL AND PROBE SUBSTRATES MDZ 
AND DEX 
The in vitro metabolism of tramadol to its 2 primary metabolites (ODT and NDT) is displayed for pediatric 
HLM batches of 1 and 3 months of age in figures S1 and S2, respectively, provided in the Appendix. In 
vitro clearance values were modelled versus the tramadol incubation concentration. Additionally, 
fractional activities were measured in both pediatric HLM batches versus the adult HLM pool for 
tramadol’s primary metabolites, as well as for the probe substrates dextromethorphan (DEX) and 
midazolam (MDZ), providing information about the activity of CYP2D6 and CYP3A4 in these batches, 
respectively. Fractional activities for either ODT/NDT, DEX, or MDZ (Table 2) were calculated as the ratio 
of their intrinsic clearances, i.e. CLintpedHLM/CLintadultHLM. 
 
 
 
FIGURE 2: DDI CLINICAL TRIAL SIMULATION OF TRAMADOL AND RIFAMPICIN TO ASSESS THE CYP2B6-3A4 CONTRIBUTION. THE FIGURE DEPICTS 
THE RESULTS OF 100 TRIAL SIMULATIONS MIMICKING THE ORIGINAL TRIAL, WHEN CYP2B6-3A4 CONTRIBUTIONS ARE ASSUMED TO BE 10-42%, 
RESPECTIVELY. BLACK HORIZONTAL LINES REPRESENT THE IN VIVO OBSERVED RATIO OF AUC GEO MEANS (SOLID) AND 90% CONFIDENCE LIMITS 
(DASHED). THE SOLID RED LINE REPRESENTS THE AVERAGE RATIO OF SIMULATED AUC GEO MEANS. SINCE THE SOLID BLACK LINE STILL IS IN THE 
90% CONFIDENCE REGION (GREYED AREA) OF THE SIMULATED RATIO, WE ASSUME THAT CYP2B6 CONTRIBUTION SHOULD BE BETWEEN 0 AND 
10%. 
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TABLE 2: FRACTIONAL ACTIVITIES OF PEDIATRIC TRAMADOL METABOLISM (RELATIVE TO ADULT ACTIVITY) FOR THE FORMATION OF ODT AND 
NDT ARE PROVIDED, TOGETHER WITH THOSE FOR THE PROBE SUBSTRATES DEX AND MDZ REPRESENTATIVE OF CYP2D6 AND CYP3A4 ACTIVITY, 
RESPECTIVELY. 
 Fractional activity of tramadol 
to ODT / NDT 
Fractional activity 
of DEX  
Fractional activity of 
MDZ 
1 month 
3 months 
1.61 / 0.21 
1.91 / 0.14 
1.59 
1.71 
0.25 
0.05 
 
 The lines in Figure 3, panel A display the ‘assumed’ or ‘theoretical’ maturation of CYP2D6 [17] and 
CYP3A4 [18] on the per mg microsomal protein level, expressed as fractional activity relative to adult up 
to 1 year of age, whereas the points display in vitro measured fractional activities for the two pediatric 
batches, which are also displayed in Table 2. These values represent measured fractional activities of 
the pediatric intrinsic clearance relative to the measured adult intrinsic clearance for tramadol, 
midazolam (MDZ), and dextromethorphan (DEX). MDZ and DEX were included as probe substrates in 
the in vitro HLM batches in order to correct for batch-specific activities of CYP3A4 and CYP2D6, 
respectively. Fractional activity of ODT formation in the pediatric batches is 1.6 and 1.9-fold higher than 
in the pooled adult HLM batch, for 1 month and 3 months of age, respectively. This is highly analogous 
to the fractional activity of DEX for the 2 pediatric batches, being 1.6- and 1.7-fold higher (Table 2). 
Correction of the measured batch-specific fractional activities for ODT and NDT formation with the 
theoretical fractional activities of DEX and MDZ, denoted by equation 4, can be found in Figure 3, panel 
B. Because the corrected fractional activity of ODT formation for both batches (“corrODT 1M” and 
“corrODT 3M”) strictly follows the maturation profile of CYP2D6, ODT formation is highly correlated 
with CYP2D6 maturation. 
𝑐𝑜𝑟𝑟𝑂𝐷𝑇 =
𝑓𝑟𝑎𝑐𝑡𝑂𝐷𝑇𝑖
𝑑(𝑓𝑟𝑎𝑐𝑡𝐷𝐸𝑋𝑖 − 𝑡ℎ𝑒𝑜𝑟𝐷𝐸𝑋𝑖)
 
EQUATION 4 
in which corrODT is the fractional activity of ODT formation corrected by the batch-specific fractional 
activity of DEX at a given age i, fractODT is the fractional activity of ODT formation for a given age i, 
d(fractDEX-theorDEX) is the distance from the measured fractional activity of DEX to the theoretical 
maturation of DEX at a given age i (i.e.1 and 3 months). (analogous for NDT) 
Tramadol’s NDT formation was not well correlated with MDZ metabolism, as the NDT formation 
corrected by the batch-specific CYP3A4 activity for the 3 months batch is not following the maturation 
profile in Figure 3, panel B. 
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4.3 COMPARISON OF PEDIATRIC PBPK PREDICTIONS WITH PEDIATRIC IN VIVO REFERENCE 
DATA 
Pediatric PBPK predictions of total tramadol clearances were compared to tramadol clearances derived 
using 2 published maturation models (exponential and Hill-type), as well as from a WinNonlin® fit 
incorporating urine observations. Figure 4 displays the total tramadol clearance as a function of PMA 
(left) and body weight (right). The Hill and exponential model are depicted by a solid black and red line, 
respectively, while the WinNonlin® fit is illustrated as light brown points together with their smoother 
function. Dark blue points are the mechanistic pediatric PBPK predictions of the total tramadol clearance. 
An underprediction of the PBPK predicted total tramadol clearance is apparent from both plots (i.e. as 
a function of PMA or weight) when comparing with any of the in vivo maturation models. 
 
 
 
FIGURE 3: THEORETICAL MATURATION OF CYP2D6 (17) (RED LINE) AND CYP3A4 (18) (BLACK LINE) EXPRESSED AS FRACTIONAL ACTIVITY VS. AGE. 
IN THE LEFT PLOT ODT/NDT ACTIVITY (SOLID DOTS) FOR 2 PEDIATRIC HLM BATCHES (1 AND 3 MONTHS) ARE DEPICTED TOGETHER WITH THE 
ACTIVITIY OF PROBES (OPEN TRIANGLES) DEX (ACT2D6) AND MDZ (ACT3A4). IN THE RIGHT PLOT, THE RATIO OF EACH CORRESPONDING PAIR IS 
TAKEN AS DESCRIBED IN THE BODY TEXT AND INDICATED AS CORRODT AND CORRNDT. ODT FORMATION FOLLOWS THE CYP2D6 MATURATION 
PROFILE, WHILE NDT FORMATION DOES NOT FOLLOW THE CYP3A4 MATURATION PROFILE. 
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FIGURE 5: MATURATION OF CYP2D6 TRAMADOL CLEARANCE AS A FUNCTION OF PMA (LEFT) AND BODY WEIGHT (RIGHT). PBPK PREDICTIONS, 
REPRESENTED AS BLUE DOTS, ARE COMPARED TO IN VIVO MATURATION FUNCTIONS: HILL MODEL (19) (BLACK), EXPONENTIAL MODEL (20) 
(RED), AND WINNONLIN FITS (LIGHT BROWN). 
Figure 5 displays the maturation of tramadol clearance mediated by CYP2D6 as a function of PMA (left) 
and bodyweight (right). Noticeable from these plots is that PBPK predictions of tramadol CYP2D6 
clearance are in line with the Hill model (black line) and the WinNonlin® fits, but not with the exponential 
maturation model.  
 
 
 
 
 
 
 
 
 
 
FIGURE 4: MATURATION OF TOTAL TRAMADOL CLEARANCE AS A FUNCTION OF PMA (LEFT) AND BODY WEIGHT (RIGHT). PBPK PREDICTIONS, 
REPRESENTED AS BLUE DOTS, ARE COMPARED TO IN VIVO MATURATION FUNCTIONS: HILL MODEL [19] (BLACK), EXPONENTIAL MODEL [20]  
(RED), AND WINNONLIN FITS (LIGHT BROWN). 
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Figure 6 depicts the maturation of renal clearance (as a function of PMA and bodyweight) and enables 
comparison of PBPK predicted renal clearance and in vivo observed renal clearance. In vivo estimates 
for the renal clearance of unchanged tramadol are only available from the WinNonlin® fits because only 
in this modeling approach, urinary data was considered. PBPK predicted renal clearance is very 
analogous to the in vivo estimates.   
 
Finally, figures 7 and 8 display the complete age span from 40 to 1300 weeks PMA (25 years) for the 
total and CYP2D6 clearance maturation, comparing PBPK predictions (blue dots) and Hill function 
predictions (red dots). Tramadol clearance is underpredicted over the complete pediatric life span. 
CYP2D6 clearance predictions are in line with in vivo observations in very early life (40-53 weeks PMA, 
Figure 8), but start to deviate from the in vivo maturation trend from 53 weeks PMA (1 year) onwards 
until 700 weeks PMA (13 years). For adults, predictions are again in line with in vivo. 
 
 
 
 
FIGURE 6: MATURATION OF RENAL TRAMADOL CLEARANCE AS A FUNCTION OF PMA (LEFT) AND BODY WEIGHT (RIGHT). PBPK PREDICTIONS, 
REPRESENTED AS BLUE DOTS, ARE COMPARED TO WINNONLIN FITS (LIGHT BROWN). 
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FIGURE 8: MATURATION OF CYP2D6 TRAMADOL CLEARANCE AS A FUNCTION OF PMA. COMPARING THE PBPK PREDICTIONS (BLUE 
DOTS) TO THE IN VIVO HILL MATURATION FUNCTION (RED DOTS) REVEALS THAT THE LARGEST UNDERPREDICTION IN CYP2D6 
CLEARANCE IS MANIFESTED BETWEEN 2-13 YEARS (100-650 WEEKS) OF AGE 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE 7: MATURATION OF TOTAL TRAMADOL CLEARANCE AS A FUNCTION OF PMA. COMPARING THE PBPK PREDICTIONS (BLUE DOTS) TO THE 
IN VIVO HILL MATURATION FUNCTION (RED DOTS) REVEALS THAT THE LARGEST UNDERPREDICTION IN TOTAL CLEARANCE IS MANIFESTED 
BETWEEN 2-13 YEARS (100-650 WEEKS) OF AGE 
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5 DISCUSSION 
The first step in building a pediatric PBPK model is to develop an accurate, robust adult PBPK model. 
Although our group already demonstrated that PBPK models of tramadol could be built up from actual 
HLM or rhCYP in vitro enzyme kinetic data [16], we choose to use a PBPK modelling approach that was 
built from in vivo clearance values, to be able to predict pediatric PK, since it is the most accurate model 
for describing adult tramadol PK in healthy volunteers. In this approach, intrinsic clearance values are 
calculated from in vivo clearance values from healthy adult volunteers, using a well-stirred model, to 
obtain a PBPK model that accurately predicts the in vivo clearance. In addition, specific CYP enzyme 
contributions can be incorporated in this adult PBPK model, which is described in the “materials and 
methods” section. Pediatric predictions derived from this adult PBPK model are mechanistic because all 
relevant pathways observed in adults are used for predicting the PK in pediatrics, based on knowledge 
of functionality maturation in different tissues (e.g. liver eliminating capacity, renal filtration rate, etc.). 
Although in the adult PBPK model a CYP2D6, a CYP2B6-CYP3A4, and a renal component were 
implemented, we only focused on prediction of the total, CYP2D6 and renal clearance component for 
the pediatric populations, since in vivo reference data were available for these pathways. After having 
studied the adult in vitro metabolism in HLM, we assessed whether formation of the primary 
metabolites O-desmethyltramadol (ODT) and N-desmethyltramadol (NDT) in pediatric HLM is governed 
by the same enzymes as in adult HLM. The result of this experiment would indicate if our approach of 
applying known maturation functions [17, 35] of the responsible CYP enzymes in adults to predict the 
pediatric clearance, is valid. Therefore, in order to assess the fractional activity of ODT and NDT 
formation relative to adult HLM, pooled adult HLM were incubated with tramadol, as well as probe 
substrates DEX (CYP2D6) and MDZ (CYP3A4) in pediatric and adult HLM. Fractional activity is calculated 
by taking the ratio of the activity observed in pediatric HLM and the activity observed in pooled adult 
HLM, as described in the materials section. High fractional activities were found for ODT (1.6- and 1.9-
fold,Table 2) which can be explained by the fact that we have observed a relatively low CYP2D6 activity 
in the pooled adult HLM batch (data not shown). Because we also measured CYP2D6 fractional activity 
for the probe substrate (Table 2), we were able to calculate the difference between the measured 
CYP2D6 (DEX) fractional activity and the theoretical (based on in vitro ontogeny) CYP2D6 activity. This 
difference illustrates to what extent the measured CYP2D6 activity deviates from what one would 
expect for a given age. Correction of the measured ODT fractional activity with the previously calculated 
difference, which yields “corrODT 1M” and “corrODT 3M” in Figure 3 panel B, confirms us that ODT 
formation in pediatrics, just as in adults, is CYP2D6-mediated. Applying an analogous correction to NDT 
formation with measured MDZ activity yields predictions in Figure 3, panel B that are not in line with 
the CYP3A4 activity at all. A possible explanation is that CYP3A4 is not the only CYP enzyme contributing 
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to the formation of NDT, also confirmed by other reports [16, 37]. This comparison at the in vitro level 
enabled us to validate the assumption that in adult as well as in early life, CYP2D6 is the major isoform 
contributing to the metabolism of tramadol to O-desmethyltramadol, making this metabolite a valid 
probe to study CYP2D6 maturation. Nevertheless, it would be valuable to test more pediatric batches 
in addition to the pediatric batches described in this study in order to compare/validate the ontogeny 
functions for the enzymes of interest over a broader age range. In addition, since the ontogeny data for 
different CYP isoforms are available, the extent of pediatric in vitro metabolism can be predicted, 
extrapolating from adult in vitro metabolism data. This approach can serve as guidance for interpreting 
pediatric metabolism studies, e.g. a significant elevation of an assumed 3A4 metabolite in combination 
with an anticipated low 3A4 activity, may e.g. indicate CYP3A7 involvement, if substrate overlap is 
expected.  
Pediatric PBPK predictions of tramadol were performed with the pediatric module of the Simcyp® 
Simulator, which was first used for the setup of an adult PBPK model. At the in vivo level, the maturation 
of total tramadol clearance could be compared between PBPK predicted and in vivo observed data sets 
(Figure 4). The clearance as a function of weight or PMA by the PBPK model is underpredicted compared 
to the in vivo maturation profiles. As has been described above, the clearance prediction for this PBPK 
model is based on 3 hepatic components (CYP2D6, CYP3A4, and CYP2B6) and one renal component 
(GFR). Possible explanations for an underprediction are (i) incorrect maturation function for either of 
the implemented CYP enzymes, (ii) other metabolic pathways contributing to tramadol’s metabolism in 
pediatric life (FMO, CYP3A7) [12, 38] or (iii) neglecting other minor pathways in tramadol metabolism 
[10]. Therefore, the total clearance of tramadol was decomposed in its constituents and compared to 
in vivo observations, when possible. To this end, (i) since we had strong in vitro proof that ODT is a good 
CYP2D6 activity probe, we compared the predicted vs. in vivo observed tramadol CYP2D6 clearance 
increase, documented in Figure 5; and (ii) we compared the tramadol renal clearance increase versus in 
vivo maturation, illustrated in Figure 6. Concerning the renal clearance maturation, we could only 
compare our PBPK predictions to the WinNonlin® fits (light brown) since this was the only in vivo model 
that incorporated urinary data for estimation of the clearance parameters. The comparison of the renal 
clearance, plotted as a function of PMA, between PBPK and WinNonlin® fits yielded good agreement, 
while the comparison as a function of WT was less good but still acceptable. As for the CYP2D6 clearance 
maturation, PBPK predictions are in close agreement with the Hill maturation model (black) and the 
WinNonlin® fits (light brown), but not with the exponential maturation model (red). So which in vivo 
model is the best representation of the CYP2D6 clearance increase? Both the exponential and the Hill 
model are population PK models built on plasma observations for parent and ODT metabolite, and share 
an allometric relationship in their covariate structure, but the age models are respectively exponential 
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and Hill-type. Furthermore, the exponential model is based on plasma observations for 57 neonates and 
young infants, using a fixed metabolite volume of 224 L/70kg whereas the Hill model incorporates 
plasma observations from 295 subjects from early to adult life and estimates a metabolite volume based 
allometric principles from dogs. Because in neither model urinary data was included, we performed a 
WinNonlin® fitting procedure including urinary data of parent and metabolite. This allowed estimation 
of the ODT moiety-related volume and its associated clearance value, as well as volume and clearance 
of tramadol. Although the WinNonlin® parameter estimates are few in number, they agree with the Hill 
function as descriptor for maturation in CYP2D6 clearance. We believe that the Hill model is the better 
representation of clearance maturation in pediatrics because this maturation function is physiologically 
more plausible, since the ‘developmental’ processes of cells tend to reach their end state at a certain 
point in childhood, while ‘growth’ processes take over the increasing elimination capacity of such organs. 
As the Hill model is also based on the larger data set, we choose the Hill model as a more correct in vivo 
model to compare the PBPK predictions against. It turns out that the CYP2D6 clearance maturation from 
PBPK aligns much better with our WinNonlin® fits and the Hill model than with the exponential model. 
Finally, the maturation from birth to adult life is presented for total and CYP2D6 tramadol clearance in 
figures 7 and 8, respectively. The maturation increase for the total and the CYP2D6 clearance seem to 
agree with the in vivo model in very early life, with CYP2D6 absolute clearance values that are also in 
line with in vivo observed values. However, until the age of 13 (700 weeks PMA), both predicted 
clearance parameters display a relatively constant underprediction, which disappears again in 
adulthood. It might be that in children the maturation of liver size as a function of bodyweight is 
underestimated, since demographic parameters in Simcyp® are mainly based on UK growth charts 
(personal communication). We acknowledge that choosing the ages where clearances deviate 
significantly from predictions can be subject to discussion, which again highlights the need for  
developing adequate evaluation techniques in PBPK. 
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6 CONCLUSION 
In conclusion, PBPK modelling and simulation techniques allow a mechanistic prediction of maturation 
of CYP2D6-mediated and renal tramadol clearance in very early life. Some underprediction occurred 
between 2-13 years for total and CYP2D6 tramadol clearance. Care has to be taken when selecting in 
vivo maturation models as a reference, since these ‘top-down’ models also rely on assumptions made. 
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8 APPENDIX 
Tables 
TABLE A1: OVERVIEW OF DRUG-SPECIFIC PBPK INPUT USED FOR PEDIATRIC PREDICTIONS 
Physchem data  
Molecular weight 263.38 
Log Po:w 1.35 
Pka monoprotic base 9.41 
B:P 1.09 
Fup 0.8 (user input) 
Elimination (liver)  
CLint CYP2D6 0.301139 µL/min/pmol 2D6 
CLint CYP2B6 0.02949 µL/min/pmol 2B6 
CLint CYP3A4 0.01538 µL/min/pmol 3A4 
Hepatic uptake 1.58 a 
Elimination (kidney) 6.6 L/h 
a readers are referred to Chapter 3 for more information on this value 
 
TABLE A2: OVERVIEW OF THE NUMERIC VALUES FOR THE DIFFERENT POPPK DERIVED MATURATION FUNCTIONS 
 Parameter Exponential model 
Allegaert et al, 2008 [20] 
Hill model 
Allegaert et al, 2015 [19] 
CYP2D6 CLstd (L/h/70kg) 4.11 10.5 
 SLPCL (weeks PMA -1) 0.207  
 TM50 (weeks PMA)  40.3 
 Hill coef  9.09 
Non-CYP2D6 CLstd (L/h/70kg) 11.6 21.6 
 SLPCL (weeks PMA -1) 0.0275  
 TM50 (weeks PMA)  39.0 
 Hill coef  6.76 
CLstd: the estimated population clearance, standardized to a 70 kg person using an allometric model, 
SLPCL: slope parameter estimating magnitude of clearance increase with PMA, TM50: PMA at which 
clearance is 50 % of the mature value, Hill coef: Hill coefficient, which determines the steepness of the 
maturation curve 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
FIGURE A1: IN VITRO CLEARANCE FROM TRAMADOL TO ODT (LEFT) AND NDT (RIGHT) VS. SUBSTRATE CONCENTRATION FOR A PEDIATRIC BATCH 
AGED 1 MONTH 
 
 
 
 
 
 
 
 
 
FIGURE A2: IN VITRO CLEARANCE FROM TRAMADOL TO ODT (LEFT) AND NDT (RIGHT) VS. SUBSTRATE CONCENTRATION FOR A PEDIATRIC BATCH 
AGED 3 MONTHS 
  
5    
 136 
 
 
 
  137 
CHAPTER 6 
 
 
 
 
 
 
 
 
 
PBPK AND ITS VIRTUAL POPULATIONS: THE IMPACT OF 
PHYSIOLOGY ON PEDIATRIC PHARMACOKINETIC 
PREDICTIONS OF TRAMADOL 
 
 
 
 
 
 
 
 
This chapter is based on: 
PBPK and its virtual populations: the impact of physiology on pediatric pharmacokinetic predictions of 
tramadol. Under review.  
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1 ABSTRACT 
Background & Objective 
In pediatric PBPK models, age-related changes in the body (system) are known to occur: tissue volumes, 
tissue blood flow rates, tissue composition, as well as renal and enzymatic function need to be adapted. 
Given the sparsity of and the variability associated with relevant physiological parameters, the 
implementation of these adaptations may be different across the available PBPK software tools. In this 
work, three commercially available PBPK softwares (PK-Sim®, Simcyp®, Gastroplus®) were investigated 
regarding their differences in system-related information, possibly affecting clearance prediction. 
Methods 
To this end, tramadol was used as model compound. Each adult PBPK clearance model was calibrated 
to the tramadol adult clearance prediction obtained from a published pooled popPK model. The 
resulting PBPK (retrograde) clearance models were qualified in terms of total, CYP2D6, and renal 
clearance. Tramadol pediatric clearance predictions were compared between the different PBPK 
(bottom-up) models and the popPK (top-down) model in the lifespan range from neonates to 
adolescents. Fold prediction errors were used to evaluate the results.  
Results 
Marked differences in liver maturation between PBPK models were observed. In the neonatal age 
category, the median fold error on the total clearance was 0.79, 0.34, and 0.69 for PK-Sim, Simcyp, and 
Gastroplus, respectively. For the CYP2D6 clearance, the median fold errors were 1.00, 0.35, and 0.47 
for PK-Sim, Simcyp, and Gastroplus, respectively. Interestingly, in the case of CYP2D6, the PBPK model 
with the shortest maturation half-life (PK-Sim) agreed best with the in vivo CYP2D6 maturation model. 
Obviously, the differences in physiological data to leverage system-related parameters, leads to marked 
differences in hepatic clearance prediction in early life between the various PBPK softwares tested.  
Conclusion 
Consensus on the most suited pediatric data to use should harmonize and optimize pediatric clearance 
predictions. Moreover, the combination of bottom-up and top-down approaches, using a convenient 
probe substrate, has the potential to update system-related parameters in order to better represent 
pediatric physiology. Continued research using a broader range of compounds could strengthen these 
findings.  
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2 INTRODUCTION 
Physiologically-based pharmacokinetic modelling and simulation (PBPK-M&S) is a relatively old concept 
[1], but received renewed interest recently. It holds  potential in support of pediatric drug development 
and pharmacotherapy, both considered to be at the forefront of clinical pharmacology. ‘Bottom-up’ 
PBPK-M&S methods make an a priori distinction between the system (i.e. the human body) and the drug 
properties (e.g. molecular descriptors, physicochemical and permeability parameters, metabolic 
intrinsic clearance (CLint)). PBPK models may be used to predict the in vivo clearance and drug 
distribution in relevant subpopulations. Based on a mechanistic understanding of the drug disposition 
in healthy adult subjects, qualified PBPK models may be used to mechanistically predict pediatric 
pharmacokinetics (PK) [2, 3]. 
Drug clearance in PBPK may be predicted using the metabolic parameters Km, Vmax or CLint. In the 
bottom-up modelling process, the CLint is used to reflect the intrinsic capacity of the liver to metabolize 
a given drug. This drug-specific CLint may represent a ‘lumped’ total liver CLint, but may also be assigned 
to different contributing enzymes. Besides, it may either be derived from in vitro metabolism assays or 
from in vivo phenotypic data. In the latter case, the in vivo observed clearance for a test drug is back-
calculated to the CLint at the enzyme level (retrograde clearance model) [3, 4]. Such a retrograde 
clearance model has the ability to simulate the drug’s PK in any given population for which the system’s 
data are available. This retrograde model has the advantage that it accurately incorporates the relevant 
routes of in vivo drug clearance in a mechanistic way. A disadvantage is that for drugs with many 
complex processes involved in their drug disposition, the setup of this retrograde model may become 
challenging. 
Key in this approach is furnishing the system’s data, relevant for the population under study. The 
collection of the correct physiological information that captures relevant differences compared to 
healthy volunteers, may be very challenging e.g. in pediatrics, renally impaired and cirrhotic patients. In 
very young children (<2 years of age), age-related physiological changes occur in tissue volumes, tissue 
blood flow rates, tissue composition, as well as in renal and enzymatic function [5]. To date, several 
groups have collected information on tissue volumes, tissue  composition, and blood flows [6-9], as well 
as changes in enzyme activity [10, 11] as a function of age, bodyweight, height, or their composite 
parameters (BSA, BMI). In addition, anthropometric data, e.g. the NHANES III study [12] and/or national 
census initiatives, provide information on the variability of these metrics in the population. Integrating 
this information in a PBPK M&S platform allows to create physiologically relevant virtual subjects, 
constituting a realistic ‘virtual’ population. Commercially available PBPK platforms (PK-Sim®, Simcyp®, 
Gastroplus®) have integrated this information in order to create virtual pediatric subjects [3, 13]. 
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However, given the sparsity of and the variability associated with relevant physiological parameters, 
virtual pediatric subjects created by different available PBPK software tools may differ. Possible 
differences in liver blood flow, plasma protein binding, liver size, mg protein per gram of liver (MPPGL), 
and ontogeny of drug metabolizing enzymes may influence the prediction of hepatic clearance. The 
maturation of the glomerular filtration rate (GFR) has been studied quite extensively [14-17], but the 
question remains which of these maturation models is used to describe the GFR development in silico 
in the different softwares, and how this impacts the simulation results.  
Obtaining an accurate prediction of clearance is a prerequisite for a successful dose extrapolation 
towards pediatric subjects. Hence, this study addresses the impact of possible differences in 
physiological information as present in commercial softwares on the prediction of the hepatic and renal 
clearance in kids. To this end, tramadol is used as model compound. Tramadol is a centrally acting 
analgesic drug with weak opioid activity, broadly studied in different pediatric age groups and adults 
[18-28]. Multiple relevant CYP enzymes (CYP2D6, CYP3A4, CYP2B6) are involved in its metabolism [29]. 
Not until recently, a pooled population pharmacokinetic analysis was published, describing the 
maturation of the total and CYP2D6 clearance over the complete pediatric lifespan to adulthood [30]. 
The ‘top-down’ estimated maturation functions from this published work were quantitatively compared 
to the PBPK-predicted, physiology-driven clearances across age groups. For each software package 
separately, first, an adult clearance model was constructed and qualified. Second, pediatric predictions 
were performed for different age groups. Finally, maturation in pediatric clearance was compared 
between predictions and observations.  
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3 METHODS 
3.1 PBPK MODELLING SOFTWARE AND SETUP OF THE TRAMADOL ADULT PBPK MODEL 
In order to develop a whole-body PBPK model, three specialized software tools were used. Simcyp® 
(v14.1, Certara, Inc., NJ, USA), PK-Sim® (v6.2, Bayer Technology Services, Leverkusen, Germany), and 
Gastroplus® (v9.0, SimulationsPlus (Cognigen), California, USA) were used for mechanistic prediction of 
adult and pediatric drug disposition. These tools provide the necessary building blocks to construct a 
user-defined PBPK model. Specific details pertaining to the different software tools can be found in 
scientific literature [3, 31, 32]. 
A specific workflow was followed to mechanistically implement the adult tramadol clearance for each 
software package and is clarified in the following steps. First, clearance and distribution parameters 
after intravenous administration of tramadol in healthy adult subjects were gathered from literature. In 
a pooled population pharmacokinetic analysis by Allegaert et al. [30], the standardized total clearance, 
CYP2D6 clearance and volume of distribution were estimated. They are presented in Table 2, column 
‘Reference’. In addition, the individual CYP contributions were determined from in vivo data. The 
CYP2D6 contribution was calculated as the ratio of CL2D6/CLTOT in the pooled popPK model and 
represented 43% of the hepatic clearance. The CYP2B6 contribution was determined before as 10% of 
the hepatic clearance, see Chapter 5. The remaining CYP3A4 contribution is 47%. Second, for each PBPK 
software separately, a distinct so-called ‘retrograde’ clearance model was constructed. The total 
clearance was mechanistically integrated as the sum of the hepatic metabolism by CYP2D6, CYP3A4 and 
CYP2B6,and the renal excretion. The contributions for these pathways in the PBPK clearance module 
were set to represent their in vivo contributions using in vivo derived phenotypic information (the 
‘retrograde’ clearance model). In short, the hepatic clearance was back-calculated - using the well-
stirred liver model - to the hepatic intrinsic clearance (CLintH), using the fraction unbound in blood (fub) 
and the hepatic blood flow. CYP-enzyme specific intrinsic clearances (CLintCYP) were obtained from 
CLintH using the in vitro-to-in vivo (IVIVE) scalars liver weight, microsomal protein per gram liver (MPPGL), 
and enzyme abundances. The parameters used for this retrograde back-calculation are provided in 
Table 1, under ‘Parameters used for retrograde calculation’, and include the hepatic blood flow, fub, 
liver weight, individual CYP contributions in the hepatic clearance, and the CYP enzymes’ liver 
concentrations. Except for the CYP contributions, all other parameters were different for every software 
package and were collected as follows. For PK-Sim® and Simcyp®, an adult virtual population (Caucasian, 
n=1000, range 25-45 years, 50% females) was created from which these parameters are calculated as 
the medians. For Gastroplus® these values were collected from the graphical user interface, without 
creating a virtual population (see discussion for further details). Obviously, the intrinsic clearances for 
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CYP2D6, CYP3A4, and CYP2B6 are different per software package and are provided in Table 1 (section 
‘PBPK Input Parameters’). Third, all the drug-related (physicochemical and elimination) input 
parameters used for the bottom-up prediction of the clearance in every software package are presented 
in Table 1 (section ‘PBPK Input Parameters’). The adult PBPK model development was performed using 
the CYP2D6 ‘extensive’ metabolizer (EM, UM) genotype, since a PM has no CYP2D6 activity, due to two 
null-alleles leading to absence of functional CYP2D6 protein [33]. 
The tissue distribution of tramadol was governed by the tissue-to-plasma (Kp) ratios predicted using the 
Rodgers and Rowland models for basic amines [34]. The B:P ratio was adjusted per software (as 
indicated in Table 1), as needed, in order to provide reliable in silico estimates of the in vivo volume of 
distribution. 
The PBPK models, set up in the different software packages, were qualified for adults, based on their 
prediction of the total, renal, and CYP2D6 clearance. For PK-Sim® and Simcyp®, a virtual adult population 
was created (Caucasian, n=1000, range 25-45 years, 50% females) to qualify the retrograde PBPK model. 
The median of the predicted total, renal, and CYP2D6 clearance and volume of distribution are provided 
in Table 2. For Gastroplus®, the typical American individual of 86.27 kg was chosen for qualification of 
the retrograde PBPK model, and no population variability was incorporated in the predictions (see 
discussion). The predicted total, renal, and CYP2D6 clearance and volume of distribution are provided 
in Table 2. Clearance values were individually calculated from the predicted plasma concentration-time 
curves as dose/AUC. The different clearance values for CYP2D6, CYP3A4 and CYP2B6 were calculated by 
multiplying the total clearance value with the respective CYP contributions (calculated as fraction of the 
total dose) per virtual individual.  
3.2 PREDICTION OF PEDIATRIC CLEARANCE 
Different PBPK software packages were instructed to predict pediatric pharmacokinetics in specified age 
groups, as defined below: 
 Neonate (40 – 44 weeks PMA) 
 Infant (44 weeks PMA – 2 yrs PNA) 
 Young Child (2 – 6 yrs) 
 Child (6 – 12 yrs) 
 Adolescent (12 – 18 yrs) 
 Young Adult (18 – 25 yrs) 
 Adult (25 – 45 yrs) 
    6 
 145 
TABLE 1: A REPRESENTATION OF THE PARAMETERS USED FOR RETROGRADE CALCULATION PER SOFTWARE TOOL, AND THE PBPK INPUT 
PARAMETERS THAT WERE USED AS INPUT FOR THE PBPK MODEL 
a Vmax/Km; CLint values could only be provided as Vmax (pmol/min/pmol CYP) and Km (µM) values 
CLH: hepatic clearance, CLintH: hepatic intrinsic clearance, CLintCYP: CYP-specific intrinsic clearance, fub: 
fraction unbound in blood; fup: fraction unbound in plasma, B:P: blood-to-plasma ratio, CLr: renal 
clearance 
 
In the next step, the different clearance models were used to mechanistically predict the changes in 
clearance as a function of age. The system’s information contained in the different PBPK software 
packages was used for pediatric predictions. In PK-Sim® and Simcyp®, 1000 virtual subjects were created 
per age group. For Gastroplus®, 1 virtual subject (representing the typical or population average subject) 
Parameter PK-Sim Simcyp Gastroplus 
Parameters used for retrograde calculation 
Back-calculation from CLH to CLintH 
Hepatic blood flow (L/h) 99.15 84.92 91.02 
fub 0.73 0.73 0.73 
Back-calculation from CLintH to CLintCYP 
Liver Weight 2.07 kg 1.58 kg 1.77 kg 
Individual CYP contribution in the hepatic 
clearance 
CYP2D6 43% - CYP3A4 47% - CYP2B6 10% 
CYP2D6 liver concentration 0.42 nmol/g 0.26 nmol/g 0.30 nmol/g 
CYP3A4 liver concentration 4.36 nmol/g 4.87 nmol/g 4.22 nmol/g 
CYP2B6 liver concentration 1.86 nmol/g 0.37 nmol/g 0.43 nmol/g 
PBPK Input Parameters 
Molecular weight (Da) 263.4 263.4 263.4 
logP 1.35 1.35 1.35 
fup 0.8 0.8 0.8 
Compound type (pKa) Base (9.41) Base (9.41) Base (9.41) 
B:P 1.07 1.09 1.075 
CLintCYP2D6 (µL/min/pmol) 0.337 0.739 35.72/100a 
CLintCYP3A4 (µL/min/pmol) 0.0341 0.0472 2.81/100 a 
CLintCYP2B6 (µL/min/pmol) 0.0201 0.0809 6.04/100 a 
CLr (L/h/70kg) 6.62 7.11 6.36 
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was created for the following age periods: 41-50 weeks PMA (1 subject per week); 52-62 weeks PMA (1 
subject every 2 weeks); 64-88 weeks PMA (1 subject every 4 weeks); 1-25 years of age (1 subject every 
year). These exact virtual subjects (for each PBPK software) were used as input (in fact their covariates 
bodyweight and PMA) to the structural model from the popPK analysis by Allegaert. This way, every 
virtual subject was linked to a PBPK-predicted clearance and a popPK-predicted clearance. The 
difference between the PBPK-predicted and the popPK-predicted clearances was expressed as fold 
prediction difference. The median of the fold prediction differences was calculated per age group and 
per software (Table 3). In addition, the evolution of the median fold prediction differences over the 
pediatric age range was assessed visually per software package (Figure 2). This complete workflow was 
iterated for total, CYP2D6, and renal tramadol clearance. 
3.2.1 PK-SIM 
The information used for building virtual populations in PK-Sim®, is based on the NHANES III study [12] 
and Annals of the ICRP [7]. NHANES III mainly provides anthropometric data, while the ICRP study 
focuses on mean organ weights and blood flows. Organ densities are all assumed to be 1 g/mL. Virtual 
populations are created within PK-Sim® using the algorithm “PK-Pop”. The paper by Willmann et al. [13] 
elaborates on how virtual subjects are set up to represent a physiologically plausible population. This is 
the only software tool of the three that For the population simulations, the Healthy Male Caucasian was 
selected. In the hepatic clearance prediction, CYP2D6 (10.5 pmol/mg microsomal protein, MP), CYP3A4 
(109 pmol/mg MP), and CYP2B6 (46.5 pmol/mg MP) enzyme abundances in the software were based 
on  Rodrigues et al. [35] (Table 1). The MPPGL is considered to be 40 mg/g liver, independent of age. 
CYP2D6 ontogeny is based on published literature studies [36, 37] and is graphically represented in the 
Appendix. CYP3A4 ontogeny information is described in [10, 11]. Since no ontogeny function is currently 
present for CYP2B6, functional CYP2B6 activity data were digitized from Pearce et al. [38] using Web 
PlotDigitizer v3.8. The ontogeny model best describing CYP2B6 maturation was a power function, 
provided in Appendix. The geometric standard deviation was assumed to be 1.7. Liver blood flow (QH) 
is defined as the sum of portal and arterial liver blood flow. In pediatrics, QH follows the changes in 
cardiac output [7], although the percent of the cardiac output perfusing the liver remains the same as 
in adults. The adult renal clearance was defined in the PBPK model structure as an arbitrary fraction 
(1.43) of the GFR. The renal clearance is predicted in an age-dependent manner by taking the changes 
in GFR maturation into account (Hayton equation, based on age) [10]. 
3.2.2 SIMCYP 
Virtual populations in Simcyp® are built from the NHANES database, UK census data, and meta-analyses 
of numerous literature studies. First, individuals are selected by age, then linked to height, weight and 
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BSA. These anthropometrics are then used for an age-dependent prediction of different organ weights 
and volumes, e.g. cardiac output is related to age, while liver volume is related to BSA [11, 39]. QH is 
maintained as a fixed fraction of the cardiac output over the complete human lifespan [7]. Stochastic 
variation is applied using a correlated Monte-Carlo method. In this study, the North Caucasian Healthy 
Volunteer population was chosen for the adult simulations and the Pediatric population for pediatric 
simulations. The evolution of hepatic enzyme ontogeny and values for enzyme abundances are 
published in the literature for the CYP enzymes CYP3A4, CYP2D6, and CYP2B6 [11, 40, 41]. Furthermore, 
given the polymorphic nature of CYP2D6 and CYP2B6, the following abundances are used: CYP2D6 PM 
0, EM 8, and UM 16 pmol/mg MP; CYP2B6 PM 6 and EM 17 pmol/mg MP. MPPGL varies with age, as 
published by Barter et al. [42]. Renal clearance was defined in the PBPK model as a fixed clearance 
estimate. Developmental variation was applied by the multiplication with a ‘renal function’ value, which 
is calculated using the pediatric GFR function (based on BSA) relative to adult [11]. Demographic 
information pertaining to percentages of CYP phenotypes in the population was kept constant 
throughout the simulations. Specifically for CYP2D6, this implies 8.2% poor – 5.3% ultrarapid – 86.5% 
extensive metabolizers, and for CYP2B6 11% poor – 89% extensive metabolizers.  
3.2.3 GASTROPLUS 
In Gastroplus®, age-related anthropometric data are derived from the NHANES study as well. In the 
Gastroplus® manual, the method for generating organ physiology values is described and involves 
calculating BMI and fat-free mass from weight, height, and bioimpedance. Then, constant perfusion 
rates per mL tissue are set [9] and blood volumes are calculated [6]. For each tissue, the weight, volume, 
density, and perfusion are calculated. In addition, the Gastroplus® manual also provides the results from 
an exhaustive literature search concerning changes in pediatric physiology over time, from preterm to 
adult. Subsections concern body and tissue sizes, blood parameters, and tissue compositions. Hepatic 
enzyme abundances that were as follows: for CYP2D6, 8 pmol/mg MP, for CYP3A4, 111 pmol/mg MP, 
and for CYP2B6, 11 pmol/mg MP. Ontogeny profiles implemented are the ones from Johnson et al. [11]. 
The renal clearance was implemented in the PBPK model structure as a fraction of the renal blood flow. 
Since renal blood flow varies over age, so will the renal clearance. Since tramadol renal clearance could 
not be implemented as arbitrary fraction of the GFR, using the renal blood flow turned out to be the 
second best option. In the Gastroplus® simulations, no variability was incorporated and only for selected 
ages the typical individual was used to predict pediatric clearance. It is however possible to perform 
populations simulations, but variability is considered stochastic noise instead of originating from 
correlated covariates, and the end-user is only able to extract plasma concentration-time profiles, 
without parameters related to a drug’s fate (e.g. metabolic activity of CYP enzymes). 
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4 RESULTS 
4.1 QUALIFICATION OF THE ADULT PBPK MODEL 
The tramadol adult retrograde PBPK model that was constructed in different software packages 
(Simcyp®, PK-Sim®, Gastroplus®) was calibrated to the pooled population PK (popPK) model from 
Allegaert et al. [30] in terms of the PK parameters clearance (total, CYP2D6, and renal) and volume of 
distribution. Table 2 presents the agreement between predicted and observed adult PK parameters. 
Given the difference in median bodyweight between the different virtual populations, clearance values 
were standardized to 70kg. In addition, the predicted CYP enzyme contributions in the hepatic clearance 
(f2D6, f3A4, and f2B6 in Table 2) agree well with in vivo reference fractions (0.43, 0.47, and 0.1, respectively), 
used to build the retrograde clearance model. Since for PK-Sim® and Simcyp®, population simulations 
were used in qualifying their adult clearance model, simulated 5th (Q5) and 95th (Q95) percentiles are 
displayed for their CYP enzyme contributions. Except for CYP2B6, the Q5 - Q95 ranges for the enzyme 
contributions are similar between Simcyp® and PK-Sim®. Since the pooled popPK model does not 
provide an estimate for the renal clearance, it was extracted from an internal Grünenthal Research 
Report and was scaled in the PBPK models using GFR or kidney blood flow (see methods). Only Simcyp® 
predicts this value to be 1.13-fold higher, due to a built-in algorithm for renal clearance. 
TABLE 2: OVERVIEW OF THE REFERENCE PK PARAMETERS (AS EXTRACTED FROM THE POPPK MODEL) AND PBPK-PREDICTED PARAMETERS FOR 
THE ADULT POPULATION. CONSISTENCY BETWEEN THESE PARAMETERS QUALIFIES THE PBPK CLEARANCE MODEL 
 Reference PK-Sim Simcyp Gastroplus 
PK parameters 
Vss (L/kg) 2.63a 2.62 2.64 2.63 
CLtot,EM (L/h/70kg) 32.13 a 32.82 33.73 31.86 
CL2D6,EM (L/h/70kg) 10.70 a 10.85 10.57 10.75 
CLr (L/h/70kg) 6.60 b 6.62 7.11 6.36 
Median BW 70.00 67.00 74.00 86.27 
Fractions of hepatic clearance Q50 (Q5-Q95) 
f2D6 0.43 0.430 (0.146-0.751) 0.423 (0.182-0.689) 0.429 
f3A4 0.47 0.440 (0.192-0.704) 0.476 (0.234-0.732) 0.468 
f2B6 0.10 0.108 (0.0305-0.264) 0.0637 (0.00765-0.288) 0.101 
a [30]; b Internal Research Report Grünenthal GmbH 
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FIGURE 1: MATURATION OF THE TOTAL, CYP2D6 AND (EARLY) RENAL TRAMADOL CLEARANCE AS PREDICTED BY THE 
POPPK MODEL. DOTS FOR TOTAL AND CYP2D6 CLEARANCE REPRESENT THE POPULATION PREDICTIONS (BODYWEIGHT 
AND PMA) FROM ACTUAL INDIVIDUALS  IN THE CLINICAL TRIALS, AND THE LINES THE BEST FIT CURVE THROUGH THESE 
DATA. DOTS FOR THE RENAL CLEARANCE REPRESENT THE ESTIMATED CLEARANCES FOR THESE SUBJECT  BY WINNONLIN 
4.2 PEDIATRIC PREDICTIONS 
4.2.1 TOP-DOWN VS. BOTTOM-UP CLEARANCE PREDICTIONS 
The predicted increase in total, CYP2D6 and renal clearance as a function of age in actual pediatric 
subjects is depicted in Figure 1. The total and CYP2D6 clearance maturation (for extensive metabolizers) 
was extracted from the popPK model by Allegaert et al. [30]. Individual predictions based on the actual 
subjects’s age and weight are displayed as dots. The observations of renal clearance (displayed with a 
smoother function) were obtained via a one-by-one fitting procedure in WinNonlin® for a subset of the 
neonates/infants enrolled in the Allegaert study. This procedure is  described in more detail in Chapter 
5. This analysis focuses on total, CYP2D6, and renal clearance only, because the popPK model by 
Allegaert provides estimates for just total and CYP2D6 clearance, while the renal clearances are derived 
from the WinNonlin® model (see above). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As indicated in the methods section, in PK-Sim® and Simcyp®, 1000 virtual subjects were created per 
age group, while for Gastroplus® 1 typical population representative was created at selected ages. Each 
virtual subject, originating from a given PBPK software, was used as input for both the PBPK, as well as 
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the popPK clearance model. Therefore, every virtual subject was linked to a PBPK-predicted clearance 
and a popPK-predicted clearance. Figure 2 provides a smoothed image of the evolution of the median 
fold prediction differences between PBPK and popPK over the pediatric age range, for tramadol total, 
CYP2D6 and renal clearance (the latter only accounting for the first 12 weeks of life). Table 3 provides 
the actual numbers, stratified per age group. PK-Sim® and Gastroplus® predict the total clearance within 
2-fold, while Simcyp® underpredicts the total clearance in the first 30 weeks of life. Only from 2 years 
of age onwards, 95% of the total clearance predictions fall within 2-fold of the observed maturation 
profile. CYP2D6 clearance is predicted within 2 fold (even within 20%) of the in vivo maturation by PK-
Sim®. Simcyp® and Gastroplus® underpredict the CYP2D6 clearance below the 2-fold boundary up to 55 
weeks and 43 weeks PMA, respectively. Concerning the renal clearance, both Simcyp® and PK-Sim® are 
within the 2-fold boundary. The Gastroplus® renal clearance is acceptable from 44 weeks PMA onwards. 
 
  
FIGURE 2: MEDIAN FOLD PREDICTION DIFFERENCE OF 3 DIFFERENT PBPK SOFTWARE PLATFORMS (PK-SIM, SIMCYP, AND GASTROPLUS), 
COMPARED TO POPPK PREDICTIONS WITH THE SAME VIRTUAL SUBJECTS FOR THE TOTAL, CYP2D6, AND RENAL CLEARANCE. 
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 TABLE 3: TABLE WITH MEDIAN FOLD ERRORS PER AGE CATEGORY AND PER SOFTWARE FOR CLTOT AND CL2D6 
 Neonate Infant Young Child Child Adolescent Young Adult Adult 
PK-Sim 
CLTOT 0.79 0.82 1.02 1.07 1.03 1.01 1.03 
CL2D6 1.00 0.94 1.06 1.08 1.05 0.99 1.03 
Simcyp 
CLTOT 0.34 0.65 0.84 1.08 1.16 1.12 1.04 
CL2D6 0.35 0.63 0.76 0.94 1.08 1.05 1.01 
Gastroplus 
CLTOT 0.69 0.70 0.95 0.83 0.94 0.98 0.99 
CL2D6 0.47 0.71 1.00 0.82 0.94 0.99 1.01 
 
In order to provide the full picture, all clearance contributors are depicted in Figure 3. Although there is 
no in vivo maturation function available to compare with the CYP3A4 and CYP2B6 predicted clearances, 
it remains interesting to note the differences between softwares. 
The total tramadol clearance consists of 4 different elimination routes, 3 hepatic and 1 renal. From these 
4 elimination routes, only the CYP3A4 maturation is consistent between the 3 software packages. The 
maturation of CYP2D6 is fastest in PK-Sim®, followed by Gastroplus®, and Simcyp®. Whereas CYP2B6 
has a very pronounced ontogeny profile in Gastroplus®, both in Simcyp® and PK-Sim® its activity is 
already relatively high at birth. Renal clearance in PK-Sim® and Simcyp® initially is the same, but 
increases faster in PK-Sim®. Renal clearance in Gastroplus® even decreases in the first 2 years of life, 
starting off from an initial higher clearance. 
4.2.2 EFFECT OF PEDIATRIC PHYSIOLOGY ON THE BOTTOM-UP CLEARANCE PREDICTION 
Parameters that determine the prediction of hepatic clearance are the hepatic blood flow, fraction 
unbound in blood, liver weight, and enzyme abundances of the different enzymes involved. Figure 4 
illustrates the evolution of these parameters in the first 2 years of life, whereas Figure 5 displays the 
development of these parameters from 2 year onwards. Figure 4 shows that minor differences exist 
between the different virtual populations, created per software, in terms of bodyweight and hepatic 
blood flow versus PMA. On the other hand, liver weight is consistently higher for PK-Sim®, and fraction 
unbound is slightly higher in the first few weeks for the Gastroplus® population. The CYP3A4 abundance 
is in good agreement across the different virtual populations, though CYP2D6 and CYP2B6 ontogenic 
differences are observed. CYP2D6 abundance rapidly reaches mature levels in the PK-Sim® population, 
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FIGURE 3: CYP2D6, CYP2B6, CYP3A4 AND RENAL CLEARANCE AS A FUNCTION OF PMA FROM BIRTH TO ADULTHOOD. THESE 4 ELIMINATION 
ROUTES MAKE UP THE TOTAL TRAMADOL CLEARANCE. THE ONLY CLEARANCE SHOWING CONSISTENCY IN MATURATION OVER THE 3 SOFTWARE 
TOOLS, IS THE CYP3A4 MATURATION. 
followed by Gastroplus® and then Simcyp®, which both show a pronounced maturation profile. CYP2B6 
abundance is again highest for the PK-Sim® population, followed by Simcyp®, with both starting off with 
relatively high levels at birth. The Gastroplus® virtual population displays a distinctive CYP2B6 
maturation profile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 shows that there is still an important increase in bodyweight, hepatic blood flow, and liver 
weight with PMA beyond 2 years of age, while the unbound fraction in blood and the different CYP 
abundances (on a pmol/g liver basis) remain relatively constant. The exception is CYP2B6, and we will 
further elaborate on this in the discussion. 
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FIGURE 5: ILLUSTRATION OF THE BODYWEIGHT AND THE UNDERLYING PARAMETERS THAT DETERMINE MATURATION OF HEPATIC CLEARANCE 
AS A FUNCTION OF PMA FROM 2 YEARS TO ADULTHOOD. STILL DIFFERENCES ARE OBSERVED IN MATURATION FOR CYP3A4 AND CYP2B6, WHILE 
CYP2D6 SEEMS TO HAVE STABILIZED. AN IMPORTANT DIFFERENCE IN HEPATIC BLOOD FLOW IS OBSERVED IN GASTROPLUS AS, COMPARED TO 
THE OTHER MODELS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE 4: ILLUSTRATION OF THE BODYWEIGHT AND THE UNDERLYING PARAMETERS THAT DETERMINE MATURATION OF HEPATIC CLEARANCE 
AS A FUNCTION OF PMA IN THE FIRST 2 YEARS OF LIFE. MEDIAN ABUNDANCE OF THE CYP2D6, CYP3A4, AND CYP2B6 ENZYMES IS VARIABLE 
BETWEEN THE SOFTWARE TOOLS. DIFFERENCES IN HEPATIC BLOOD FLOW AND LIVER WEIGHT ARE PRESENT AS WELL, ALTHOUGH THE 
MATURATION TREND IS SIMILAR. 
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5 DISCUSSION 
The three most extensive and broadly applied PBPK M&S software tools (PK-Sim®, Simcyp®, Gastroplus®) 
were evaluated at the level of their system’s properties for predicting changes in pediatric PK. To this 
end, a retrograde clearance model for tramadol was created for each software tool. Using the 
physiological information, contained in each software package (Table 1, ‘Parameters used for retrograde 
calculation’), an intrinsic clearance at the level of the contributing CYP enzyme was calculated with the 
well-stirred liver model (Table 1, ‘PBPK Input Parameters’). In vivo information about the tramadol total 
and CYP2D6 clearance was available from Allegaert et al [30]. 43% of the hepatic clearance could be 
attributed to CYP2D6. Based on a previous study [43], described in Chapter 5, the remaining 57% was 
subdivided into 47% CYP3A4 and 10% CYP2B6. Since the popPK model did not provide an estimate for 
the adult renal clearance, it was extracted from an internal Grünenthal Research Report and was scaled 
down using GFR maturation for Simcyp® and PK-Sim®, and kidney blood flow for Gastroplus®. As is 
described in the methods section and presented in the results section, each retrograde clearance model 
for each PBPK software was qualified for the adult predictions in terms of total, CYP2D6, and renal 
tramadol clearance (Table 2). 
After qualification of the adult clearance models, 7 different age groups were defined for the pediatric 
predictions (see methods section). In PK-Sim® and Simcyp®, the clearance for every pediatric age group 
was predicted using a virtual population of 1000 subjects from that age category. In Gastroplus®, instead 
of virtual populations, a virtual population representative, i.e. the typical individual, was used for the 
predictions. Next, the total and CYP2D6 tramadol clearance predictions were compared to the 
estimated maturation profiles from a pooled popPK study by Allegaert et al. [30], depicted in Figure 1. 
The comparison of the in vivo and in silico maturation profiles of total and CYP2D6 clearance was first 
evaluated per age group and is illustrated, per software, in the Appendix. When comparing the total, 
CYP2D6 and renal tramadol clearance over the complete lifespan, specific attention was given to the 
developments in the first 2 years of age. What drives the difference between these clearance 
predictions? First of all, there is a difference in the ontogeny function for CYP2D6 at the level of the 
CYP2D6 fractional activity to adult. The equations describing this ontogeny are identical in Simcyp® and 
Gastroplus® and were previously described by Johnson et al. [11]. The ontogeny function for CYP2D6 
within PK-Sim® assumes that maturation takes places in utero and is graphically represented in the 
Appendix in Figure A1. As a consequence, the CYP2D6 clearance does not have the typical maturation 
shape for term neonates. Second, the notably longer maturation half-life for Simcyp® CYP2D6 clearance 
originates from the MPPGL maturation model, not present in the two other PBPK packages. Based on 
these findings, tramadol CYP2D6 clearance maturation seems best described assuming an progressively 
matured CYP2D6 enzyme activity at birth (without MPGGL maturation). Very recently, this finding is 
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independently confirmed by another group using propafenone as an in vivo probe for CYP2D6 activity 
[44]. The CYP3A4 clearance is in good agreement between the different software packages. There is of 
course a lot of data available for CYP3A4, making it a well characterized CYP enzyme. Maturation occurs 
later compared to CYP2D6, with adult CYP3A4 activity present around 2 years of age. The maturation 
differences in CYP2B6 clearance between the softwares cannot be solely attributed to the underlying 
physiological information. CYP2B6 ontogeny is implemented in Gastroplus® and Simcyp® as described 
in [11]. Since PK-Sim® does not provide, at this time, an ontogeny function for CYP2B6, it was user-
provided. As described in the methods section, for PK-Sim®, the CYP2B6 maturation function was fitted 
as an exponential function to the dataset from [38]. Next, it was integrated into PK-Sim® with the 
associated variability from the dataset (geometric standard deviation of 1.7), an analogous procedure 
as for other enzyme ontogeny functions. However, this geometric standard deviation was initially 
estimated as 5.12, given the huge variability in the dataset. It was reduced to 1.7 for the predictions 
since higher values provided technical issues in qualifying the adult retrograde model. These issues 
associated with a high CYP2B6 variability were also visible from the Simcyp® adult model results – for 
Simcyp®, the variability was not changed since here it is assumed to result from an underlying CYP2B6 
polymorphism .  The CLint2B6, which in vivo represents 10% of the total hepatic CLint, is calculated to 
contribute only 6% (median) to the predicted hepatic clearance with an associated broad 90% prediction 
interval (Table 2). As confirmation, the predicted CYP2B6 contribution aligns again with in vivo if the 
highly-skewed variability is progressively reduced in the predictions (data not shown). Furthermore, 
although the ontogeny function for CYP2B6 is the same in Simcyp® and Gastroplus®, again the high 
variability masks this maturation trend in the CYP2B6 clearance prediction of Simcyp® (Figure 3). Renal 
clearance prediction is in line with in vivo observations, except for the first 4 weeks of age in the 
Gastroplus® software (Figure 2). This difference is further illustrated in Figure 3. The maturation in GFR 
accounts for the changing elimination capacity of the kidneys over time. Since in Gastroplus®, the renal 
clearance could not be described as an arbitrary fraction of GFR, we chose a fraction of the kidney blood 
flow as surrogate. The renal clearance is initially high and decreases in Gastroplus®, whereas it more 
slowly matures in PK-Sim® and Simcyp®. The reason for the overprediction in Gastroplus® might be that 
the filtration capacity depends on more than just blood flow (e.g. also on the vascular resistance [10]). 
Therefore, GFR is the better predictor for maturation of the renal elimination function. We should 
however be cautious with interpreting the data for tramadol renal clearance since this maturation 
function i) is based on only 9 subjects, and ii) was not estimated as part of the population PK model. 
Because of the strict a priori distinction of drug- and system-specific information, PBPK M&S allows to 
investigate critical processes underlying drug disposition beyond compound-specific pharmacokinetic 
properties. The underlying physiological information that determines the hepatic extraction of tramadol, 
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is provided for the first 2 years of life (Figure 4) and beyond (Figure 5). The different clearances, as 
subdivided in Figure 3, are the resultant of CYP ontogeny, liver weight, and to a minor extent fraction 
unbound in blood and hepatic blood flow. Note the high correlation between the CYP abundance 
profiles and the maturation of the different clearance pathways, indicating a typical behavior for low 
extraction compounds. Notably, although the unbound fraction in blood is an important parameter for 
low hepatic extraction compounds, tramadol displays low plasma protein binding (fup= 80%). Therefore, 
a change in plasma protein binding will hardly affect the unbound fraction.  
The concentrations that drive drug ADME in vivo are unbound drug concentrations. Moreover, in order 
to correctly capture hepatic clearance, an accurate prediction of the unbound intracellular hepatocyte 
concentration is required. Each evaluated software package has its own philosophy on how to handle 
the prediction of these hepatocyte unbound drug concentrations. The default model in Simcyp® and 
Gastroplus® is a hepatic well-stirred liver model, which is perfusion rate-limited. Unbound, unionized 
drug concentrations instantaneously cross the hepatocyte membrane, so that they are the same in 
hepatocytes and plasma. In Simcyp®, it is this concentration that drives metabolism. In Gastroplus®, 
unbound (ionized + unionized) concentrations, as calculated by the Rodgers and Rowland equations, 
drive metabolism, independent of the distribution model chosen. The consequence is that, by default, 
ionization has an important effect on drug elimination in Gastroplus®, but not in Simcyp®. The modeler 
should be aware of this difference when scaling up in vitro data to in vivo (IVIVE). In PK-Sim®, the kinetics 
of drugs distributing to tissues are handled by P*SA (P= permeability, SA= surface area of the tissue), 
while the extent of tissue distribution of drugs is defined by the tissue-to-plasma partition coefficient. 
In this philosophy, there is no arbitrary division between perfusion or permeability limitations. 
Depending on which step is fastest, P*SA or blood flow, permeability or perfusion-limited behavior will 
occur in silico. Although the methods for calculation of the permeability parameters are described in 
[45], they are usually unknown and rarely accessible directly. 
Virtual populations of individuals created in the different software packages are different. Not 
necessarily at the anthropometric level (NHANES), but in the physiology that is used to build the 
underlying structure of the virtual system. The reason for this lies in the implementation of different 
literature sources and datasets (see methods section). The effect is most visible in the younger pediatric 
ages where data are often highly variable and sparse. Furthermore, the concentration of CYP enzymes 
in liver samples that determine in vivo abundancies, still is obtained using semi-quantitative techniques 
(e.g. Western blots). This also results in uncertainty about which CYP concentrations to use in the IVIVE 
(Table 1, enzyme liver concentrations). Some groups have already started quantitative LC-MSMS 
analyses in order to measure in vivo concentrations of proteins [46, 47]. In addition, concerning the 
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PBPK distribution model, accurate and precise measurement of cardiac output and blood flows to the 
different tissues is difficult to achieve, let alone defining the relative changes that occur in pediatric life. 
In conclusion, all PBPK software tools were able to predict the total and CYP2D6-related clearance 
maturation within 2-fold of the observed maturation profile, between 2 years of age and adulthood. In 
neonates and infants, clearance prediction was not always within 2-fold for every software and varied 
largely between the packages. Interestingly, the PBPK tool with the shortest CYP2D6 maturation half-
life (PK-Sim®), provided the best prediction of in vivo CYP2D6 clearance maturation. Very recently, this 
finding was confirmed by another group, which derived an in vivo ontogeny function from in vivo 
propafenone data [44]. Although two independent research groups reaching the same conclusion with 
different approaches, strengthens this result, investigating more compounds would still be needed to 
further validate our findings. All physiological information required to build virtual subjects is publically 
available. However, there still is a significant difference in the data sources that are used per software 
package, leading to marked differences in predicted PK parameters. Consensus on the selection of the 
best pediatric data to use, should help to harmonize and optimize pediatric clearance predictions.  
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7 APPENDIX 
7.1 PK-SIM ONTOGENY FUNCTIONS FOR 
7.1.1 CYP2D6 
 
Figure A1: Ontogeny function for CYP2D6 in PK-Sim® versus PMA in years. The maturation half-life for 
CYP2D6 is much faster than estimated by Johnson et al, 2006. At term age, a newborn is 40 weeks or 
0.77 years PMA, coinciding with a CYP2D6 fractional activity of about 70% relative to adult. 
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7.1.2 CYP2B6 (EXTRACTED FROM CURRENT LITERATURE) 
 
  
Figure A2: CYP2B6 activity data from Pearce et al., 2016 were digitized and were modeled in order to 
extract an ontogeny model for CYP2B6 in PK-Sim®. Next, the data were normalized to the activity at 25 
years to obtain a relative activity value to adults. 
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7.2 PEDIATRIC PBPK PREDICTIONS PER AGE CATEGORY AND PER SOFTWARE 
7.2.1 PK-SIM 
7.2.1.1 TOTAL CLEARANCE 
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7.2.1.2 CYP2D6 CLEARANCE 
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7.2.2 SIMCYP 
7.2.2.1 TOTAL CLEARANCE 
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7.2.2.2 CYP2D6 CLEARANCE 
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7.2.3 GASTROPLUS 
7.2.3.1 TOTAL CLEARANCE 
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7.2.3.2 CYP2D6 CLEARANCE 
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1 INTRODUCTION 
Children represent a vulnerable population for drug treatment, and it is important to get the dose right 
in order to ensure optimal treatment effects while at the same time avoiding side effects/toxicity. Both 
in pediatric drug development as well as in off-label drug use, the pediatric drug dose may be 
extrapolated from adults by scaling the pharmacokinetic (PK) parameters [1]. Generally, scaling of PK 
parameters is done according to allometric principles using body weight or body surface area, either 
linearly (for volumes) or exponentially (for clearances) [2]. However, especially in the first few years of 
life, the biochemical and physiological properties in children are changing non-linearly with bodyweight 
or body surface area. Recent analyses have pointed out that these methods are not suited to extrapolate 
the adult dose over the entire pediatric age range and that these scaling methods should be used with 
caution [3]. The optimal way to predict pharmacokinetic changes over the complete pediatric age range, 
and by extension over the human life span from pediatrics to geriatrics, is by integrating the biochemical 
and physiological changes occurring in each stage of life a priori in the predictions. This may be achieved 
by developing and verifying pediatric physiologically-based pharmacokinetic (PBPK) models. PBPK 
models do combine pediatric physiological information with drug-specific information in a mechanistic 
way, in order to predict the exposure to xenobiotics in neonates, infants, and children. 
Although many successful pediatric PBPK applications exist, limitations in and inconsistencies between 
in silico predictions and in vivo observations do sometimes emerge [4]. In order to identify and address 
current methodological and/or data information gaps, the general aim of the work described in this 
thesis was to perform an in-depth evaluation of the PBPK approach for a reliable bottom-up clearance 
prediction of the model compound tramadol in pediatric life. More specifically, we sought to identify the 
underlying reasons for inaccuracies in the predictions and offer alternative approaches to improve these.  
Tramadol was chosen as model compound in order to compare the clearance maturation in children, 
calculated by applying a bottom-up PBPK approach, with the one obtained using a top-down approach 
on in vivo data. If a PBPK bottom-up approach is applied in in a pediatric context, a specific workflow is 
required [5], which is in line with the different objectives of the current work. As a first step in the 
development of a pediatric bottom-up clearance model for tramadol, an adult clearance model has to 
be constructed. This clearance model mechanistically represents the different elimination pathways of 
tramadol in adults. Therefore, in vitro metabolism experiments were conducted and the relative 
importance of each individual liver enzyme in the hepatic clearance was assessed. By verifying the 
bottom-up clearance predictions against observed adult in vivo data, the adult clearance model is said 
to be ‘qualified’. For this specific application, the model was qualified in terms of absolute total 
clearance prediction, as well as the CYP2D6 and renal contributions to it (Objectives 1 & 2). Second, this 
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qualified clearance model was used for predicting maturation in the clearance over the pediatric age 
range. In essence, the drug-related data are retained from the qualified adult model, but the 
physiological data now represents a pediatric population in silico. Changes in this physiological data, 
relative to the adult, include ontogeny of enzymes/transporters, altered tissue composition, tissue 
volumes and blood flows. Finally, these pediatric (bottom-up) clearance predictions were compared to 
a (top-down) derived clearance maturation function using in vivo observed pediatric data. For the latter 
goal, the total, CYP2D6 and renal tramadol clearance were investigated (Objectives 3 & 4). 
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2 BOTTOM-UP INVESTIGATION OF TRAMADOL ADULT CLEARANCE 
2.1 IN VITRO METABOLISM INVESTIGATION 
In the bottom-up investigation of tramadol clearance, it is absolutely key to obtain a quantitatively solid 
understanding of the different enzymatic and other pathways contributing to the clearance. Tramadol 
in vivo adult clearance can be subdivided in a renal component (ca. 25%) and hepatic metabolism (75%). 
In order to characterize this hepatic metabolism, in vitro metabolism assays with tramadol were 
performed in human liver microsomes (HLM) and human recombinant enzyme systems (rhCYP). Results 
from this analysis are described in Chapter 3. First, the in vitro kinetic parameters (Km, Vmax, CLint) 
describing the formation of the metabolites O-desmethyltramadol (ODT) and N-desmethyltramadol 
(NDT) were estimated using non-linear regression analysis. The formation rate of NDT (CLint = 1.63 
µL/min/mg microsomal protein, MP) seemed to be twice as fast as the formation rate of ODT (CLint = 
0.80 µL/min/mg MP), while the Km-value for ODT (57.5 µM) was 4 times lower than that for NDT (242 
µM). Although the Km-values could be estimated in vitro, the in vivo plasma concentrations (max 5 µM 
after a 100mg i.v. bolus dose) never come close to saturating any of the two metabolizing routes. Hence, 
the hepatic clearance of tramadol was considered linear and CLint values were used for the bottom-up 
predictions of the hepatic clearance. 
In order to quantify the efficiency with which the substrate is metabolized or its metabolites are formed 
over an array of substrate concentrations, typically Km and Vmax parameters are determined. As theory 
states, metabolic efficiency declines with higher substrate concentrations and reaches a plateau value 
at Vmax. Although this illustration of theory is correct, unintentionally it implies a specific experimental 
design, i.e. incubation of high substrate concentrations to locate the Vmax. From a physiological angle, 
there are some points of criticism to make on this approach. In most cases, the drug concentrations 
interacting with phase I/II enzymes in vivo, are below the Km-value [6]. In addition, when incubating 
poorly soluble compounds in vitro, the Vmax at high substrate concentrations might be a combination 
of enzyme as well as solubility saturation. Therefore, a better approach to obtain reliable in vitro 
metabolism parameters, is to fit a model to the metabolism data, which is a re-arrangement of the 
Michaelis-Menten equation allows estimation of the parameters intrinsic clearance (CLint) and Km. 
When applying this alternative approach, the apparent in vitro clearance is expected to reach a plateau 
at the CLint-value for low substrate concentrations instead. An additional advantage is that confidence 
intervals on the CLint value can be directly estimated from the model. The availability of this confidence 
interval then allows to implement uncertainty in the prediction of the hepatic clearance. It was this 
modelling approach that was applied to estimate the CLint and Km values from the HLM and rhCYP 
metabolism assay data. 
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In addition, the individual liver enzyme contribution in the formation of the two tramadol metabolites 
was determined (phenotyping experiment). In the HLM assay, chemical inhibition was used to inhibit 
specific CYP enzymes, whereas the rhCYP assay can be considered a phenotyping experiment in itself, 
since only one specific CYP enzyme is expressed. From the chemical inhibition assay, it was concluded 
that formation of ODT was mainly mediated by CYP2D6 (80%), while NDT formation was mediated in 
part by CYP3A4 (65%) and in part by CYP2B6 (30%). In the rhCYP assay, the CLint/Km values were 
determined for the different CYP enzymes involved (CYP2D6, CYP2B6, CYP3A4). Moreover, Inter-System 
Extrapolation Factors (ISEF) were used to correct for the activity difference between the genetically 
engineered rhCYP systems and the ex vivo prepared HLM [7]. This way, the activity measured in ‘artificial’ 
rhCYP assays may be translated to the HLM system, which is assumed to be more representative for the 
in vivo situation. ISEF values were specifically calculated for this experiment. Midazolam and 
dextromethorphan were incubated alongside tramadol in both in vitro assays as probe substrates for 
CYP3A4 and CYP2D6, respectively. The calculated ISEF value for CYP3A4 was 0.23 and for CYP2D6 0.45. 
This implies that the activity of CYP3A4 and CYP2D6 is respectively 4.3- and 2.2- times higher in the 
rhCYP compared to the HLM assay and should be corrected (with the ISEF) to make the data of both 
assays comparable. We did not include a study-specific CYP2B6 probe in the experiments, because a 
CYP2B6 probe with adequate in vivo data and a straightforward IVIVE was not available at that time. In 
addition, CYP2B6 was considered a minor contributor to the hepatic clearance of tramadol. Thus, the 
standard Simcyp® ISEF of 0.43 was used instead. 
In vitro phenotyping experiments identify the enzymes involved in a compound’s metabolism. On the 
one hand, the design of a CYP phenotyping experiment in HLM systems implies co-incubation of 
substrate drug and a chemical inhibitor of a specific CYP-enzyme. These so-called chemical inhibition 
assays use an ex vivo liver matrix, expressing a whole arsenal of enzymes. A major drawback of this 
approach is selectivity issues, since chemical inhibitors tend to not only inhibit just one CYP enzyme. 
Although this can be circumvented by using monoclonal antibodies against CYP isoforms, this would 
heavily increase the cost of such an experiment. Chemical inhibitors for specific enzymes should be 
incubated at an optimal concentration, high enough to substantially block the enzyme, but not too high 
to avoid inhibiting more than the enzyme of interest  [8]. On the other hand, CYP phenotyping in rhCYP 
systems studies the interaction between the substrate drug and one specific CYP enzyme in a genetically 
engineered in vitro system, assuring selectivity for only one enzyme. Metabolic activities of recombinant 
CYP enzymes are often overemphasized, compared to HLM. Although Inter-system extrapolation factors 
(ISEF), relative activity factors (RAF) or relative expression factors (REF) may be used to correct for this 
difference, Chen et al., 2011 [9] discussed the inferiority of CYP abundance factors (such as REF) in in 
vitro-to-in vivo extrapolation (IVIVE), and the difficulty of using RAF due to variability of CYP abundance 
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between the HLM and rhCYP systems. This makes the ISEF the correction factor of choice for 
recombinant enzyme systems, which is the approach we applied in our work. 
2.2 MECHANISTIC IN VITRO-TO-IN VIVO EXTRAPOLATION 
Mechanistic IVIVE is a technique used to predict the organ (liver) clearance based on data obtained from 
(sub)cellular in vitro metabolism assays. Drug-specific factors Km, Vmax, and CLint are combined with 
physiological information in order to mechanistically scale the in vitro metabolism parameters to a 
hepatic in vivo clearance. Since the physiological information, used for this purpose, is fully integrated 
in the PBPK-M&S platform Simcyp®, the latter was used for the IVIVE. IVIVE clearance models were 
constructed by supplying the in vitro metabolism data from the two assays (HLM and rhCYP), described 
in the previous section. In addition, a retrograde clearance model was set up that uses in vivo phenotypic 
information to derive contributions for different elimination pathways. In this retrograde clearance 
model, the CYP2D6 contribution was calculated from the difference in tramadol hepatic clearance 
between CYP2D6 poor and extensive metabolizers. Besides, the CYP2B6 contribution was determined 
using a clinical trial simulation approach mimicking a tramadol drug-drug interaction study with co-
administration of rifampicin to induce the CYP2B6 activity. Details on the construction of the IVIVE and 
retrograde clearance models are presented in Chapter 3. 
In the initial bottom-up extrapolation from in vitro to in vivo, the 2 IVIVE clearance models (from HLM 
and rhCYP data) underpredicted the absolute clearance value more than 2-fold and the CYP enzyme 
contributions were not in line with in vivo CYP contributions. Two underlying issues, creating this 
apparent mismatch, were identified. First, concerning the underprediction of the hepatic clearance, 
papers by Berezhkovskiy [10] and Hallifax [11] suggested an intracellular accumulation for basic amines 
(such as tramadol) in hepatocytes due to the pH difference across the hepatocyte membrane. However, 
in scientific literature, there is still debate whether the value of the cytosolic pH is 7.0 or rather 7.2. 
Depending on the pH difference across the membrane and taking into account tramadol’s pKa (9.41), 
an intracellular accumulation of 2.5- or 1.58-fold is expected for intracellular pH-values of 7.0 and 7.2, 
respectively. Since the sensitivity analysis in Chapter 3 pointed out that the hepatic accumulation factor 
greatly influences the prediction of the hepatic clearance, it was decided to use a factor of 1.58 in the 
simulations, since it is the more conservative and thus ‘safer’ option for the prediction of the clearance. 
Second, in order to investigate the disagreement in CYP contributions between in vitro and in vivo, a 
separate study was set up (Chapter 4). In this study, probe substrates midazolam (CYP3A4) and 
dextromethorphan (CYP2D6) were used to determine the batch-specific enzyme activity in pooled HLM, 
used for the tramadol experiments. The measured batch-specific CYP2D6 and CYP3A4 enzyme activities 
in HLM were compared to the enzyme activity, typically expected for a representative healthy volunteer. 
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This typically expected activity was calculated from in vivo data, using a retrograde modelling approach. 
The results indicate that while CYP3A4 activity was well contained in vitro and only deviated 10% from 
the expected population activity value, measured CYP2D6 HLM activity appeared to have decreased by 
2-fold. In other words, when translating these findings to predict tramadol’s in vivo metabolism, the 
CYP2D6 contribution should have been higher than initially estimated. Although pooled HLM (n=50) 
were used for the experiments, the CYP2D6 batch-specific enzyme activity did not represent the average 
population activity. The lot-to-lot variability was determined by the supplier as a function of the number 
of donors, using Monte Carlo analysis [12]. From this analysis, it was apparent that the coefficient of 
variation was only around 10% for 50 donors. However, Foti et al. [13] also observed a reduction in 
CYP2D6 activity in human liver microsomes. They concluded that the CYP2D6 enzyme appears to be less 
stable than the other CYP enzymes in vitro. Therefore, in order to monitor the CYP2D6 activity in the 
HLM experiments, Chapter 4 suggests to incubate a CYP2D6 probe alongside the test substrate tramadol. 
From this probe substrate activity data, an activity-adjustment factor (AAF) can be calculated, which 
corrects for any difference in measured and expected HLM activity. In this specific study, the calculation 
of AAF for midazolam and dextromethorphan involved a retrograde well-stirred and a parallel tube 
approach, respectively. Although this may give the impression that model selection is very arbitrary and 
the best model is picked to fit our purpose, it is not. The back-calculation of the in vivo CLint is more 
sensitive to the model selection for dextromethorphan (60% difference in in vivo CLint), compared to 
midazolam (13% difference in in vivo CLint). The reason is that the part of the blood clearance that is 
due to the CYP isoform these probes represent, is 71 L/h for dextromethorphan (by CYP2D6) and 22 L/h 
for midazolam (by CYP3A4). It is obvious that dextromethorphan’s CYP2D6 clearance is approaching the 
limiting value of 90 L/h for hepatic blood flow. Therefore, dextromethorphan IVIVE will, as theory states, 
be better represented by the parallel tube model. In addition, the article that was used to derive the 
dextromethorphan in vivo CLint in Chapter 4, also favored the parallel tube approach and argued its 
feasibility. As a general approach, we propose to include reference probe substrates, indicative of the 
activity of the major enzymes involved in the metabolism of the test drug any time in vitro metabolism 
assays are initiated for a given test drug. Probe substrates specific for the different CYP enzymes can be 
looked up in the paper of Walsky & Obach [14]. A weakness of the study described in Chapter 4 was 
that only one compound was considered to assess the potential value of the use of AAF, and that data 
on more compounds in addition to tramadol need to be generated to further strengthen this finding. 
The liver model that was used in these IVIVE predictions, was the well-stirred liver model. Other models 
that describe liver extraction are the parallel tube and dispersion model. Latter models typically provide 
an important advantage over the well-stirred liver model for high clearance compounds. For a low 
clearance compound, such as tramadol, the choice for the mathematically simpler well-stirred liver 
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model seems appropriate. It needs mentioning however, that upon applying the parallel tube model to 
tramadol in vitro data, the clearance increased approximately 20%. Although this higher clearance is 
closer to the observed adult clearance value, still the well-stirred model was preferred over the parallel 
tube model. It is the only liver model that could be used in the PBPK software tools as time-dependent 
model. The parallel tube and dispersion models can (for now) only be used as static liver models, 
independent of time. Additionally, this finding does not invalidate our pediatric predictions (in which 
the well-stirred liver model was used), since the retrograde model that is in vivo-calibrated, was used to 
this end.  
The retrograde clearance model has been an essential aspect in the IVIVE model building process and 
in the mechanistic understanding of the different tramadol clearance contributors. Since it is 
constructed using in vivo phenotypic information, a retrograde model combines the mechanistic nature 
of a bottom-up model, with the prediction accuracy of a top-down model. Hence, it may serve as a 
reference, concerning hepatic clearance prediction and CYP enzyme involvement, to other tramadol 
IVIVE models, built up from in vitro metabolism data. Although such retrograde models provide 
attractive features, they display limitations as well. The assumptions that underlie a correct use of these 
retrograde models can be summarized as: i) the liver is perfusion rate-limited and behaves as a well-
stirred or parallel-tubed compartment, ii) the investigated compound’s hepatic clearance is linear, iii) 
composed of only a few major metabolic pathways, and iv) preferably dominates the total clearance. In 
line with the objectives of our work, the most adequate tramadol adult clearance model should be able 
to accurately capture tramadol total clearance, as well as CYP2D6 and renal contributions. The 
retrograde clearance model is created by mechanistically incorporating the in vivo observed renal and 
hepatic clearance with relevant enzyme contributions. Therefore, it will always accurately represent the 
total clearance with the appropriate renal and hepatic contribution. Additionally, the CYP2D6 
contribution is also adequately built in into the model, as is indicated in Table 1, Chapter 5. Eventually, 
the tramadol retrograde model, backed-up by a body of in vitro metabolism evidence (as described 
above), was deemed fit and qualified for the bottom-up prediction of tramadol’s pediatric total, CYP2D6, 
and renal clearance. 
  
  7 
 183 
3 BOTTOM-UP PREDICTION OF TRAMADOL PEDIATRIC CLEARANCE 
Using the retrograde model defined in Simcyp® as described above, the clearance was predicted 
bottom-up across the pediatric age range. Chapter 5 describes the comparison of these predicted 
clearances with the observed in vivo clearances. The in vivo reference data were derived from 2 
published top-down (NONMEM) population PK models, and 1 WinNonlin® modelling effort with 
individually fitted clearance values. The data set for this WinNonlin® modelling analysis consisted of only 
richly sampled subjects with available plasma and urine data from the original NONMEM data set. The 
population PK models provided estimates for the maturation of total and CYP2D6 clearance, while the 
WinNonlin® fits added renal clearance estimates for the richly sampled subjects.  
The two available (NONMEM) population PK models that should serve as a reference to compare the 
bottom-up predictions with, differed tremendously in the estimated total and CYP2D6 tramadol 
clearance maturation. Figures 4 and 5 in Chapter 5 illustrate this statement. From these two top-down 
models, the Hill-type model was chosen as the relevant maturation model, as it adequately described 
tramadol clearance maturation in vivo. This is because the Hill-type model: i) is per se physiologically 
more plausible than an exponential model; ii) was modelled using a pooled, extended dataset from 
neonates to adults; and iii) produced similar estimates for CYP2D6 clearance as the WinNonlin® fits. 
Although in very early life, an exponential function is an acceptable approximation of a Hill-function to 
describe maturation, caution is always advised when analyzing sparse data in a population PK analysis. 
This is certainly true in situations where identifiability issues for some estimated parameters, i.e. CYP2D6 
clearance in the current population model, are present.  
By visually comparing the Simcyp® bottom-up predicted clearance values to the in vivo Hill maturation 
model, the bottom-up approach seemed to capture the overall maturation trend well. However, a 
general underprediction was apparent in the total and CYP2D6 clearance maturation, but not in the 
renal clearance. This is illustrated in Chapter 5 for neonates/infants (Figures 4-6) and for the complete 
pediatric lifespan from birth to adulthood (Figures 7-8). Although reasons for the underprediction of the 
total tramadol clearance may be sought in alternative metabolic routes, this is unlikely to be the real 
explanation since the CYP2D6 clearance maturation suffers from a similar underprediction. Therefore, 
in Chapter 5, reasons for the underprediction were attributed to a difference in physiology (e.g. liver 
size) between the real and virtual pediatric subjects, both affecting predicted total and CYP2D6 
clearance in a similar way. In order to challenge this theory, in Chapter 6, two other commercially 
available PBPK software packages (PK-Sim® and Gastroplus®) were evaluated in addition to Simcyp®. 
Prediction differences among the total and CYP2D6 clearance maturation - if observed - would only be 
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the result of differences in physiological information, included in these softwares, if for the rest similar 
assumptions were used to build the models.  
The workflow implemented for the pediatric bottom-up clearance prediction in PK-Sim® and 
Gastroplus®, was analogous to the one described for Simcyp®. In short, physiological information 
contained in each software package was used to construct a software-specific retrograde model. The in 
vivo clearance values that were used to calibrate the retrograde models were extracted from the 
tramadol pooled popPK publication [15]. This way, similar tramadol retrograde models were obtained 
for the adult population and were qualified for total, CYP2D6 and renal clearance (see Chapter 6, Table 
2). The choice of the PBPK software package has a significant impact on the predicted maturation of 
total, CYP2D6 and renal clearance (Chapter 6, Figure 2). As is derived from the Figures 4 and 5 in that 
chapter, each software tool has its own physiological database from which information is extracted in 
order to generate the virtual subjects. Since the retrograde models were constructed with physiological 
information specific to each software tool, differences in the predicted pediatric clearances would only 
appear if the relative maturation functions (in e.g. blood flows, organ size, enzyme ontogeny) differed 
between softwares. The renal clearance is similar between PK-Sim® and Simcyp®, but initially starts off 
higher in Gastroplus® and then declines. However, this comparison may not be completely fair, since 
for Gastroplus®, only the kidney blood flow was assumed to drive the maturation of the renal clearance, 
while GFR controlled the maturation in the other two softwares. The parameter mostly affecting 
tramadol clearance prediction in early life, is the ontogeny of CYP enzymes (expressed as pmol CYP/g 
liver tissue). While the ontogeny for CYP3A4 seems very similar for the different packages, this is not 
the case for CYP2D6 and CYP2B6. Ontogeny information on CYP2D6, a major contributor to the total 
clearance of tramadol, is quite different between virtual populations, generated by the different 
softwares. Whereas PK-Sim® assumes a mature CYP2D6 activity at term age, Simcyp® and PK-Sim® 
display a pronounced ontogeny function over the first 20 weeks of life. In addition, Simcyp® 
implemented maturation at the scalar ‘microsomal protein per gram liver’ (or MPPGL) as well, further 
slowing down the maturation of CYP enzymes. Clearly, this difference in physiological information 
explains the prediction bias for tramadol total and CYP2D6 clearance maturation. To come back to the 
initial underprediction issue raised in the previous paragraph, it is not the liver size, but rather the 
CYP2D6 ontogeny and MPPGL maturation that take too long, causing Simcyp® to underpredict the total 
and CYP2D6 clearance observed in Chapter 5. In addition, the conclusions from Chapter 5 & 6 relating 
to the maturation of CYP2D6 activity in Simcyp® seem to contradict, with CYP2D6 clearance in early life 
being well captured in Chapter 5 and not well-captured in Chapter 6. In Chapter 5, different publications 
were used to extract reference adult and pediatric data and an overlay of bottom-up and top-down 
clearance maturation was used to judge the PBPK model. In Chapter 6 a much cleaner approach was 
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adopted by calibrating the PBPK models to the adult part of the pooled popPK model, so that any 
discrepancy between PBPK and popPK predicted pediatric clearances was only due to the maturation 
function. In addition, the same virtual subjects were used to predict the clearance in the PBPK and the 
popPK models, making a one-on-one comparison feasible allowing to calculate a prediction error per 
subject. Interestingly, PK-Sim® that assumed the shortest maturation half-life for CYP2D6, provided the 
best predictions compared to in vivo. This finding suggests that CYP2D6 activity should be almost fully 
mature at birth. This was independently confirmed by another group, using in vivo derived ontogeny 
functions from propafenone [16]. This statement may lead to the belief that ontogeny functions are 
more accurate when they are based on in vivo data instead of in vitro data. The question is whether this 
observation is only valid for CYP2D6 or if this is part of a generalizable concept for most/all liver enzymes. 
It might be that for CYP2D6 alone in vitro activity data is inappropriate, given its specific stability issues 
in vitro (see Chapter 4). To check this, a similar analysis should be conducted for multiple enzymes, 
based on multiple model compounds to confirm this finding. However, in our opinion, there are 2 sides 
to the story. In vivo-derived maturation functions are appropriate to predict the in vivo situation per se. 
The downside is that they may be confounded by many other physiological factors, whilst the in vitro-
derived ontogeny functions present a ‘cleaner’ approach. This is because in the latter situation 
confounding is physically eliminated by resecting relevant liver tissue and measuring subcellular 
activities ex vivo. So why would in vitro-derived functions be inappropriate? The answer is to be found 
in the variability associated with these ex vivo measurements and the way the ex vivo matrix is resected 
and prepared. Illustrative of this fact, are the source data for CYP2D6 maturation, which are different 
for Simcyp/Gastroplus [17, 18] compared to PK-Sim [17, 19]. This means that while in theory the in vitro-
derived functions are much cleaner, apparently the variability on the in vitro activity data is that high 
that it results in different CYP2D6 maturation functions for different software tools. This indicates that 
there is a high need for standardization in the way hepatic microsomes are prepared and consensus 
needs to be achieved about the activity data to be used for appropriate maturation functions. Again, 
this should be confirmed for other enzymes as well. 
At this time, hepatic and kidney transporters [20] are not accounted for in the tramadol popPK model 
(neither in the current PBPK models), but their influence cannot be completely ruled out on the 
estimation of the CYP2D6 clearance maturation in the popPK approach. We believe however, that this 
popPK analysis still provides a much ‘cleaner’ vision on CYP2D6 maturation, compared to using 
parent/metabolite urinary ratios. Furthermore, tramadol total clearance was best described by PK-Sim®, 
although a minimal bias still persisted (be it within the 2-fold boundary). Thus it might still be possible 
that another enzyme, contributing relatively more in early life and disappearing with aging, may still be 
involved (e.g. CYP3A7, FMO1) [21]. 
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The general aim of this PhD dissertation was to evaluate bottom-up predictions of the hepatic clearance 
and identify the gaps leading to prediction inaccuracies in the bottom-up predicted (in silico) compared 
to the top-down estimated (in vivo) clearances. Identification of these gaps should lead to an increased 
understanding and subsequently implement the missing or suboptimal elements in the PBPK model 
structure. Since PBPK M&S makes the a priori distinction between the system’s and the drug’s 
properties, mechanistic model development with a well-chosen probe substrate offers a way to look 
beyond the drug’s specific properties. Its PK is representative for some part of the underlying system 
that is under investigation. In casu, all elements to study the maturation of CYP2D6 were in place: i) 
tramadol’s hepatic extraction is about 25% (low hepatic extraction), making it sensitive to differences 
in enzyme abundance; ii) CYP2D6 is a major contributor to tramadol’s metabolism; and iii) in vivo 
maturation functions of total and CYP2D6 clearance were available from a pooled popPK analysis. This 
way, tramadol provided us, via its metabolism, a means to study the ontogeny of the CYP2D6 enzyme, 
rather than just focusing on the disposition of tramadol. 
To conclude, the investigation of tramadol’s in vitro metabolism in HLM and rhCYP systems, yielded 
pro’s and con’s to both systems in providing enzyme contributions to the hepatic clearance. 
Furthermore, these contributions were scaled up from in vitro (HLM and rhCYP) to in vivo, the so-called 
in vitro-to-in vivo extrapolation (IVIVE). An important observation in this context was that, although 
pooled HLM were used for the experiments, the in vitro activity of the CYP2D6 enzyme did not represent 
the typical population in vitro value. Calculation of an AAF by specific probe substrates, i.e. 
dextromethorphan for CYP2D6, appears to resolve this in vitro inaccuracy, but needs to be confirmed 
with additional compounds. The construction of a retrograde tramadol clearance model (initially 
performed in Simcyp®), in parallel to the IVIVE clearance models, provided an invaluable feedback 
system to iteratively check assumptions and identify mechanisms involved in tramadol elimination. 
Eventually, this tramadol retrograde model, certified by the body of collected in vitro metabolism data, 
was qualified in terms of total, CYP2D6, and renal tramadol clearance in order to initiate pediatric 
bottom-up clearance predictions. Next, the most relevant, commercially available PBPK modeling and 
simulation softwares (PK-Sim®, Simcyp®, Gastroplus®) were implemented with the tramadol retrograde 
model for prediction of the pediatric clearance. These software tools seemed hugely versatile platforms 
enabling modelers to construct complex generic whole-body PBPK models, using a spectrum of pre-
defined building blocks to approximate any clinical scenario in silico. Although 3 similar variants of the 
same retrograde clearance model for tramadol were constructed in the 3 software tools, comparison 
of the bottom-up clearance predictions with the top-down estimation of the clearance, revealed 
marked differences. The origin of this discrepancy could be traced back to the level of the 
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biological/physiological data underlying the clearance predictions in every tool. Apparently, uncertainty 
surrounded the ontogeny function of the CYP2D6 enzyme in children, under 2 years of age. Interestingly, 
the PBPK model with the shortest maturation half-life for CYP2D6 (PK-Sim®), correctly predicted CYP2D6 
maturation in tramadol clearance in early life, as well as over the complete pediatric age range. This 
research, combining bottom-up and top-down modelling methodologies, showed potential to identify 
and fill knowledge gaps in the developing pediatric physiological information, thereby increasing the 
confidence with which doses are predicted for pediatrics 
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1 BROADER INTERNATIONAL CONTEXT & RELEVANCE 
1.1 FINDING THE RIGHT DOSE FOR CHILDREN 
Over the years, different approaches have been applied in order to derive an appropriate dose of a drug 
for children, starting from the dose administered to adults. Different options are available to calculate 
the pediatric dose for first-in-pediatric trials as well as in clinical practice. A set of rules, defined in many 
pharmacological textbooks are applied clinically, which use some covariates (body surface area, body 
weight, age) to scale the adult drug dose to the pediatric one, e.g. Clark’s, Young’s, Webster’s, Fried’s, 
Shirkey’s, Salisbury rules. These rules are arbitrary, typically using linear scaling of some covariate to 
derive the child’s dose (BSA or bodyweight). An internal FDA study of 2012 pointed out that any of these 
rules is not suitable to calculate an appropriate drug dose for every age group. Above 3 months of age 
the Shirkey, Webster, Clark and Salisbury rules provided the best results with 60% of children meeting 
an acceptable dose prediction. Below 3 months of age, Clark’s and Salisbury’s rules predicted an 
acceptable dose for 45% of pediatric patients, while the other methods landed at 5%. Therefore these 
methods were deemed unreliable [1]. The reason is that the correlation between dose and some 
covariate over the full pediatric age range is non-linear. It is well known that in selected cases, e.g. 
carbamazepine, children even need higher weight-adjusted doses than adults. Hence, in a linear scaling 
technique (i.e. only correcting for body weight with a fixed allometric exponent of 1, see below) 
involving some easily obtainable covariate, these scenarios are unanticipated [2]. In order to provide a 
solution, some authors have suggested to calculate the pediatric dose using a single fixed (based on 
allometric theory) or an estimated (from the data) allometric exponent. The theoretical concept is that 
this exponent correlates the dose to metabolic function. This method already provided better results 
than the empirical dosing rules, but still underperforms in early life. The rationale for dose adjustment 
in pediatric indications should be driven by differences in pharmacokinetics, pharmacodynamics, 
disease or a combination of these factors [2, 3]. When the clearance mechanisms are immature or 
impaired, any empirical scaling method is prone to inaccuracies if not specifically corrected for. Indeed, 
approaches providing superior predictive power incorporated different estimated exponents varying 
with weight or age, or involved interspecies scaling using adult rat, dog and human clearance values [1, 
4]. The only solution to transcend empiricism in pediatric dose scaling is by implementing 
physiologically-based modelling, either in the form of bottom-up [5-7] or top-down [8-10] models. 
Moreover, it is currently recognized that pediatric doses should be derived based on actual acquired 
(clinical) data using a combination of bottom-up and top-down methods. The bottom-up approach 
allows to ‘explore’ and anticipate in vivo changes in pediatric dose safety/efficacy/toxicity by combining 
known physiological and genetic information with in vitro data. In the top-down approach, clinical 
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studies are set up to ‘confirm’ appropriate dosing regimens with acceptable safety/efficacy profiles and 
explain the observed in vivo variability [11]. Furthermore, given the future direction of the 
pharmacological area to a more personalized medicine approach, an apt combination of ‘bottom-up’ 
and ‘top-down’ techniques is the only way forward in terms of understanding and treating pediatric 
disease by providing the right dose at the right time. 
As Cella et al. [2] state, efforts in two distinct areas of pediatric pharmacology research are needed. The 
first is to re-examine dose recommendations for older drugs, frequently used off-label in pediatric 
clinical practice. The collected pharmacokinetic, safety and efficacy data in adults and various pediatric 
age groups, may be implemented in a model-based approach to rethink dosing algorithms in the clinic, 
based on the totality of available data . The second area is the early drug development phase in which 
no data in children are readily available. Typically, PBPK models are used as a model-based bridging tool 
(from preclinical and adult clinical data) to calculate primary PK parameters and predict pediatric doses 
[2]. Although PBPK models are increasingly applied in early development, they are only as good as the 
scientific knowledge base used to construct them. Still today, knowledge gaps remain in some of the 
system’s parameters, including the frequency, and functional activity of transporters, and of many 
metabolic enzymes beyond the CYPs,  as well as the components of tissues influencing drug distribution, 
beyond the established ones consisting of lipids, phospholipids, and plasma proteins. In addition, some 
system’s parameters, e.g. the ontogeny of CYP enzymes and transporters, or disease effects on CYP and 
transporter activity, are derived from in vitro or ex vivo tissues/tissue fractions and typically contain a 
certain level of uncertainty with respect to how representative they are for the in vivo situation. 
Improved confidence in (patho)physiological model parameter values may be gained by simultaneous 
modeling of the PK of several compounds, exposed to the same clinical conditions, e.g. neonatal 
immaturity, disease state, pregnancy, co-medication. In this situation, drugs can be used as in vivo 
probes to reflect and quantify the underlying properties of the system [12]. This PhD dissertation 
describes such efforts. Specifically, this work evaluates currently applied PBPK models by challenging 
their bottom-up prediction capabilities to a top-down model-based approach, using clinically collected 
pediatric PK data of the off-label used drug tramadol. Specifically, the bottom-up prediction of tramadol 
hepatic clearance was compared to the top-down estimated hepatic clearance in pediatric life, with a 
particular focus on CYP2D6 maturation in neonates and infants. This analysis showed that there is a 
substantial difference in the in vitro ontogeny information about CYP2D6 that is integrated in different 
PBPK software platforms (PK-Sim®, Simcyp®, Gastroplus®). By comparing bottom-up predicted with top-
down estimated CYP2D6 clearance maturation, it was concluded that the true CYP2D6 activity should 
be already progressively matured at birth, which was independently confirmed by a recent publication 
from another group [13]. We acknowledge that uncertainty associated with in vitro derived enzyme 
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ontogeny can be decreased by deriving these ontogeny functions from in vivo data. Therefore, adequate 
probes allow to derive in vivo ontogeny functions of specific enzymes, in this case tramadol for CYP2D6. 
Furthermore, CYP2D6 is a relevant metabolic enzyme involved in the breakdown of many lipophilic, 
basic drugs, e.g. different antidepressants, antipsychotics, antiarrhythmics, antiemetics, ß-blockers and 
opioids [14]. Hence, since this work updated our current understanding of the system’s parameter 
‘CYP2D6 ontogeny’, it can be considered relevant for the bottom-up prediction of any CYP2D6-
metabolized compound in pediatric drug research. Obviously, in order to increase the confidence 
related to CYP2D6 maturation, more compounds are needed that can confirm these findings. Moreover, 
although the workflow presented in this thesis provides an attractive and promising technique, the 
general approach still needs validation by expanding to more compounds, treated by (other) multiple 
enzymes/transporters. 
1.2 PRECISION DOSING AND PBPK 
 
In his State of the Union Address, U.S. President Barrack Obama announced a research initiative that 
aims at taking precision medicine to a new level – the Precision Medicine Initiative (PMI). This program 
will leverage disease prevention and treatment strategies that account for individual variability in 
genetic make-up, environment, and lifestyle. Proteomics, metabolomics, genomics, and bioinformatics 
methods will all contribute to patient characterization and should lead to a better understanding of the 
mechanisms of disease. Ultimately, the knowledge gained from this PMI platform will inform clinical 
practice and support an optimal individual therapy. The immediate focus of the PMI lies in facing the 
long standing challenges in cancer research. In the longer term, the PMI wants to apply the precision 
medicine concept in order to generate knowledge applicable to the full range of health and disease [15, 
16]. 
An integral part of precision medicine is the administration of a precise dose of medication to a specific 
individual to treat his/her disease, which is a critical step in the larger mission to deliver personalized 
healthcare. Modelling and simulation in drug research includes top-down (mixed-effects modelling) and 
bottom-up (physiologically-based modelling) techniques. Both modelling approaches have a proven 
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track record of rationalizing drug development and making it more efficient [17, 18]. However, they 
have yet to become a tool in ‘point-of-care testing’, a medical diagnostic technique at or near the point 
of care. At the PBPK side, work is in progress to create ‘virtual twins’. A virtual twin is the in silico 
counterpart of a real patient that matches the patient’s characteristics. These characteristics would 
include both intrinsic factors (age, weight, height, sex, race, and genetic information on, among others, 
metabolic enzymes and transporters) and extrinsic factors (environmental factors and co-medications). 
In this way, appropriate prior information, relevant for drug dosing, is incorporated to calculate the 
‘precise’ dose for a given individual at the bedside. Because PBPK models have already implemented 
the mechanistic and structural framework to combine these intrinsic and extrinsic factors, this modelling 
technique is bound to profit from the large amounts of biochemical and physiological data that will 
become available during the PMI research program [7, 19]. Although the concepts put forward in this 
paragraph seem very promising and attractive, they still are in a premature stage. While scientists are 
developing ways to integrate these ideas (virtual twins, tool in point-of-care testing) into a modeling 
framework, and the necessary data are being collected, this work-in-progress is needed to preserve a 
role for PBPK in the precision dosing era. 
1.3 PBPK AND THE LEARN-CONFIRM PARADIGM 
In 1997, a commentary by Sheiner [20] illustrated that theory of alternating induction and deduction 
could be applied to drug development. The induction phase represents learning from experience, while 
deduction seeks to confirm from what has been learned. Applying this principle to drug development 
would make the whole process more adequate (better drugs) and efficient (sooner). In his vision, the 
application of modelling and simulation in clinical drug development stimulates the implementation of 
the ‘learn-confirm’ paradigm. In rational and more quantitative model-based drug development, these 
two elements (learn & confirm) reflect a proper balance that should be maintained throughout the 
development timeline. The better the ‘learn’ phase (science), the more efficient and appropriate the 
‘confirm’ phases (phase 3 and drug approval). In this mindset, physiologically-based PK is perfectly 
positioned as it offers a way to integrate knowledge on a drug’s properties, routinely collected during 
drug development, in all of its forms, in combination with our vast knowledge of the (human) biological 
system and how this determines PK and/or PD. In the preclinical stage, mainly in silico/in vitro drug data 
are collected. At this point, by differentiating system- and drug-related parameters, PBPK is already 
capable of predicting drug exposure in vivo in both animals and man. Different ‘what-if’ scenarios may 
be investigated and varying study designs explored. As the drug development program moves along, 
clinical in vivo data from healthy volunteers and patients are increasingly becoming available. A pivotal 
milestone in this process is to evaluate whether mechanistic preclinical (in vitro and animal) models 
accurately predict the acquired first-in-human in vivo data. This evaluation appraises the present 
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understanding (learning) of the drug’s absorption and disposition, and of the biological system, and 
hence may or may not be confirmatory. Therefore, some authors suggested to expand the classical 
paradigm to ‘predict-learn-confirm’ [21, 22]. This is exactly why PBPK nowadays is considered to be an 
integral part of pediatric drug development. The mechanistic framework allows to gain insights into the 
drug’s absorption & disposition and in pediatric physiology in one effort. Leong et al. [21] stated that 
the utility of PBPK models includes optimization of the pediatric study design, evaluation of clinically 
relevant covariate effects, and the attainment of insights related to the ontogeny of previously 
undocumented biological processes. As a consequence, even before one pediatric plasma sample for a 
new drug candidate is analyzed, different dosing regimens, clinical trial designs, and drug-drug 
interactions have already been explored in silico. This implies that the ‘learning’ in pediatric drug 
development has shifted from post to pre pediatric clinical trials, making them ‘confirmatory’ rather 
than ‘exploratory’. 
The real innovation of this technology is that at any point in the global drug development process, the 
PBPK model is iteratively updated to represent the state-of-art understanding of the new candidate’s 
pharmacology. Even more than simply being a quantitative modelling and simulation tool, aimed at 
rationalizing drug development, PBPK ensures the continuous flow of data from preclinical to and within 
clinical phases of development. It becomes a platform by which scientists from different disciplines and 
backgrounds may communicate and leverage the existing knowledge of the drug as well as of the 
biological system. 
Applied to this PhD dissertation, the ‘predict-learn-confirm’ concept was really tangible at two points in 
this project, in particular in the extrapolation of tramadol’s in vitro enzymatic contributions to an in vivo 
hepatic clearance (IVIVE). First, freshly obtained tramadol intrinsic clearances (CLints) for each CYP 
enzyme from HLM, were scaled to the in vivo hepatic clearance. In this initial attempt, an 
underprediction of about 50% in the hepatic clearance was apparent (‘predict’). An important 
shortcoming of in vitro HLM assays, lies in the fact that no cellular membrane is present and the 
metabolic enzymes are freely accessible. Basic lipophilic amines (such as tramadol), however, tend to 
accumulate in the intracellular environment, and are unable to do so in the HLM assay. The 
phenomenon in which basic drugs (or the other way around for acids) accumulate in more acidic (blood 
pH = 7.4 vs. intracellular pH = 7.2) environments, is called ion trapping (‘learn’). A ratio of 1.58, 
representing the fold intracellular accumulation of tramadol, was implemented in the IVIVE and 
enhanced the prediction of the hepatic clearance (‘confirm’). Although we had the intention to further 
confirm this behavior in in vitro hepatocyte cultures (with intact cell membranes), there was no 
guarantee that the same phenomenon would occur in the hepatocytes in vitro [23]. Therefore, given 
the uncertainty associated with this specific aspect of the in vitro model, we did not perform these 
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experiments. Second, in the comparison of CYP enzyme contributions between the HLM IVIVE clearance 
model (in vitro) and the retrograde clearance model (in vivo), the in vitro HLM contribution of CYP2D6 
was underpredicted (‘predict’). Subsequent incubations with dextromethorphan, a CYP2D6 probe, in 
that same HLM batch, yielded a similar underestimation of the CYP2D6 contribution (‘learn’). To resolve 
this issue, an activity-adjustment factor (AAF) was calculated, based on the probe substrate data of 
dextromethorphan. Multiplication of the CYP2D6 activity with the AAF, corrected the inaccurate CYP2D6 
contribution (‘confirm’). Additional compounds need to be studied though, to confirm this finding.  
1.4 DID PEDIATRIC REGULATIONS BY FDA & EMA DELIVER? 
Since 2002 in the U.S. (FDA) and 2007 in Europe (EMA), a combination of incentives and requirements 
were put in place to ensure that medicines are regularly studied, developed and approved to meet the 
therapeutic needs of children. What has changed since then and, more importantly, did these initiatives 
deliver? 
In the 5-year EMA progress report [24], the initiatives seemed to have had an impact on the number of 
pediatric clinical trials and pediatric subjects enrolled in such studies. By the end of 2012, 600 pediatric 
investigations were agreed upon by the Agency, of which 453 concerned medicines not yet authorized 
in the E.U.. The consequence is apparent in Figure 1. Now, for the first time, children below 23 months 
of age are enrolled in clinical trials, who were normally not included prior to 2008. In addition, the 
numbers of participating children in clinical trials in E.U. has increased vastly [24]. 
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In the U.S., the enactment in 2012 of the U.S. Food and Drug Administration Safety and Innovation Act 
(FDASIA) updated the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children 
Act (BPCA) and made them permanent. This has led to an enormous increase in the number of pediatric 
studies and permitted new pediatric labeling of more than 600 products, 149 of which occurred since 
the passage of FDASIA [25]. Moreover, a fundamental change in U.S. and E.U. company culture is 
apparent, since pediatric drug development is now accepted as an integral part of the overall drug 
development program [24, 25]. Although these reports indicate positive effects on the extent of 
pediatric drug research and the availability of drugs for children, a study by Corny et al. [26] questions 
the impact of regulatory measures at the clinical level. The objective of Corny’s study was to compare 
unlicensed and off-label drug use in children, before and after governmental initiatives in E.U. and U.S. 
in 2007. In Europe, only a marginal decrease in unlicensed and off-label drug use prevalence was 
observed. In the U.S., there was not even a single report on studying pediatric unlicensed or off-label 
drug use after 2007. Obviously, there is a discrepancy between the efforts by industry to provide more 
and better drugs for children, and the clinical adoption of these new drug therapies (in E.U.). Reasons 
for this discrepancy may be that clinicians continue to use older drugs because they have more 
experience with these drugs in current day-to-day clinical practice. In addition, wide ranges of 
unlicensed and off-label drug use rates were observed. This is mainly due to differences in off-label and 
unlicensed use between institutions, as well as inconsistencies in the definition of ‘unlicensed’ and ‘off-
label’ [26]. Although off-label and unlicensed drug use in children will never be completely ruled out, 
health care institutions should continue to collaborate in pediatric research networks (e.g. European 
Network of Paediatric Research (EMA), National Pediatric Research Network (FDA), SAFEPEDRUG and 
BPCRN (local initiatives)) with the main aim to harmonize the way in which pediatric drugs are applied 
in clinical practice. Provided that essential fundamental pediatric drug research is continued to increase 
our understanding of the processes that differ between adults and children, and that efforts remain to 
harmonize the research results and clinical implementation, only then, significant improvements will be 
made in a safer and more effective use of therapeutic agents in children.  
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2 FUTURE PERSPECTIVES 
PBPK models are being increasingly used in drug research and development for the prediction of ADME 
in healthy volunteers and/or pediatrics. At this point, however, they are far from perfect. Our knowledge 
of their strengths and weaknesses increases, as their applications grow. The main challenge facing the 
further successful expansion of these models’ application probably lies in the system-related 
parameters. With the growing understanding of physiological processes changing over a person’s life 
time and with disease, and more specifically the way that system (body) elements interact with the drug, 
physiologically-based models are becoming increasingly complex. Hence, the amount and the level of 
detail needed in the systems-related parameters increases exponentially. Systems data, such as the 
abundance, activity, and ontogeny of non-CYP enzymes and transporters in various tissues, absorption-
related data and how these are changing with age/disease status, are generally still lacking. Moreover, 
the quality and extent of biological data needed for predictions becomes even more challenging when 
applying PBPK for the mechanistic prediction of biologics or safety/efficacy assessments. The collection 
of this kind of data is typically difficult, therefore, initiatives bringing together industrial and academic 
partners that share in the burden as well as in the benefit of these research projects, may be set up in 
a pre-competitive manner [17, 18, 27]. In the meantime, a strategy to investigate the effect of a given 
diseased condition on drug disposition, may consist of altering the relevant (set of) physiological 
parameter(s) in the PBPK software to represent a diseased value, e.g. the influence of hypo-
albuminaemia (decreased plasma albumin concentrations in the model) on drug elimination and 
distribution (manuscript accepted). In this manuscript, treatment of critically ill patients suffering from 
hypo-albuminemia, is suggested to benefit from increasing the dose/dosing frequency, based on 
albumin levels. However, PBPK simulations in virtual hypoalbuminemic patients predict that the dose 
should not be increased (and rather decreased in some situations). This manuscript illustrates that the 
full (patho)physiological knowledge of critical illness does not need to be fully clarified in order to help 
resolve selected issues in understanding some aspects of the drug’s behavior in a particular disease. 
This example shows that PBPK models are hugely versatile and may be deployed in all areas of drug 
research. Given the a priori separation of drug and system data in a fully mechanistic framework, any 
population may be studied under any situation, as long as the detail in both data sets allows. Moreover, 
fully integrated sensitivity analyses may further indicate which parameters strongly influence the 
altered drug disposition in several conditions and lead to designing the necessary set of 
studies/experiments to decrease the uncertainty in some of the most influential assumptions .  
The integration of pharmacokinetic and pharmacodynamic data in fully mechanistic PBPK-PD models, 
with associated variability, should come to fruition in the near future. By mapping drug-receptor 
interactions and their variation due to age/disease, etc., pharmacological responses may be predicted 
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and extrapolated to different populations. However, due to the increasing model complexity, PBPK-PD 
models should be rigorously evaluated and reported in a transparent and reproducible manner. In fact, 
as of July 29, 2016 the EMA has made their ‘Guideline on the qualification and reporting of PBPK 
modelling and simulation’ available for public consultation [28], stressing the importance of 
transparency in PBPK M&S. Underlying assumptions should always be specified so that identification of 
the relevant physiological processes is clearly defined [7, 18]. In particular for pediatrics, it is becoming 
more evident that, due to the increasing number of pediatric studies, adult safety profiles cannot be 
directly translated to children even when the disease processes are the same [7]. It is essential that 
future studies involve defining the pediatric PK-PD relationship to better assess safety and efficacy, if 
prospective clinical studies on PK-derived dosing recommendations suggest a different outcome 
between adults and children. Efforts should continue to define how one can optimally combine top-
down and bottom-up approaches in order to increase our understanding of developmental 
pharmacology, by looking beyond compound-specific properties [10, 29]. A methodology that could 
prove really useful in this setup are microdose/microtracer studies, especially for drugs with complex 
metabolism and/or poor understanding of ontogeny. Microtracer studies involve the administration of 
radiolabeled drug together with a therapeutic dose of the drug via the same or another route, while in 
microdose studies, only the radiolabeled drug is given in a subtherapeutic dose. Recently, initiatives 
exposing infants to 14C-paracetamol and 14C-midazolam proved the feasibility of this approach. A 
perceived risk of adverse effects exists due to the administered radio-activity but it is unfounded [30]. 
Currently, there is a clear distinction between the typical ‘bottom-up’ and ‘top-down’ approaches. Quite 
recently, it has been suggested that combining both approaches in a so-called ‘middle-out’ approach 
could have beneficial value [31-33]. Bottom-up techniques have the great advantage of extrapolating 
outside the studied population and experimental conditions. The compromise is that they are defined 
by a complex system of differential equations with a considerable number of model parameters. 
Typically, model parameters that carry much uncertainty and are hard to derive in vitro or in silico, are 
adjusted so that the model could match the clinical observations. However, there are considerable 
methodological issues (i.e. structural and practical identifiability), hampering the successful 
implementation of this ‘middle-out’ approach. Methodological research and advances in computer 
sciences should enable this field to further develop as the middle-out approach integrates information 
from in vitro or in silico experiments together with information derived from observed clinical data [31, 
34]. By combining the separate skill sets of the historically separated ‘bottom-up and ‘top-down’ 
techniques, mechanistically sound models with clinical relevance should result [32]. 
Maybe one of the most important areas needing attention, is the communication between scientists 
involved in the broader context of physiologically-based PKPD modelling. Because of the highly-versatile 
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nature of these tools, scientists from many diverse disciplines in industry (experimentalists, biologists, 
epidemiologists, pharmacists, pharmacologists and mathematical modellers), who have traditionally 
been working apart, need to learn how to interact and communicate on a new level [17, 27]. At the 
same time, many pediatric prescribers from the clinical setting still dwell in the empiricism of the 
previous era. Modellers and care physicians need to be able to communicate at the same level in order 
for the patient to benefit from the innovation in pharmacological research [2]. From the moment 
different stakeholders in industry as well as in the clinic will be able to efficiently communicate with one 
another, only then will the true value of model-based pharmacological research emerge, yielding 
improved health in (pediatric) patients.  
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